Computed from this object's own state — the author has not yet attested the surfaces below. This is not a fixed disclaimer: the conditions below are each testable, and a build in which they are met renders READY.
In adults with heart failure and reduced ejection fraction, what is the hazard of a first cardiovascular death or heart failure hospitalization with sacubitril/valsartan compared with enalapril?
In this section: Registration and administrative information (PROSPERO field set) · Protocol registration · Protocol amendment history · Author attestation · What this object claims to contain
| Review title | Sacubitril/valsartan in adults with heart failure and reduced ejection fraction |
|---|---|
| Review question (PICO) | In adults with heart failure and reduced ejection fraction, what is the hazard of a first cardiovascular death or heart failure hospitalization with sacubitril/valsartan compared with enalapril? |
| Background / rationale | Not recorded — this object holds no background field, and an introduction generated without one would be argument that no source in this review supports |
| Eligibility criteria | A randomised trial of sacubitril/valsartan against enalapril, in adults with heart failure and reduced ejection fraction, reporting cardiovascular death or heart failure hospitalization as a time-to-first-event hazard ratio. All four conditions, and the last is a condition on the quantity reported, not on the trial's quality: several excluded trials are large, well conducted and directly on topic, and report something that is not this. |
| Information sources | 12 source layers, listed on the Extraction tab |
| Search strategy | Not recorded — this object records no search strategy, so no query, date or yield can be shown and nothing on the Search tab describes one |
| Study selection process | Two independent screens were run, adjudicated by Mahmood Ahmad. |
| Number of screeners | Not recorded — this object records no screener count |
| Data extraction items | Extracted per trial on this object: registry id; primary publication; year; design; arms; per-arm counts and the published effect; the randomised total, separately from the analysed denominator. Fields not listed here were not extracted. |
| Outcomes and prioritisation | Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio |
| Risk of bias method | A Cochrane RoB-2 assessment has now been performed by two independent AI assessors from different model families, neither of which assembled this object. Both judgement sets are published in full, including every signalling-question answer, and the per-domain agreement rate is reported as measured rather than after reconciliation. No domain in any trial was rated HIGH by either assessor. Five of fifteen domain judgements disagreed and remain unadjudicated. |
| Synthesis methods | Pooled under random-effects with the REML estimator. Whether they were prespecified is not recorded on this object. |
| Subgroup analyses | Not recorded — this object records no subgroup-analysis field at all, so whether any were prespecified is UNKNOWN -- which is not the same as none having been |
| Meta-bias assessment | Not recorded — no funnel, Egger or Peters value is held on this object, so no meta-bias assessment is claimed |
| Certainty assessment | GRADE, recorded for 1 outcome(s) (GRADE). The ratings are on the Certainty tab. |
| Confidence level | 95% |
| Funding | Not recorded — no funding statement is recorded for this review |
| Competing interests | Not recorded — no declaration is recorded |
| Built | 2026-08-09 |
| Schema | 2 |
Method: timestamped public git commit — repository https://github.com/mahmood726-cyber/rapidmeta-finerenone, path ssot/arni-hfref/arni-hfref.json.
| Commit | Committed (UTC) | Subject and permalink |
|---|---|---|
961400264a06 | 2026-08-10T05:13:40Z | ssot(arni-hfref): certified build, cross-family gate passed https://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/961400264a06bd940bef11e02b528ea0f73a8dee |
6272db4f0ee9 | 2026-08-12T19:43:11Z | recover: preserve the only surviving generator; install the destructive-git guard https://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/6272db4f0ee9ec88018ed33db0ee9a1f0997be9d |
Permalinks are pinned to the commit SHA, not to a branch. A branch link moves and would prove nothing.
| Verdict | established |
|---|---|
| Protocol committed | 2026-08-12T11:27:47Z |
| Strengthened | 2026-08-12T12:05:56Z |
| First query attempted | 2026-08-12T12:19:18Z |
| First query executed | 2026-08-12T12:22:39.556Z |
| Margin vs registration | +51 min 31 s to the attempt, +54 min 52 s to the first successful execution |
| Margin vs strengthened | +13 min 22 s to the attempt, +16 min 43 s to the first successful execution |
The protocol commit precedes the first executed query on both readings of 'first query'. The 12:19:18Z attempt is reported even though it returned nothing, because reporting only the successful execution would move the first-query time three minutes later and make the claim look better than it is. This is the test a PROSPERO record cannot offer: the timestamps are set by the repository and by the APIs, not by us, and both are independently checkable.
That the text of this object existed, in this public repository, at the committer timestamp shown, and has not been altered since without producing a new commit. The permalink is pinned to the commit SHA rather than to a branch, so it resolves to that exact state forever; a branch link would move and would prove nothing. Anyone can verify the timestamp and the content independently of this page and independently of its authors.
It does not establish prospectiveness. A commit proves when text entered this repository; it cannot prove that no earlier or parallel version existed elsewhere, that the data had not already been seen when the text was written, or that the analysis plan was fixed before the results were known. It also says nothing about the independence of the people who wrote it. Those are claims about conduct, and a timestamp cannot carry them.
| Commit | Committed (UTC) | Subject | Relative to the search |
|---|---|---|---|
973f031773d3 | 2026-08-12T11:27:47Z | protocol(arni-hfref): register the review protocol before the search runs https://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/973f031773d384f54bc1a6107931614aa5fda7ea | before the search |
dde501167666 | 2026-08-12T12:05:56Z | protocol(arni-hfref): strengthen section 9 so RoB-2 is pre-registered, not merely intended https://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/dde501167666f41ffdc81a07df1628734ce327a0 | before the search |
f89e9872418b | 2026-08-13T15:03:28Z | Amendment: post-hoc aetiology-split sensitivity analysis added https://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/f89e9872418bbbd95cbeaf67814d1dbd56371bf2 | AFTER the search |
The full commit history is projected, not only its head. A log that displays only its current state is no better than a mutable document, and the point of registering by commit is that every earlier state stays readable. Each entry records whether it post-dates the first executed query, because an amendment made after the search is a different act from one made before it and must not be presented as the same.
These are the surfaces a human author discharges by checking them and recording that they did. An attestation records that someone checked what is already here; it never alters a number and never raises a cell's source tier. A slot naming no person, no source or no date reads as absent.
| Surface | Status | What must be checked |
|---|---|---|
| Screening decisions | Awaiting attestation | That every record in `screening.records` was screened against the stated eligibility criteria, that each recorded decision and reason matches the record it names, and that the search was screened by the number of reviewers the write-up claims. |
| Data extraction against source | Awaiting attestation | That every extracted cell -- arm sizes, effect estimates, intervals and their scales -- was read back against the source named on that cell, and matches it. |
| Per-study risk of bias | Awaiting attestation | That the RoB-2 assessment recorded in `rob2` was carried out as pre-registered, that both assessors' domain judgements and signalling answers are reproduced without reconciliation, and that the five open disagreements are adjudicated. The assessment now exists; what this attestation still requires is a human adjudication of the disagreements and a check of the assessors' cited sources. |
| GRADE domain ratings | Awaiting attestation | That each GRADE domain rating and the resulting certainty were reviewed against the evidence cited in its own `basis in sources`. |
Full build. Every randomised trial located that compares sacubitril/valsartan with enalapril in heart failure with reduced ejection fraction and reports the composite of cardiovascular death or heart failure hospitalization as a time-to-first hazard ratio is held and pooled. Every trial that was looked at and not pooled is in one screening log, whatever it failed on, including the four that reached this review only by reconciliation against a published review's included-study table. Each row names the criterion it fails and the quantity it reports instead -- with one row that does neither, and says so: a trial that could not be retrieved at all is recorded as undetermined, with what was established, the document it was what could not be, and the date each attempt was made. That row is not an exclusion and is not counted as one. There is exactly one source list, `screening.records`. The object does also hold a second array, `screening.excluded`, and it is not a second table in any sense a reader has to reconcile: it is a view computed from the records at build time, row for row, so it cannot say anything the records do not. An earlier version of this sentence claimed there was no second array at all, which was false of the structure, and a review leg was right to read the structure rather than the sentence.
In this section: PubMed (ncbi e-utilities esearch) · ClinicalTrials.gov API v2 · How to re-run this search
Query as executed:
("sacubitril valsartan"[tiab] OR "LCZ696"[tiab] OR sacubitril[tiab] OR Entresto[tiab])
AND (enalapril[tiab] OR "angiotensin converting enzyme inhibitor"[tiab] OR ACEI[tiab])
AND ("heart failure"[MeSH Terms] OR "heart failure"[tiab] OR HFrEF[tiab])
AND (randomized controlled trial[pt] OR randomised[tiab] OR randomized[tiab] OR trial[tiab])
| Endpoint | https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi |
|---|---|
| Parameters | db=pubmed, retmode=json, term=<string above> |
| Filters applied | none — no language filter, no date filter, as registered |
| Executed (UTC) | 2026-08-12T12:22:39.556Z (response 12:22:40.277Z) |
| Hit count | 331 — read from esearchresult.count, not counted or computed |
| Records retrieved | 331 of 331 (idlist length 331 at retmax=1000) |
Query as executed:
query.intr=sacubitril valsartan OR LCZ696 query.cond=heart failure filter.overallStatus=COMPLETED|TERMINATED|ACTIVE_NOT_RECRUITING
| Endpoint | https://clinicaltrials.gov/api/v2/studies |
|---|---|
| Filters applied | only the registered filter.overallStatus; no language filter, no date filter |
| Executed (UTC) | 2026-08-12T12:26:16.427Z (response 12:26:16.604Z) |
| Hit count | 92 — read from totalCount, not counted or computed |
| Records retrieved | 92 of 92, via nextPageToken pagination |
Every string above is the string as executed, copied from the capture rather than from the protocol, so a reader can re-run it. Hit counts are the values the APIs returned (esearchresult.count and totalCount) and were not counted or computed here. Where the two differ from the registered strings, that would be recorded as a departure rather than silently reconciled.
Captured by: screener/searcher A (Claude, Anthropic family); a second cross-family screener runs separately. Source: evidence/2026-08-12/search-and-screening/01_SEARCH_CAPTURE.md.
In this section: Adjudication: ANSWER-HF · PARAGON-HF NCT01920711 · PMID 31475794 · PARADISE-MI NCT02924727 · PARAGLIDE-HF NCT03988634 · PMID 37212758 · ANSWER-HF NCT04853758 · PMID 41396086 · PIONEER-HF NCT02554890 · EVALUATE-HF NCT02874794 · OUTSTEP-HF NCT02900378 · Parallax NCT03066804 · HFN-LIFE NCT02816736 · Pathadka 2020 PMID 33553256 · Bano 2021 PMID 34395116 · Zhao 2022 PMID 35874853 · Li 2019 · Every record the search retrieved
Screener A said: excluded at stage 1 on the outcome axis, then held as undetermined. Resolved by named human adjudication — Mahmood Ahmad, 2026-08-13T13:55:30Z.
Screener A's exclusion and its subsequent undetermined holding both stand unaltered in the screening record. The adjudication overrides them; it does not erase them.
This review's decision: excluded.
Fails the frozen question on all three axes, and any one of them is sufficient. Population: it enrolled an ejection fraction of 45% or higher, which is preserved rather than reduced. Comparator: it randomised against valsartan, not enalapril. Measure: its primary is the cumulative number of cardiovascular deaths and total, first and recurrent, heart failure hospitalizations, analysed as a rate ratio.
What it actually reports: a rate ratio of 0.87 with a 95% interval of 0.75 to 1.01 for total heart failure hospitalizations and cardiovascular death
Why that is not this review's measure: A recurrent-event rate ratio counts repeat events per person over time; a time-to-first hazard ratio counts each person once, at their first event. The two share a scale and a direction and answer different questions, and storing this trial's 0.87 in a hazard-ratio field would be indistinguishable, to any reader and to most software, from a hazard ratio of 0.87. It is stored nowhere in this object except in this sentence.
This review's decision: excluded.
Population: acute myocardial infarction with left-ventricular dysfunction or pulmonary congestion, not chronic heart failure with reduced ejection fraction. Comparator: ramipril, not enalapril. Outcome: its composite counts incident heart failure -- a first presentation in people who did not have heart failure at randomisation -- which is not hospitalization for heart failure in an established heart failure population.
This review's decision: excluded.
Population: ejection fraction above 40% after a worsening heart failure event. Comparator: valsartan. Measure: the primary is the time-averaged proportional change in NT-proBNP, a biomarker ratio-of-change, and its hierarchical secondary is a win ratio. Neither is a hazard ratio for a clinical event.
What it actually reports: a ratio of change in NT-proBNP of 0.85 with a 95% interval of 0.73 to 0.999, and an unmatched win ratio of 1.19 with a 95% interval of 0.93 to 1.52
This review's decision: excluded.
This is the hardest exclusion in the table and the only one that passes the population and the comparator: 190 patients with heart failure with reduced ejection fraction due to Chagas cardiomyopathy, randomised double-blind against enalapril. It fails on the measure. Its primary endpoint is the change in left-ventricular ejection fraction at six months, and its only composite analysis of cardiovascular death and heart failure hospitalization is inside a hierarchical endpoint analysed by win ratio, reported as 1.80 with a 95% interval of 1.27 to 2.63. No time-to-first hazard ratio for the composite is separately reported. The registry record is consistent with all of this and posts no results of its own, which is why this row is sourced to the publication.
This review's decision: screened, not eligible.
Right population and right comparator -- acute decompensated heart failure with reduced ejection fraction, randomised against enalapril -- and the wrong quantity over the wrong horizon. The brief noted a conflict between a rule excluding follow-up under twelve weeks and a rule keyed to the trial's own endpoint, and left both standing. It is resolved here against the frozen question and only one rule survives: the trial is excluded because it reports no time-to-first hazard ratio for cardiovascular death or heart failure hospitalization, which is section 3.2.4, the outcome axis. Follow-up length is a consequence of that endpoint and is not an independent criterion in this object, because a short trial that did report the composite as a hazard ratio would be eligible and a long one that did not would still not be. Two rules that disagree are one object with two descriptions, which is the failure this batch has paid for before. [Upgraded 2026-08-13: this exclusion is now read at primary source rather than inferred. The trial methods define the composite as death, rehospitalisation for heart failure, lvad implantation, transplant listing, an unplanned acute heart failure visit, a diuretic dose increase over 50%, or an added heart failure drug, with Cox hazard ratios computed for that set. That is a broader composite than our estimand and includes all-cause rather than cardiovascular death.]
What it actually reports: the time-averaged proportional change in NT-proBNP over eight weeks
registry: https://clinicaltrials.gov/study/NCT02554890
| Evidence basis | Primary source read |
|---|---|
| Previously | third-party convergent inference |
| Upgraded (UTC) | 2026-08-13T08:25:07Z |
| What was read | the trial methods, endpoint definition, and analysis section of the primary publication |
| Citation | Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380(6):539-548. |
| Analysis the trial reports | Cox proportional-hazards ratios computed for that composite |
| Source | https://pubmed.ncbi.nlm.nih.gov/30415601/ |
The composite as the trial itself defines it:
Our frozen estimand is the time to a first event of cardiovascular death or hospitalisation for heart failure. The trial computes a hazard ratio, so the measure matches, but the composite it is computed over is a different and substantially broader event set: it counts all-cause death rather than cardiovascular death, and it adds four events that are not hospitalisations at all -- an lvad, a transplant listing, an unplanned outpatient visit, and two purely pharmacological events, a diuretic increase over 50% and the addition of another heart failure drug. A hazard ratio over that set is not an estimate of our quantity and pooling it would silently redefine the outcome.
The exclusion decision is unchanged. What changed is its basis: it previously rested on agreement between third-party sources about what the trial reported, and it now rests on the endpoint definition read in the trial methods. A decision that is right for a reason nobody checked is not the same as one that is right for a reason someone read.
This review's decision: screened, not eligible.
Randomised against enalapril in heart failure with reduced ejection fraction, and its endpoint is a vascular-mechanics measurement. It reports no hazard ratio for the composite.
What it actually reports: the change from baseline in aortic characteristic impedance at twelve weeks
This review's decision: screened, not eligible.
Randomised against enalapril in heart failure with reduced ejection fraction. Its endpoint is an activity measure, not a clinical event, and it reports no hazard ratio for the composite.
What it actually reports: change in daily physical activity measured by accelerometry
This review's decision: screened, not eligible.
Fails the population as well as the measure: it enrolled an ejection fraction above 40%, and its comparator is individualised medical therapy rather than enalapril alone.
What it actually reports: change in NT-proBNP and in six-minute walk distance
This review's decision: screened, not eligible.
Advanced, NYHA class IV heart failure, randomised against valsartan rather than enalapril, with a biomarker endpoint. Recorded because the brief listed a trial called life and this is the trial that name resolves .
What it actually reports: the area under the curve for NT-proBNP over twenty-four weeks
This review's decision: screened, not eligible.
This is the only excluded record in this object that reports the quantity this review pools, for the composite this review pools, and it is excluded anyway. It is not a randomised trial: it is a population-based new-user cohort drawn from the Hong Kong-wide electronic health record, 1056 people dispensed sacubitril/valsartan against 2181 dispensed enalapril, with treatment assigned by prescribers rather than by allocation. The frozen question is answered from randomised evidence only, so design decides this row before the endpoint is reached. Recording the endpoint anyway is deliberate: its 0.58 sits below the lower bound of this object's randomised pooled interval, so a reader can see what the design rule is holding out, rather than being asked to take the rule on trust. The prior meta-analysis that surfaced it reached the same decision from the other direction -- its own sensitivity analysis removes this study for being retrospective, and the heterogeneity of the pool it sat in falls from severe to none when it does.
What it actually reports: a hazard ratio of 0.58 with a 95% interval of 0.45 to 0.75 for the composite of cardiovascular mortality or heart-failure-related hospitalization, estimated by Cox regression with inverse-probability-of-treatment weighting
This review's decision: screened, not eligible.
Right population and right comparator: a randomised comparison of sacubitril/valsartan with enalapril, in equal allocation, in heart failure at a tertiary hospital in Pakistan, 181 against 183, followed for twelve months or to an event. It fails on the measure. Its full text contains no hazard ratio, no Cox model and no time-to-event analysis of any kind; it reports proportions and relative risk reductions, and it keeps hospitalization and death apart instead of combining them. Neither of those quantities can be converted into a time-to-first hazard ratio without the event times the paper does not report.
What it actually reports: heart-failure-related hospitalization as a proportion in each arm -- 13.8% against 22.4%, p = 0.03 -- with a relative risk reduction of 38.3% for hospitalization and of 52% for heart-failure-related death, the two counted separately rather than as one composite
This review's decision: screened, not eligible.
A randomised comparison of sacubitril/valsartan with enalapril, 52 against 45, in pulmonary hypertension due to heart failure with reduced ejection fraction, followed for six months. Population and comparator hold; the measure does not. Its declared primary endpoint is echocardiographic right-ventricular function, and it reports no hazard ratio for any clinical event -- it states only that readmission for recurrent heart failure did not differ. Worth recording how that was confirmed: the full text does contain four instances of the string "HR", and every one of them is the abbreviation for heart rate in a table of baseline characteristics. A search for the quantity rather than for the string is the reason this row says no hazard ratio instead of the reverse.
What it actually reports: right-ventricular function at six months -- tricuspid annular plane systolic excursion, systolic pulmonary artery pressure and their ratio -- as means with standard deviations, alongside major adverse cardiac events given as counts per arm
This review's decision: screened, eligibility could not be established.
Eligibility is undetermined, not decided. Neither inclusion nor exclusion is asserted here, and the trial is not pooled -- so this row records a limit of the search rather than a judgement about the trial. Its likely weight is small and is stated rather than used as a reason to stop looking: 126 randomised participants against the 8399 of the largest trial already pooled. If this trial does report the composite as a time-to-first hazard ratio, this object is missing it, and this row is the place that will say so.
What it actually reports: Not established, and this row links the only document in which this trial was actually read. What that document states is that it is a randomised trial of sacubitril/valsartan against enalapril in elderly patients with dilated cardiomyopathy, 62 against 64, followed for six months, and that it contributed to that review's all-cause mortality pool, which that review analysed as a dichotomous risk ratio rather than as a time-to-event quantity. What could not be established is what the trial itself reports, because the trial itself could not be retrieved: it is cited to Chinese Journal of Geriatrics 2019, pages 520 to 524, with no DOI to resolve; a PubMed search returns no record for it, and a Crossref bibliographic query returns no matching work. All three were tried on the date in this row. It is therefore recorded as undetermined rather than assigned the exclusion its neighbours received -- an earlier version of the reconciliation block did assert that it reports no time-to-first hazard ratio, which nothing staged supported then and nothing supports now.
prior_meta: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710849/
Every record the registered search retrieved, listed individually with the decision, the stage at which it was taken, and for an exclusion the axis it failed and the quantity it reports instead. Exclusions are on the outcome axis as often as on quality, which is what the pre-registered estimand criterion produces: a large, well-conducted, on-topic trial is excluded when it reports something that cannot be converted into a time-to-first-event hazard ratio. Two records are undetermined, not excluded.
| FullText/INCLUDE | 7 |
|---|---|
| FullText/exclude | 2 |
| TiAb/exclude | 412 |
| TiAb/undetermined | 2 |
| Source | Record | Title | Stage | Decision | Axis failed | What it reports instead |
|---|---|---|---|---|---|---|
| PubMed | 42542200 | Impact of estimated total blood volume on NT-proBNP response to angiotensin receptor-neprilysin inhibition in acute heart failure: insights from the premier study American heart journal 2026 | TiAb | exclude | COMPARATOR | NT-proBNP response; Premier randomised against standard treatment, not enalapril |
| PubMed | 42382224 | Provider Preferences About a Polypill for Heart Failure With Reduced Ejection Fraction: Development of a Multicenter Physician Survey Containing a Discrete Choice Experiment Journal of cardiac failure - intersections 2026 | TiAb | exclude | RANDOMISATION | discrete-choice preference weights |
| PubMed | 42211603 | Expert Opinion on Optimising Guideline-Directed Medical Therapy and Expanding the Role of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) for Heart Failure Management in India Cureus 2026 | TiAb | exclude | RANDOMISATION | narrative expert opinion |
| PubMed | 41923142 | Sacubitril/Valsartan Versus Enalapril in Chagas Cardiomyopathy With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis Cardiology in review 2026 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 41912806 | The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial Nature medicine 2026 | TiAb | exclude | INTERVENTION | XXB750 is the intervention; sacubitril/valsartan is an active reference arm |
| PubMed | 41910669 | You evaluation of the PARACHUTE-HF trial: role of sacubitril/valsartan compared to enalapril on outcomes in patients with heart failure from Chagas disease Heart failure reviews 2026 | TiAb | exclude | RANDOMISATION | narrative commentary on PARACHUTE-HF |
| PubMed | 41870675 | ANSWER-HF: sacubitril-valsartan reduces NT-proBNP in heart failure due to Chagas cardiomyopathy despite no reverse remodeling Heart failure reviews 2026 | TiAb | exclude | RANDOMISATION | narrative commentary on ANSWER-HF |
| PubMed | 41773097 | Efficacy and Safety of Sacubitril/Valsartan Versus Enalapril in the Treatment of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis Cureus 2026 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 41725865 | Challenges in managing pediatric heart failure, especially in resource-limited settings Annals of pediatric cardiology 2025 | TiAb | exclude | RANDOMISATION | editorial narrative |
| PubMed | 41501364 | Early drop in blood pressure following angiotensin receptor-neprilysin inhibitor initiation in decompensated heart failure Hypertension research 2026 | TiAb | exclude | RANDOMISATION | observational blood-pressure change |
| PubMed | 41396086 | Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial Journal of the American College of Cardiology 2026 | FullText | INCLUDE | — | |
| PubMed | 41335448 | Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial (PARACHUTE-HF) Jama 2026 | FullText | INCLUDE | — | |
| PubMed | 41085477 | Reply to the letter regarding the article Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial European journal of heart failure 2025 | TiAb | exclude | RANDOMISATION | correspondence |
| PubMed | 41085412 | Letter regarding the article Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial European journal of heart failure 2025 | TiAb | exclude | RANDOMISATION | correspondence |
| PubMed | 40916703 | Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial European journal of heart failure 2025 | TiAb | exclude | OUTCOME | baseline characteristics only; no effect estimate of any kind |
| PubMed | 40839760 | Sacubitril/valsartan and quality of life assessed using the EQ-5D-3L level sum score in patients with HFrEF and HFmrEF/HFpEF European heart journal. Cardiovascular pharmacotherapy 2025 | TiAb | exclude | OUTCOME | EQ-5D-3L level sum score change |
| PubMed | 40835369 | Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines Journal of the American College of Cardiology 2025 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 40755965 | Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi/ARB: a systematic review and meta-analysis Clinical kidney journal 2025 | TiAb | exclude | RANDOMISATION | pooled renal outcome estimates |
| PubMed | 40678912 | Changes in cardiac structure and function are associated with health-related quality of life in HFrEF: Results from the EVALUATE-HF trial European journal of heart failure 2025 | TiAb | exclude | OUTCOME | association between echocardiographic change and KCCQ score |
| PubMed | 40510943 | Evaluation of the 6-Month Effect of Sacubitril-Valsartan Compared to ACEI and ARB on LVEF in Heart Failure Patients: A Double-Blind Randomized Clinical Trial Journal of pharmacy and bioallied sciences 2025 | TiAb | exclude | OUTCOME | change in LVEF at 6 months |
| PubMed | 40450497 | Effects of Sacubitril/Valsartan on Renal Function in Adults With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Heart, lung and circulation 2025 | TiAb | exclude | RANDOMISATION | pooled renal function estimates |
| PubMed | 40389107 | Uptitration of Sacubitril/Valsartan in Acute Heart Failure: Insight from the premier Study Journal of cardiac failure 2026 | TiAb | exclude | COMPARATOR | Premier randomised against standard treatment, not enalapril |
| PubMed | 40353367 | Association between NT-proBNP changes and clinical outcomes in paediatric patients with heart failure: Insights from PANORAMA-HF and PARADIGM-HF ESC heart failure 2025 | TiAb | exclude | OUTCOME | association between NT-proBNP change and outcomes |
| PubMed | 40319618 | Cost-Effectiveness Analysis of ARNI Compared With ACEI Among Patients With HFrEF in Malaysia Value in health regional issues 2025 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 40268473 | Effects of Sacubitril/Valsartan on Myocardial Tissue in Heart Failure With Left Ventricular Ejection Fraction Below 50 Circulation journal 2025 | TiAb | exclude | OUTCOME | myocardial tissue characterisation measures |
| PubMed | 40265590 | Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With HFrEF in PARADIGM-HF Journal of the American Heart Association 2025 | TiAb | exclude | OUTCOME | sex-subgroup hazard ratios, not the trial-level estimand; secondary report of PARADIGM-HF |
| PubMed | 40088233 | Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF Jacc. Heart failure 2025 | TiAb | exclude | OUTCOME | natriuretic-peptide subgroup estimates pooled across an HFrEF and an HFpEF trial |
| PubMed | 39970741 | Sacubitril/Valsartan vs ACE Inhibitors or ARBs: A Systematic Review and Meta-Analysis of Randomized Trials Jacc. Advances 2025 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 39927747 | Impact of heart failure medications on cognitive function: A systematic review European journal of clinical investigation 2025 | TiAb | exclude | RANDOMISATION | narrative synthesis of cognitive outcomes |
| PubMed | 39888167 | Real-world comparative effectiveness of sacubitril/valsartan versus RAS inhibition alone in patients with de novo heart failure ESC heart failure 2025 | TiAb | exclude | RANDOMISATION | adjusted estimates from a non-randomised cohort |
| PubMed | 39792134 | Sacubitril/valsartan versus valsartan initiation in patients naive to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF European journal of heart failure 2025 | TiAb | exclude | COMPARATOR | comparator is valsartan |
| PubMed | 39661383 | Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure Jama cardiology 2025 | TiAb | exclude | RANDOMISATION | prescribing proportions |
| PubMed | 39563094 | Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with HFrEF: Insights from PARADIGM-HF European journal of heart failure 2025 | TiAb | exclude | OUTCOME | background-therapy subgroup estimates; secondary report of PARADIGM-HF |
| PubMed | 39544776 | Enhancing ventricular remodeling and cardiac function in post-acute myocardial infarction with sacubitril/valsartan American journal of translational research 2024 | TiAb | exclude | POPULATION | post-acute myocardial infarction, not chronic HFrEF |
| PubMed | 39473218 | The in-hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta-analysis ESC heart failure 2025 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 39439294 | Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of PARADIGM-HF and PARAGON-HF European journal of heart failure 2025 | TiAb | exclude | OUTCOME | heart-rate change and its association with outcome |
| PubMed | 39387766 | Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF Trials Jacc. Heart failure 2025 | TiAb | exclude | OUTCOME | race-subgroup estimates pooled across an HFrEF and an HFpEF trial |
| PubMed | 39320292 | Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in HFrEF in PARADIGM-HF Journal of the American College of Cardiology 2024 | TiAb | exclude | OUTCOME | hypotension event rates |
| PubMed | 39319469 | Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial Circulation 2024 | FullText | exclude | POPULATION | children 1 month to <18 years. Also fails outcome: global rank endpoint, Mann-Whitney probability 0.52 (0.47-0.58), MW odds 0.91 (0.72-1.14). |
| PubMed | 39284545 | Incidence and risk factors of hypotension-related adverse events among Japanese patients receiving sacubitril/valsartan or enalapril: PARALLEL-HF Journal of cardiology 2025 | TiAb | exclude | OUTCOME | hypotension-related adverse event incidence |
| PubMed | 39262640 | Influenza Vaccination and Cardiovascular Events in Japanese Patients With Heart Failure - Findings From the PARALLEL-HF Trial Circulation reports 2024 | TiAb | exclude | OUTCOME | vaccination-stratified event rates |
| PubMed | 39260836 | Comparative effects of sacubitril/valsartan and ACEI/ARB on endothelial function and arterial stiffness: a protocol for systematic review and meta-analysis BMJ open 2024 | TiAb | exclude | RANDOMISATION | protocol for a synthesis; no results |
| PubMed | 39217458 | Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: IPD Analysis of 6 Randomized Clinical Trials Circulation 2024 | TiAb | exclude | OUTCOME | standardised kidney composite outcomes |
| PubMed | 39215531 | In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the premier trial European heart journal 2024 | TiAb | exclude | COMPARATOR | randomised against standard treatment, not enalapril |
| PubMed | 39210725 | Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of PARADIGM-HF and PARAGON-HF Jama cardiology 2024 | TiAb | exclude | OUTCOME | all-cause hospitalisation rates |
| PubMed | 39163041 | Sacubitril-Valsartan in Patients Requiring Hemodialysis Jama network open 2024 | TiAb | exclude | POPULATION | haemodialysis population |
| PubMed | 39111953 | Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial Jacc. Heart failure 2024 | TiAb | exclude | OUTCOME | trial design description; no effect estimate |
| PubMed | 38938237 | Sacubitril/Valsartan and Cognitive Outcomes in Heart Failure With Reduced Ejection Fraction Jacc. Advances 2023 | TiAb | exclude | OUTCOME | cognitive outcome measures |
| PubMed | 38904251 | Aptamer Proteomics for Biomarker Discovery in HFpEF: The PARAGON-HF Proteomic Substudy Journal of the American Heart Association 2024 | TiAb | exclude | POPULATION | HFpEF |
| PubMed | 38863978 | Effect of sacubitril-valsartan on left ventricular remodeling in patients with acute myocardial infarction after primary PCI: a systematic review and meta-analysis Frontiers in pharmacology 2024 | TiAb | exclude | RANDOMISATION | pooled remodelling estimates |
| PubMed | 38842957 | Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2 Jacc. Heart failure 2024 | TiAb | exclude | OUTCOME | renal-function subgroup estimates |
| PubMed | 38764991 | Is Sacubitril/Valsartan a Superior Agent in Heart Failure With Reduced Ejection Fraction? A Review of Randomized Comparative Trials Hospital pharmacy 2024 | TiAb | exclude | RANDOMISATION | narrative review of trials |
| PubMed | 38705701 | Sacubitril-valsartan vs ACE/ARB in pediatric heart failure: A retrospective cohort study Journal of heart and lung transplantation 2024 | TiAb | exclude | RANDOMISATION | retrospective cohort estimates |
| PubMed | 38635062 | Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in AMI complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial Heart and vessels 2024 | TiAb | exclude | POPULATION | acute myocardial infarction with mitral regurgitation |
| PubMed | 38597935 | Sacubitril/valsartan compared to equivalent/sub-equivalent dose ARB or ACEI in HFrEF: a meta-analysis of randomized trials European journal of clinical pharmacology 2024 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 38588927 | Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure Journal of the American College of Cardiology 2024 | TiAb | exclude | OUTCOME | renal-function subgroup estimates |
| PubMed | 38508844 | Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure Journal of the American College of Cardiology 2024 | TiAb | undetermined | — | title does not name comparator or reported quantity; abstract not retrieved before the ClinicalTrials.gov 429 halt. Carried to full text. |
| PubMed | 38465175 | The Safety and Efficacy of the Early Use of Sacubitril/Valsartan After Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials Cureus 2024 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 38216822 | Add-on Sacubitril/Valsartan Therapy Induces Left Ventricular Remodeling in Non-responders to Cardiac Resynchronization Therapy Cardiology and therapy 2024 | TiAb | exclude | COMPARATOR | no enalapril comparator; add-on design |
| PubMed | 38134075 | Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia Medicine 2023 | TiAb | exclude | RANDOMISATION | descriptive real-world statistics |
| PubMed | 37989299 | Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients According to Baseline Systolic Blood Pressure - Subgroup Analysis of PARALLEL-HF Circulation journal 2023 | TiAb | exclude | OUTCOME | blood-pressure subgroup estimates; secondary report of PARALLEL-HF |
| PubMed | 37917889 | Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis Alternative therapies in health and medicine 2024 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 37619492 | Angiotensin Receptor-Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials The American journal of cardiology 2023 | TiAb | exclude | RANDOMISATION | pooled ascvd event estimates |
| PubMed | 37601056 | The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis Frontiers in pharmacology 2023 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 37554618 | Effects of Angiotensin Receptor-Neprilysin Inhibitors Versus Enalapril or Valsartan on Patients With Heart Failure: A Systematic Review and Meta-Analysis Cureus 2023 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 37427009 | Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction Cardiac failure review 2023 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 37407154 | Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan Jacc. Heart failure 2023 | TiAb | exclude | OUTCOME | anaemia incidence and prevalence |
| PubMed | 37313196 | Efficacy and safety of sacubitril/valsartan in heart failure compared to renin-angiotensin-aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials Archives of medical science 2023 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 37195574 | The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis International urology and nephrology 2024 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 37077749 | Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with ACEI and spironolactone Frontiers in cardiovascular medicine 2023 | TiAb | exclude | OUTCOME | echocardiographic reverse-remodelling measures |
| PubMed | 37000983 | Effects of Sacubitril-Valsartan in Patients With Various Types of Heart Failure: A Meta-analysis Journal of cardiovascular pharmacology 2023 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 36943907 | Urinary cGMP/BNP Ratio, Sacubitril/Valsartan, and Outcomes in HFrEF: An Analysis of the PARADIGM-HF Trial Circulation. Heart failure 2023 | TiAb | exclude | OUTCOME | biomarker ratio and its association with outcome |
| PubMed | 36874318 | The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With HFrEF Cureus 2023 | TiAb | exclude | OUTCOME | ventricular arrhythmia burden |
| PubMed | 36871177 | Effect of sacubitril-valsartan on the incidence of atrial fibrillation: A meta-analysis Journal of cardiovascular electrophysiology 2023 | TiAb | exclude | RANDOMISATION | pooled atrial fibrillation incidence |
| PubMed | 36812948 | Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure Journal of the American College of Cardiology 2023 | TiAb | exclude | OUTCOME | renal function change |
| PubMed | 36808581 | Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in HFrEF in Argentina Health economics review 2023 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 36712243 | Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction Frontiers in cardiovascular medicine 2022 | TiAb | exclude | POPULATION | acute myocardial infarction |
| PubMed | 36609948 | Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease Cardiovascular drugs and therapy 2024 | TiAb | exclude | RANDOMISATION | adjusted estimates from a comparative non-randomised study |
| PubMed | 36601956 | Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial Circulation. Heart failure 2023 | TiAb | exclude | POPULATION | paediatric population |
| PubMed | 36561058 | Effectiveness of sacubitril-valsartan versus ACE inhibitors in patients hospitalized for acute heart failure: a retrospective cohort study of the rica registry Journal of geriatric cardiology 2022 | TiAb | exclude | RANDOMISATION | retrospective registry estimates |
| PubMed | 36530836 | Effects of Sacubitril/Valsartan on Glycemic Control in Japanese Patients With Heart Failure and/or Hypertension Circulation reports 2022 | TiAb | exclude | OUTCOME | glycaemic measures |
| PubMed | 36527023 | Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials BMC medicine 2022 | TiAb | exclude | RANDOMISATION | pooled glycaemic estimates |
| PubMed | 36475871 | Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis The Annals of pharmacotherapy 2023 | TiAb | exclude | RANDOMISATION | pooled quality-of-life estimates |
| PubMed | 36404386 | Estimating the Time to Benefit for Therapies in HFrEF: A Case Study of Sacubitril-Valsartan Using Reconstructed Data from a Randomized Controlled Trial Drugs and aging 2022 | TiAb | exclude | OUTCOME | time-to-benefit estimate reconstructed from published curves |
| PubMed | 36304540 | A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction Frontiers in cardiovascular medicine 2022 | TiAb | exclude | RANDOMISATION | pooled remodelling estimates |
| PubMed | 36148074 | Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials Frontiers in cardiovascular medicine 2022 | TiAb | exclude | RANDOMISATION | pooled arrhythmia and sudden-death estimates |
| PubMed | 36132549 | The Relationship between Angiotensin-Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure (retracted) Computational and mathematical methods in medicine 2022 | TiAb | exclude | POPULATION | HFpEF; record is a retracted publication |
| PubMed | 36062622 | Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease Journal of the American Heart Association 2022 | TiAb | exclude | POPULATION | end-stage kidney disease |
| PubMed | 35990952 | Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials Frontiers in cardiovascular medicine 2022 | TiAb | exclude | RANDOMISATION | pooled quality-of-life estimates |
| PubMed | 35921043 | Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials ESC heart failure 2022 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 35874853 | The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction Pulmonary circulation 2022 | TiAb | exclude | OUTCOME | pulmonary haemodynamic measures |
| PubMed | 35859597 | Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Frontiers in cardiovascular medicine 2022 | TiAb | exclude | RANDOMISATION | pooled arrhythmia estimates |
| PubMed | 35772853 | Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the life Trial Run-In Jacc. Heart failure 2022 | TiAb | exclude | COMPARATOR | Life randomised against valsartan; this record reports run-in tolerability |
| PubMed | 35761118 | The Prevalence of Adverse Drug Reactions and Adverse Drug Events from Heart Failure Medications in Frail Older Adults: A Systematic Review Drugs and aging 2022 | TiAb | exclude | RANDOMISATION | pooled adverse-event prevalence |
| PubMed | 35717169 | Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials Cardiovascular diabetology 2022 | TiAb | exclude | OUTCOME | glycaemic measures |
| PubMed | 35654526 | Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF Jacc. Heart failure 2022 | TiAb | exclude | OUTCOME | diuretic-use subgroup estimates |
| PubMed | 35560696 | Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in HFrEF: the EVALUATE-HF trial European journal of heart failure 2022 | TiAb | exclude | OUTCOME | biomarker and echocardiographic change |
| PubMed | 35523577 | Angiotensin-converting enzyme inhibitor therapy after heart transplant: From molecular basis to clinical effects Clinical transplantation 2022 | TiAb | exclude | POPULATION | heart transplant recipients |
| PubMed | 35469709 | Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: Position Paper of the Italian Society of Cardiology European journal of internal medicine 2022 | TiAb | exclude | RANDOMISATION | consensus statement |
| PubMed | 35400328 | Effects of Sacubitril/Valsartan Versus Telmisartan in Type 2 Diabetic or Pre-Diabetic Patients with Hypertension and Without Heart Failure: Rationale and Design Cardiovascular and hematological disorders drug targets 2022 | TiAb | exclude | POPULATION | hypertension without heart failure |
| PubMed | 35343504 | Position paper of the Italian Society of Cardiology: Raas blockade in heart failure patients - Part I (Italian) Giornale italiano di cardiologia 2022 | TiAb | exclude | RANDOMISATION | consensus statement |
| PubMed | 35282662 | Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial Cardiovascular diagnosis and therapy 2022 | TiAb | exclude | POPULATION | acute anterior STEMI, not chronic HFrEF |
| PubMed | 35222898 | The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, apn, mmp-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure Journal of healthcare engineering 2022 | TiAb | exclude | COMPARATOR | comparator is valsartan |
| PubMed | 35200707 | What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies Journal of cardiovascular development and disease 2022 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 35081164 | Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials PloS one 2022 | TiAb | exclude | RANDOMISATION | pooled atrial fibrillation estimates |
| PubMed | 35035857 | Effects and Safety of Sacubitril/Valsartan for Patients with Myocardial Infarction: A Systematic Review and Meta-Analysis (retracted) Journal of healthcare engineering 2022 | TiAb | exclude | RANDOMISATION | pooled estimate; record is a retracted publication |
| PubMed | 35027945 | Long-Term Mortality and Morbidity Related to CHFrEF in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study Journal of the renin-angiotensin-aldosterone system 2021 | TiAb | exclude | RANDOMISATION | single-arm pilot statistics |
| PubMed | 34988519 | Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement Heart rhythm O2 2021 | TiAb | exclude | RANDOMISATION | descriptive prescribing statistics |
| PubMed | 34969175 | Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF European journal of heart failure 2022 | TiAb | exclude | OUTCOME | ventricular arrhythmia event estimates |
| PubMed | 34889576 | Variation in early diffusion of sacubitril/valsartan and implications for understanding novel drug diffusion The American journal of managed care 2021 | TiAb | exclude | RANDOMISATION | prescribing diffusion statistics |
| PubMed | 34797518 | Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis Clinical drug investigation 2022 | TiAb | exclude | RANDOMISATION | network meta-analysis estimates |
| PubMed | 34783839 | Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in HFpEF: The parallax Randomized Clinical Trial Jama 2021 | TiAb | exclude | COMPARATOR | comparator is individualised standard medical therapy; population HFpEF |
| PubMed | 34758252 | Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction (PARADISE-MI) The New England journal of medicine 2021 | TiAb | exclude | COMPARATOR | comparator is ramipril; population acute myocardial infarction |
| PubMed | 34716749 | The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis ESC heart failure 2021 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 34703947 | The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with HFrEF Archives of medical sciences. Atherosclerotic diseases 2021 | TiAb | exclude | INTERVENTION | intervention is dapagliflozin |
| PubMed | 34675566 | Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia ClinicoEconomics and outcomes research 2021 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 34668596 | Rationale and design of a multi-center randomized controlled trial on sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study Clinical cardiology 2021 | TiAb | exclude | POPULATION | ST-elevation myocardial infarction |
| PubMed | 34645527 | Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data Cardio-oncology 2021 | TiAb | exclude | RANDOMISATION | real-world descriptive statistics |
| PubMed | 34617669 | Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis Pharmacology research and perspectives 2021 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 34591356 | A randomized clinical trial on the short-term effects of 12-week sacubitril/valsartan vs enalapril on peak oxygen consumption in HFrEF: the ACTIVITY-HF study European journal of heart failure 2021 | TiAb | exclude | OUTCOME | peak oxygen consumption |
| PubMed | 34570120 | Anmco Position paper: Use of sacubitril/valsartan in hospitalized patients with acute heart failure (Italian) Giornale italiano di cardiologia 2021 | TiAb | exclude | RANDOMISATION | consensus statement |
| PubMed | 34464468 | Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis Clinical cardiology 2021 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 34456644 | Anmco position paper: Use of sacubitril/valsartan in hospitalized patients with acute heart failure European heart journal supplements 2021 | TiAb | exclude | RANDOMISATION | consensus statement |
| PubMed | 34428592 | Sleep Outcomes From AWAKE-HF: A Randomized Clinical Trial of Sacubitril/Valsartan vs Enalapril in Patients With HFrEF Journal of cardiac failure 2021 | TiAb | exclude | OUTCOME | accelerometer-derived sleep measures |
| PubMed | 34402869 | Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis European journal of preventive cardiology 2021 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 34395116 | Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure Cureus 2021 | TiAb | undetermined | — | title names the right comparison but neither design nor reported quantity is determinable from it; abstract not retrieved before the halt. Carried to full text. |
| PubMed | 34350772 | Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Journal of the American Heart Association 2021 | TiAb | exclude | RANDOMISATION | observational effectiveness estimates |
| PubMed | 34125356 | Five Years of Sacubitril/Valsartan - a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance Cardiovascular drugs and therapy 2022 | TiAb | exclude | RANDOMISATION | pooled safety estimates and pharmacovigilance signals |
| PubMed | 34101308 | Effect of sacubitril/valsartan vs enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial European journal of heart failure 2021 | TiAb | exclude | OUTCOME | changes in background heart failure therapy over time |
| PubMed | 34101002 | Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and atmosphere Clinical research in cardiology 2021 | TiAb | exclude | OUTCOME | prognostic model discrimination and calibration |
| PubMed | 33997628 | Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or ACEI/ARB Mayo Clinic proceedings. Innovations, quality and outcomes 2021 | TiAb | exclude | RANDOMISATION | observational renal outcome estimates |
| PubMed | 33992607 | Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study American heart journal 2021 | TiAb | exclude | OUTCOME | exercise capacity (peak VO2 / 6-minute walk) |
| PubMed | 33984319 | Days alive out of hospital in heart failure: Insights from the PARADIGM-HF and charm trials American heart journal 2021 | TiAb | exclude | OUTCOME | days alive and out of hospital |
| PubMed | 33931815 | Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper Heart failure reviews 2022 | TiAb | exclude | RANDOMISATION | consensus statement |
| PubMed | 33929386 | Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials Journal of cardiovascular pharmacology 2021 | TiAb | exclude | RANDOMISATION | pooled adverse-event estimates |
| PubMed | 33879733 | A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial Medicine 2021 | TiAb | exclude | INTERVENTION | sequential recombinant human BNP strategy; no enalapril comparator |
| PubMed | 33850915 | Narrative review in the current role of angiotensin receptor-neprilysin inhibitors Annals of translational medicine 2021 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 33847047 | Prospective ARNI vs ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics European journal of heart failure 2021 | TiAb | exclude | COMPARATOR | comparator is ramipril; population acute myocardial infarction |
| PubMed | 33822031 | Renal protection in chronic heart failure: focus on sacubitril/valsartan European heart journal. Cardiovascular pharmacotherapy 2021 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 33733623 | The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long-term studies ESC heart failure 2021 | TiAb | exclude | OUTCOME | restricted mean survival time (methodological paper) |
| PubMed | 33731544 | Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study Circulation journal 2021 | FullText | INCLUDE | — | Meets all four. Randomised 1:1; 225 Japanese adults NYHA ii-iv LVEF<=35%; sacubitril/valsartan 200 mg bid vs enalapril 10 mg bid; composite of CV death or HF hospitalisation as hazard ratio 1.09 (95% CI 0.65-1.82), P=0.6260, median follow-up 33.9 months. |
| PubMed | 33663237 | Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study Circulation. Heart failure 2021 | TiAb | exclude | OUTCOME | haemodynamic and aortic stiffness measures |
| PubMed | 33624080 | Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure European journal of preventive cardiology 2021 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 33545266 | Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review International journal of cardiology 2021 | TiAb | exclude | RANDOMISATION | synthesis of observational studies |
| PubMed | 33530704 | Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial Circulation. Heart failure 2021 | TiAb | exclude | OUTCOME | time-averaged proportional change in NT-proBNP |
| PubMed | 33522249 | Clinical Characteristics and Outcomes of Patients With HFrEF and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF Journal of the American Heart Association 2021 | TiAb | exclude | OUTCOME | COPD subgroup estimates |
| PubMed | 33489085 | Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control Therapeutic advances in endocrinology and metabolism 2020 | TiAb | exclude | RANDOMISATION | narrative mechanistic review |
| PubMed | 33357641 | Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study Indian heart journal 2020 | TiAb | exclude | OUTCOME | regional subgroup estimates; secondary report of PARADIGM-HF |
| PubMed | 33314487 | OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in HFrEF European journal of heart failure 2021 | TiAb | exclude | OUTCOME | accelerometer-measured daily physical activity |
| PubMed | 33305513 | Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling ESC heart failure 2021 | TiAb | exclude | OUTCOME | left ventricular remodelling measures |
| PubMed | 33301829 | Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence International journal of cardiology 2021 | TiAb | exclude | RANDOMISATION | narrative viewpoint |
| PubMed | 33292750 | Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy Cardio-oncology 2020 | TiAb | exclude | POPULATION | chemotherapy-induced cardiotoxicity |
| PubMed | 33277825 | Heart failure in the last year: progress and perspective ESC heart failure 2020 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 33257469 | Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis Open heart 2020 | TiAb | exclude | RANDOMISATION | pooled estimate with trial sequential analysis |
| PubMed | 33211601 | Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction Journal of applied physiology 2021 | TiAb | exclude | OUTCOME | vascular function and inflammatory markers |
| PubMed | 33189630 | Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction Jacc. Heart failure 2021 | TiAb | exclude | RANDOMISATION | observational health-status change |
| PubMed | 33155868 | Association of Sacubitril/Valsartan with Metabolic Parameters in Patients with Reduced Ejection Fraction Heart Failure at a Multidisciplinary Clinic Metabolic syndrome and related disorders 2021 | TiAb | exclude | RANDOMISATION | observational metabolic parameter change |
| PubMed | 33068250 | Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study Internal and emergency medicine 2021 | TiAb | exclude | RANDOMISATION | observational management statistics |
| PubMed | 33039448 | Estimating the Lifetime Benefits of Treatments for Heart Failure Jacc. Heart failure 2020 | TiAb | exclude | OUTCOME | projected event-free survival gain |
| PubMed | 32978755 | The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure American journal of cardiovascular drugs 2021 | TiAb | exclude | OUTCOME | accelerometer-measured activity and sleep |
| PubMed | 32977362 | Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials ESC heart failure 2020 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 32945737 | Alternative payment models and innovation: a case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure Journal of medical economics 2020 | TiAb | exclude | RANDOMISATION | health-system adoption case study |
| PubMed | 32919915 | Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial Jacc. Heart failure 2020 | TiAb | exclude | OUTCOME | NT-proBNP change by race subgroup |
| PubMed | 32919914 | Similar Yet Different: Examining the Effects of Sacubitril/Valsartan by Race in the PIONEER-HF Trial Jacc. Heart failure 2020 | TiAb | exclude | RANDOMISATION | editorial comment |
| PubMed | 32868662 | Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention Coronary artery disease 2021 | TiAb | exclude | POPULATION | ST-elevation myocardial infarction |
| PubMed | 32854838 | Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists Journal of the American College of Cardiology 2020 | TiAb | exclude | OUTCOME | subgroup estimates by prior therapy history |
| PubMed | 32848403 | Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data Therapeutics and clinical risk management 2020 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 32809261 | Serum potassium in the PARADIGM-HF trial European journal of heart failure 2020 | TiAb | exclude | OUTCOME | serum potassium and hyperkalaemia rates |
| PubMed | 32801725 | Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date Therapeutics and clinical risk management 2020 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 32800511 | Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial Jacc. Heart failure 2020 | TiAb | exclude | OUTCOME | NT-proBNP change by achieved dose |
| PubMed | 32800508 | NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: Transition Study Jacc. Heart failure 2020 | TiAb | exclude | COMPARATOR | pre-discharge vs post-discharge initiation; no enalapril comparator. Reports NT-proBNP response. |
| PubMed | 32739172 | Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis European journal of pharmacology 2020 | TiAb | exclude | RANDOMISATION | pooled estimate across trials |
| PubMed | 32648251 | Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure Cardiology journal 2020 | TiAb | exclude | RANDOMISATION | feasibility and tolerability proportions |
| PubMed | 32641226 | Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the life Trial Jacc. Heart failure 2020 | TiAb | exclude | COMPARATOR | comparator is valsartan |
| PubMed | 32468672 | Rationale and study design of OUTSTEP-HF: a randomised controlled study to assess the effect of sacubitril/valsartan and enalapril on physical activity measured by accelerometry in HFrEF European journal of heart failure 2020 | TiAb | exclude | OUTCOME | accelerometer-measured physical activity |
| PubMed | 32466836 | Use of the Win Ratio in Cardiovascular Trials Jacc. Heart failure 2020 | TiAb | exclude | OUTCOME | win ratio (methodological paper) |
| PubMed | 32407608 | Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction European journal of heart failure 2020 | TiAb | exclude | OUTCOME | liver-function subgroup and prognostic estimates |
| PubMed | 32369265 | Introduction of sacubitril/valsartan in primary care follow-up of heart failure: a prospective observational study (theseus) ESC heart failure 2020 | TiAb | exclude | RANDOMISATION | prospective observational statistics |
| PubMed | 32297449 | Angiotensin receptor neprilysin inhibition versus individualized raas blockade: design and rationale of the parallax trial ESC heart failure 2020 | TiAb | exclude | COMPARATOR | comparator is individualised raas blockade |
| PubMed | 32259909 | LCZ696 and preservation of renal function in heart failure: A meta-analysis of 6 randomized trials Reviews in cardiovascular medicine 2020 | TiAb | exclude | RANDOMISATION | pooled renal estimates |
| PubMed | 32248695 | Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction Circulation. Heart failure 2020 | TiAb | exclude | RANDOMISATION | representativeness proportions |
| PubMed | 32221582 | Effects of dapagliflozin in DAPA-HF according to background heart failure therapy European heart journal 2020 | TiAb | exclude | INTERVENTION | intervention is dapagliflozin |
| PubMed | 36263291 | Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure International journal of heart failure 2020 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 32153122 | Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease ESC heart failure 2020 | TiAb | exclude | POPULATION | end-stage renal disease |
| PubMed | 32128057 | Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital Journal of community hospital internal medicine perspectives 2020 | TiAb | exclude | RANDOMISATION | single-centre tolerability proportions |
| PubMed | 32021227 | Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan Vascular health and risk management 2020 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 32000355 | New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis Medicine 2020 | TiAb | exclude | RANDOMISATION | Bayesian network meta-analysis estimates |
| PubMed | 31997538 | Highlights in heart failure ESC heart failure 2019 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 31995119 | Prognostic Models Derived in PARADIGM-HF and Validated in atmosphere and the Swedish Heart Failure Registry Jama cardiology 2020 | TiAb | exclude | OUTCOME | prognostic model performance |
| PubMed | 31906682 | Innovations in pharmacological treatment of heart failure (Czech) Vnitrni lekarstvi 2019 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 31838035 | Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction Jacc. Heart failure 2020 | TiAb | exclude | RANDOMISATION | observational comparative effectiveness estimates |
| PubMed | 31825471 | Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial Jama cardiology 2020 | TiAb | exclude | OUTCOME | NT-proBNP change in open-label extension |
| PubMed | 31789711 | The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016 Journal of cardiovascular medicine 2020 | TiAb | exclude | RANDOMISATION | eligibility proportions in a cohort |
| PubMed | 31772612 | LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model Cardiovascular therapeutics 2019 | TiAb | exclude | POPULATION | rat model, not adult humans |
| PubMed | 36262737 | Real-World Eligibility for Sacubitril/Valsartan in HFrEF Patients in Korea: Data from the Korean Acute Heart Failure (KorAHF) Registry International journal of heart failure 2019 | TiAb | exclude | RANDOMISATION | registry eligibility proportions |
| PubMed | 31638338 | Activity Sensors to Evaluate the Effect of Sacubitril/Valsartan on Quality-of-Life in Heart Failure: rationale and design of the AWAKE-HF study ESC heart failure 2019 | TiAb | exclude | OUTCOME | accelerometer-measured activity |
| PubMed | 31625704 | Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction (retracted) Minerva cardioangiologica 2019 | TiAb | exclude | OUTCOME | longitudinal strain; record is a retracted publication |
| PubMed | 31617977 | ARNI (Angiotensin Receptor-Neprilysin Inhibitor): when, for whom and how? (French) Revue medicale suisse 2019 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 31559483 | Optimizing heart failure treatment following cardiac resynchronization therapy Clinical research in cardiology 2020 | TiAb | exclude | OUTCOME | post-CRT optimisation outcomes |
| PubMed | 31531687 | ARNIs: balancing the good and the bad of neuroendocrine response to HF Clinical research in cardiology 2020 | TiAb | exclude | RANDOMISATION | commentary |
| PubMed | 31514513 | Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan Journal of cardiovascular pharmacology and therapeutics 2020 | TiAb | exclude | RANDOMISATION | observational real-world estimates |
| PubMed | 31510768 | Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With HFrEF: PARADIGM-HF Circulation 2019 | TiAb | exclude | OUTCOME | prognostic association of congestion score |
| PubMed | 31498903 | Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System Pharmacotherapy 2019 | TiAb | exclude | RANDOMISATION | eligibility proportions |
| PubMed | 31475296 | Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial (EVALUATE-HF) Jama 2019 | TiAb | exclude | OUTCOME | change in aortic characteristic impedance |
| PubMed | 31219361 | Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal Expert review of pharmacoeconomics and outcomes research 2020 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 31172710 | Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction Korean circulation journal 2019 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 31132222 | Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry European journal of heart failure 2019 | TiAb | exclude | RANDOMISATION | registry eligibility and outcome proportions |
| PubMed | 31119890 | Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction ESC heart failure 2019 | TiAb | exclude | INTERVENTION | intervention is hydralazine/nitrates |
| PubMed | 31101372 | Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea Clinical therapeutics 2019 | TiAb | exclude | RANDOMISATION | cost-utility ratio |
| PubMed | 31093657 | Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial European heart journal 2019 | TiAb | exclude | OUTCOME | biomarker concentration change |
| PubMed | 31078482 | Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF Jacc. Heart failure 2019 | TiAb | exclude | OUTCOME | aetiology subgroup estimates; secondary report of PARADIGM-HF |
| PubMed | 31029493 | Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure Revista portuguesa de cardiologia 2019 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 31023122 | Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus ACEI or ARB in a Retrospective Analysis of Patients With Heart Failure Journal of the American Heart Association 2019 | TiAb | exclude | RANDOMISATION | retrospective cost and utilisation estimates |
| PubMed | 30982680 | Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation Journal of cardiology 2019 | TiAb | exclude | RANDOMISATION | observational tolerability statistics |
| PubMed | 30955360 | Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial Circulation 2019 | TiAb | exclude | OUTCOME | exploratory composite of death, HF rehospitalisation, lvad implantation or transplant listing; not the pre-specified estimand and not the trial primary |
| PubMed | 30846338 | B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial Journal of the American College of Cardiology 2019 | TiAb | exclude | OUTCOME | BNP and NT-proBNP concentrations |
| PubMed | 30796605 | Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities Irish journal of medical science 2019 | TiAb | exclude | RANDOMISATION | eligibility proportions |
| PubMed | 30788621 | Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction Clinical research in cardiology 2019 | TiAb | exclude | RANDOMISATION | observational arrhythmia burden change |
| PubMed | 30784673 | Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF Journal of the American College of Cardiology 2019 | TiAb | exclude | OUTCOME | extracellular matrix biomarker change |
| PubMed | 30741494 | Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial European journal of heart failure 2019 | TiAb | exclude | OUTCOME | loop diuretic dose change |
| PubMed | 30679005 | Sacubitril/valsartan: A practical guide Revista portuguesa de cardiologia 2019 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 30484837 | Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With ARNI vs Standard Therapy for HFrEF: An Analysis of Data From the PARADIGM-HF Trial Jama cardiology 2018 | TiAb | exclude | OUTCOME | 5-year number needed to treat |
| PubMed | 30415601 | Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure (PIONEER-HF) The New England journal of medicine 2019 | TiAb | exclude | OUTCOME | time-averaged proportional change in NT-proBNP from baseline to weeks 4 and 8 |
| PubMed | 30414818 | Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization Jacc. Heart failure 2019 | TiAb | exclude | RANDOMISATION | narrative review of prescribing practice |
| PubMed | 30359220 | Novel Possibilities in Pharmacotherapy of Patients With Chronic Heart Failure (Russian) Kardiologiia 2018 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 30281045 | Anmco position paper on sacubitril/valsartan in the management of patients with heart failure (Italian) Giornale italiano di cardiologia 2018 | TiAb | exclude | RANDOMISATION | consensus statement |
| PubMed | 30204280 | Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with HFrEF: the PARADIGM-HF trial European journal of heart failure 2018 | TiAb | exclude | OUTCOME | GDF-15 concentration and its prognostic association |
| PubMed | 30122239 | Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor Indian heart journal 2018 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 30054868 | Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany PharmacoEconomics 2018 | TiAb | exclude | RANDOMISATION | cost-effectiveness and budget impact estimates |
| PubMed | 30047502 | Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction - Baseline Characteristics and Treatment of PARALLEL-HF Trial Circulation journal 2018 | TiAb | exclude | OUTCOME | baseline characteristics only; no effect estimate |
| PubMed | 29979147 | Sacubitril/Valsartan: potential treatment for paediatric heart failure Cardiology in the young 2018 | TiAb | exclude | POPULATION | paediatric |
| PubMed | 29945530 | The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series Journal of oncology pharmacy practice 2019 | TiAb | exclude | RANDOMISATION | case series |
| PubMed | 29926350 | Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost American journal of cardiovascular drugs 2019 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 29917003 | Sacubitril/valsartan: from a large clinical trial to clinical practice Journal of cardiovascular medicine 2018 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 29895587 | Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial Journal of the American Heart Association 2018 | TiAb | exclude | RANDOMISATION | registry-vs-trial descriptive comparison |
| PubMed | 29891240 | Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction International journal of cardiology 2019 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 29776559 | Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study International journal of cardiology 2018 | TiAb | exclude | OUTCOME | angioedema event counts |
| PubMed | 29748349 | Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With HFrEF in the PARADIGM-HF Trial Circulation. Heart failure 2018 | TiAb | exclude | OUTCOME | biomarker prognostic association |
| PubMed | 29687191 | Sacubitril/Valsartan: From Clinical Trials to Real-world Experience Current treatment options in cardiovascular medicine 2018 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 29661699 | Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure receiving target doses of RAS inhibitors: a secondary analysis of the PARADIGM-HF trial The lancet. Diabetes and endocrinology 2018 | TiAb | exclude | OUTCOME | eGFR decline rate |
| PubMed | 29655829 | Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure Jacc. Heart failure 2018 | TiAb | exclude | OUTCOME | renal function change and associated outcomes |
| PubMed | 29653636 | Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial American heart journal 2018 | TiAb | exclude | OUTCOME | NT-proBNP change (trial design paper) |
| PubMed | 29643067 | Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial Circulation. Heart failure 2018 | TiAb | exclude | OUTCOME | hypotensive episode incidence |
| PubMed | 29617523 | Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial Jama cardiology 2018 | TiAb | exclude | OUTCOME | KCCQ physical and social limitation scores |
| PubMed | 29601093 | Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States Pharmacotherapy 2018 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 29544929 | Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction International journal of cardiology 2018 | TiAb | exclude | POPULATION | experimental animal model |
| PubMed | 29542073 | Combination Therapy of Renin Angiotensin System Inhibitors and Beta-Blockers in Patients with Heart Failure Advances in experimental medicine and biology 2018 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 29501368 | A novel agent in the treatment of heart failure with depressed systolic function (Spanish) Archivos de cardiologia de Mexico 2018 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 29469206 | Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design ESC heart failure 2018 | TiAb | exclude | OUTCOME | apnoea-hypopnoea index |
| PubMed | 29464879 | Insights into implementation of sacubitril/valsartan into clinical practice ESC heart failure 2018 | TiAb | exclude | RANDOMISATION | implementation descriptive statistics |
| PubMed | 29464817 | The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease - existing evidence, knowledge gaps, and future directions European journal of heart failure 2018 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 29431251 | Effect of sacubitril/valsartan on recurrent events in PARADIGM-HF European journal of heart failure 2018 | FullText | exclude | OUTCOME | Recurrent-event rate ratio: negative binomial RR 0.77 (0.67-0.89); Lwyy RR 0.78 (0.68-0.90); Wlw HR 0.79 (0.71-0.89); joint frailty HR 0.75 (0.66-0.86). Counts repeat events per person; the estimand counts each person once at first event. |
| PubMed | 29369824 | Was the Enalapril Dose Too Low in the PARADIGM-HF Trial? Cardiology in review 2018 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 29318651 | Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide British journal of clinical pharmacology 2018 | TiAb | exclude | OUTCOME | pharmacokinetic and pharmacodynamic parameters |
| PubMed | 29269379 | Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction Heart 2018 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 29265423 | PARADIGM-HF Trial: Secondary Analyses Address Unanswered Questions Pharmacotherapy 2018 | TiAb | exclude | RANDOMISATION | narrative review of secondary analyses |
| PubMed | 29239515 | Rationale and design of transition: a randomized trial of pre-discharge vs post-discharge initiation of sacubitril/valsartan ESC heart failure 2018 | TiAb | exclude | COMPARATOR | comparator is a different initiation timing, not enalapril |
| PubMed | 29193563 | Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF European journal of heart failure 2018 | TiAb | exclude | OUTCOME | serum uric acid concentration |
| PubMed | 29185253 | Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction Swiss medical weekly 2017 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 29137346 | Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696 Oncotarget 2017 | TiAb | exclude | RANDOMISATION | narrative safety review |
| PubMed | 29129252 | Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study) American heart journal 2017 | TiAb | exclude | POPULATION | paediatric |
| PubMed | 29042791 | Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives Vascular health and risk management 2017 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 28959905 | Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction Journal of medical economics 2018 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 28844335 | Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure Revista portuguesa de cardiologia 2017 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 28800834 | Benefits and Harms of Sacubitril in Adults With Heart Failure and Reduced Left Ventricular Ejection Fraction The American journal of cardiology 2017 | TiAb | exclude | RANDOMISATION | narrative/systematic review of benefits and harms |
| PubMed | 28793821 | The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials Journal of cardiovascular pharmacology and therapeutics 2017 | TiAb | exclude | POPULATION | hypertension, not heart failure |
| PubMed | 28784687 | Health-Related Quality of Life Outcomes in PARADIGM-HF Circulation. Heart failure 2017 | TiAb | exclude | OUTCOME | KCCQ quality-of-life scores |
| PubMed | 28720639 | Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results Journal of the American Board of Family Medicine 2017 | TiAb | exclude | RANDOMISATION | narrative safety commentary |
| PubMed | 28577679 | The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF American heart journal 2017 | TiAb | exclude | OUTCOME | coronary event outcomes, not the pre-specified composite |
| PubMed | 28330649 | Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial The lancet. Diabetes and endocrinology 2017 | TiAb | exclude | OUTCOME | HbA1c and glycaemic measures |
| PubMed | 28292483 | An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands Value in health 2017 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 28285069 | Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure The American journal of medicine 2017 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 28281174 | Potential Expanded Indications for Neprilysin Inhibitors Current heart failure reports 2017 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 28244205 | What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? European journal of heart failure 2017 | TiAb | exclude | RANDOMISATION | eligibility proportions |
| PubMed | 28158398 | Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF European heart journal 2017 | TiAb | exclude | OUTCOME | blood-pressure subgroup estimates; secondary report of PARADIGM-HF |
| PubMed | 28133468 | Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination Journal of geriatric cardiology 2016 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 28060547 | The safety of sacubitril-valsartan for the treatment of chronic heart failure Expert opinion on drug safety 2017 | TiAb | exclude | RANDOMISATION | narrative safety review |
| PubMed | 28024961 | Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study Journal of cardiology 2017 | TiAb | exclude | OUTCOME | trial design description; no effect estimate |
| PubMed | 28004291 | Sacubitril/Valsartan (LCZ696) in Heart Failure Handbook of experimental pharmacology 2017 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 27908347 | Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure Journal of the American College of Cardiology 2016 | TiAb | exclude | OUTCOME | prognostic association of NT-proBNP change |
| PubMed | 27868321 | Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction European journal of heart failure 2017 | TiAb | exclude | OUTCOME | dementia-related adverse event rates |
| PubMed | 27842179 | Reduced Risk of Hyperkalemia During Treatment of Heart Failure With MRAs by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial Jama cardiology 2017 | TiAb | exclude | OUTCOME | hyperkalaemia event rates |
| PubMed | 27747488 | Angiotensin-Neprilysin Inhibition as a Paradigm for All? Current cardiology reports 2016 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 27618854 | Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial According to Background Therapy Circulation. Heart failure 2016 | TiAb | exclude | OUTCOME | background-therapy subgroup estimates; secondary report of PARADIGM-HF |
| PubMed | 27574931 | Limitations of Sacubitril/Valsartan in the Management of Heart Failure American journal of therapeutics 2017 | TiAb | exclude | RANDOMISATION | narrative commentary |
| PubMed | 27573608 | Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience International journal of cardiology 2016 | TiAb | exclude | RANDOMISATION | editorial |
| PubMed | 27571284 | Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction Annals of internal medicine 2016 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 27471351 | Critical Questions about PARADIGM-HF and the Future Acta Cardiologica Sinica 2016 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 27438344 | Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction Jama cardiology 2016 | TiAb | exclude | RANDOMISATION | incremental cost-effectiveness ratio |
| PubMed | 27417000 | Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization Journal of the American College of Cardiology 2016 | TiAb | exclude | OUTCOME | 30-day readmission rate |
| PubMed | 27395349 | Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial Jacc. Heart failure 2016 | TiAb | exclude | OUTCOME | subgroup estimates by prior decompensation; secondary report of PARADIGM-HF |
| PubMed | 27324636 | Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure Current atherosclerosis reports 2016 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 27296397 | Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial Circulation. Heart failure 2016 | TiAb | exclude | OUTCOME | run-in noncompletion proportions and their influence |
| PubMed | 27283779 | Efficacy of sacubitril/valsartan vs enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial European journal of heart failure 2016 | TiAb | exclude | OUTCOME | achieved-dose subgroup estimates; secondary report of PARADIGM-HF |
| PubMed | 27274196 | Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date Drug design, development and therapy 2016 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 27207980 | The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan Heart 2016 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 27170530 | Initiating sacubitril/valsartan (LCZ696) in heart failure: results of titration, a double-blind, randomized comparison of two uptitration regimens European journal of heart failure 2016 | TiAb | exclude | COMPARATOR | comparator is a second uptitration regimen, not enalapril |
| PubMed | 27143684 | Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From PARADIGM-HF Circulation 2016 | TiAb | exclude | OUTCOME | outpatient worsening event rates |
| PubMed | 27092662 | Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies Journal of cardiovascular pharmacology 2016 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 27038730 | The paradigm of ARNIs: Assessing reasons for non-implementation in heart failure International journal of cardiology 2016 | TiAb | exclude | RANDOMISATION | editorial |
| PubMed | 29144684 | Sacubitril / Valsartan -- Benefit Assessment According to Social Code Book V section 35a (IQWiG report; esummary title and journal fields were empty, resolved by efetch) IQWiG Reports (non-journal) 2016 | TiAb | exclude | RANDOMISATION | health-technology-assessment benefit rating |
| PubMed | 26976916 | Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition Circulation 2016 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 26915374 | Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: PARADIGM-HF Circulation. Heart failure 2016 | TiAb | exclude | OUTCOME | ejection-fraction subgroup estimates; secondary report of PARADIGM-HF |
| PubMed | 26873495 | Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction Drugs 2016 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 26873036 | Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure Expert review of clinical pharmacology 2016 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 26754626 | Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF Circulation. Heart failure 2016 | TiAb | exclude | OUTCOME | diabetes-status subgroup estimates; secondary report of PARADIGM-HF |
| PubMed | 26746371 | Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial Jacc. Heart failure 2016 | TiAb | exclude | OUTCOME | vaccination uptake and associated event rates |
| PubMed | 26626162 | A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction Journal of clinical pharmacology 2016 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 26541915 | Comparing LCZ696 with enalapril according to baseline risk using the maggic and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF Journal of the American College of Cardiology 2015 | TiAb | exclude | OUTCOME | risk-score subgroup estimates; secondary report of PARADIGM-HF |
| PubMed | 26469827 | A new class of drugs for systolic heart failure: The PARADIGM-HF study Cleveland Clinic journal of medicine 2015 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 26386501 | Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure Clinical therapeutics 2015 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 26231885 | Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF European heart journal 2015 | TiAb | exclude | OUTCOME | age subgroup estimates; secondary report of PARADIGM-HF |
| PubMed | 26209000 | Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact Journal of cardiac failure 2015 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 26175499 | Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New paradigm The Annals of pharmacotherapy 2015 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 26049379 | Chronic heart failure: what does the horizon look like? Current opinion in cardiology 2015 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 26022006 | Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients European heart journal 2015 | TiAb | exclude | OUTCOME | mode-of-death specific hazard ratios, not the pre-specified composite |
| PubMed | 25864789 | LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block? Journal of pharmacy practice 2015 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 25849438 | Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice BMC medicine 2015 | TiAb | exclude | RANDOMISATION | commentary |
| PubMed | 25833460 | LCZ696: the next step in improving RAS inhibition? Current hypertension reports 2015 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 25813256 | The new drug is much more effective than ACE inhibitors in chronic heart failure (Czech) Vnitrni lekarstvi 2015 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 25766951 | The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure Journal of the American College of Cardiology 2015 | TiAb | exclude | RANDOMISATION | historical article |
| PubMed | 25756942 | Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances European journal of heart failure 2015 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 25597387 | LCZ696: a new paradigm for the treatment of heart failure? Expert opinion on pharmacotherapy 2015 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 28834633 | Clinical trials update from the European Society of Cardiology meeting 2014: Paradigm-hf, confirm-hf, signify, atrial fibrillation, beta-blockers and heart failure, and vagal stimulation in heart failure ESC heart failure 2014 | TiAb | exclude | RANDOMISATION | conference trials update |
| PubMed | 25416329 | A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure European heart journal 2015 | TiAb | exclude | OUTCOME | indirectly derived effect versus a putative placebo, not the head-to-head estimand |
| PubMed | 25403646 | Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure Circulation 2015 | TiAb | exclude | OUTCOME | clinical progression measures in survivors, not the pre-specified composite |
| PubMed | 25306450 | Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure Jacc. Heart failure 2014 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 25176015 | Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF) The New England journal of medicine 2014 | FullText | INCLUDE | — | Meets all four. Double-blind randomised; 8442 adults NYHA ii-iv LVEF<=40%; LCZ696 200 mg bid vs enalapril 10 mg bid; composite of CV death or first HF hospitalisation as hazard ratio 0.80 (95% CI 0.73-0.87), P<0.001; 914/4187 vs 1117/4212; median follow-up 27 months. |
| PubMed | 24828035 | Baseline characteristics and treatment of patients in PARADIGM-HF European journal of heart failure 2014 | TiAb | exclude | OUTCOME | baseline characteristics only; no effect estimate |
| PubMed | 23663006 | The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure Expert opinion on investigational drugs 2013 | TiAb | exclude | RANDOMISATION | narrative review |
| PubMed | 23563576 | Dual angiotensin receptor and neprilysin inhibition as an alternative to ACE inhibition in patients with chronic systolic heart failure: rationale for and design of PARADIGM-HF European journal of heart failure 2013 | TiAb | exclude | OUTCOME | trial design description; no effect estimate |
| CTGov | NCT03168568 | Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction (vascend) Completed 2017-05-04 | TiAb | exclude | COMPARATOR | comparator arms are valsartan and placebo |
| CTGov | NCT04688294 | The Bio-Clinical Effects of the Sacubitril-Valsartan Combination on Patients With Chronic Heart Failure Completed 2020-01-01 | TiAb | exclude | COMPARATOR | comparator is valsartan |
| CTGov | NCT00913653 | Safety/Tolerability, Pharmacokinetics/Pharmacodynamics of LCZ696 in Patients With Stable Heart Failure Completed 2009-05 | TiAb | exclude | COMPARATOR | single-arm; reports pharmacokinetic and pharmacodynamic parameters |
| CTGov | NCT03909295 | Open-label Extension Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan Terminated 2019-05-07 | TiAb | exclude | POPULATION | heart failure with preserved ejection fraction |
| CTGov | NCT03917459 | COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure Completed 2019-04-16 | TiAb | exclude | OUTCOME | erectile function score |
| CTGov | NCT03190304 | The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure Completed 2017-06-14 | TiAb | exclude | OUTCOME | exercise tolerance and vasodilation measures |
| CTGov | NCT01353508 | Sodium Excretion of LCZ696 in Patients With Hypertension, Heart Failure and Healthy Volunteers Completed 2011-03 | TiAb | exclude | POPULATION | hypertension and healthy volunteers |
| CTGov | NCT04397302 | Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction Completed 2019-01-13 | TiAb | exclude | OUTCOME | haemodynamic and echocardiographic improvement |
| CTGov | NCT01920711 | Efficacy and Safety of LCZ696 Compared to Valsartan on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF) Completed 2014-07-18 | TiAb | exclude | COMPARATOR | comparator is valsartan; population HFpEF |
| CTGov | NCT07376265 | A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients Completed 2023-10-20 | TiAb | exclude | RANDOMISATION | real-world non-randomised effectiveness estimates |
| CTGov | NCT04781881 | Special Drug Use Surveillance for Entresto Tablets Completed 2021-03-04 | TiAb | exclude | RANDOMISATION | post-marketing surveillance statistics |
| CTGov | NCT07379788 | ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling Completed 2025-01-01 | TiAb | exclude | COMPARATOR | comparator is empagliflozin combination; no enalapril arm |
| CTGov | NCT02900378 | randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure (OUTSTEP-HF) Completed 2016-12-20 | TiAb | exclude | OUTCOME | accelerometer-measured daily physical activity |
| CTGov | NCT05164653 | Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (premier) ACTIVE_NOT_RECRUITING 2021-12-27 | TiAb | exclude | COMPARATOR | comparator is standard treatment |
| CTGov | NCT05448872 | Real World Experience in HFrEF Patients Treated With Sacubitril/Valsartan Completed 2020-11-23 | TiAb | exclude | RANDOMISATION | observational descriptive statistics |
| CTGov | NCT02916160 | Sacubitril-valsartan and Heart Failure Patients: the ENTRESTO-SAS Study Completed 2016-09-22 | TiAb | exclude | OUTCOME | apnoea-hypopnoea index |
| CTGov | NCT04113109 | Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 Completed 2019-11-01 | TiAb | exclude | OUTCOME | mechanistic haemodynamic and renal clearance measures |
| CTGov | NCT03830814 | The Effects of Sacubitril/Valsartan on the Heart Functions Completed 2017-01-01 | TiAb | exclude | OUTCOME | echocardiographic function measures |
| CTGov | NCT04498780 | Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure Completed 2020-07-21 | TiAb | exclude | OUTCOME | pressure-volume loop derived measures |
| CTGov | NCT03928158 | LCZ696 in Advanced LV Hypertrophy and HFpEF Completed 2019-05-31 | TiAb | exclude | POPULATION | HFpEF with advanced left ventricular hypertrophy |
| CTGov | NCT07417215 | The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF Completed 2026-01-30 | TiAb | exclude | POPULATION | HFpEF on chronic haemodialysis |
| CTGov | NCT04753112 | Treatment of PH With ARB and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device Completed 2020-10-29 | TiAb | exclude | POPULATION | HFpEF with pulmonary hypertension |
| CTGov | NCT03300427 | The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients Completed 2018-07-05 | TiAb | exclude | OUTCOME | myocardial oxygen consumption and work efficiency |
| CTGov | NCT04575675 | Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy Completed 2020-05-29 | TiAb | exclude | INTERVENTION | intervention is dapagliflozin |
| CTGov | NCT06237309 | REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction Terminated 2024-04-11 | TiAb | exclude | INTERVENTION | intervention is REGN5381 |
| CTGov | NCT05353166 | REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure Completed 2022-06-30 | TiAb | exclude | INTERVENTION | intervention is REGN5381 |
| CTGov | NCT06142383 | A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure Terminated 2023-12-12 | TiAb | exclude | INTERVENTION | intervention is XXB750; sacubitril/valsartan is an active reference arm |
| CTGov | NCT02678312 | Study to Evaluate LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure (PANORAMA-HF) Completed 2016-11-03 | TiAb | exclude | POPULATION | children 1 month to <18 years |
| CTGov | NCT02970669 | Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in HFrEF Patients (AWAKE-HF) Completed 2016-12-16 | TiAb | exclude | OUTCOME | accelerometer-measured activity and sleep |
| CTGov | NCT03387163 | Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto in Heart Failure Completed 2018-02-09 | TiAb | exclude | RANDOMISATION | patient-reported outcome change without randomised comparison |
| CTGov | NCT06922253 | Bioequivalence Study to Compare Sacubitril and Valsartan Tablets Versus Entresto Tablets Completed 2024-12-28 | TiAb | exclude | OUTCOME | pharmacokinetic bioequivalence parameters |
| CTGov | NCT02887183 | Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes (PROVE-HF) Completed 2016-10-25 | TiAb | exclude | COMPARATOR | single-arm; no enalapril comparator |
| CTGov | NCT05963282 | Comparative Effectiveness of Entresto Versus ACEi/ARB in de Novo Heart Failure Patients Completed 2021-11-29 | TiAb | exclude | RANDOMISATION | non-randomised comparative effectiveness estimates |
| CTGov | NCT02554890 | Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode (PIONEER-HF) Completed 2016-04-29 | TiAb | exclude | OUTCOME | time-averaged proportional change in NT-proBNP |
| CTGov | NCT03717688 | The Effects of Neprilysin on Glucagon-like Peptide-1 Completed 2018-05-17 | TiAb | exclude | OUTCOME | GLP-1 concentration |
| CTGov | NCT04735354 | Sacubitril/Valsartan in HFrEF Patients: a Real World Study in India Completed 2020-10-27 | TiAb | exclude | RANDOMISATION | observational descriptive statistics |
| CTGov | NCT07023016 | Comparative Assessment of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure Completed 2023-11-01 | TiAb | exclude | COMPARATOR | comparator is ramipril |
| CTGov | NCT02690974 | Description of Tolerability of LCZ696 in HFrEF Treated in Real Life Setting Completed 2016-03-08 | TiAb | exclude | RANDOMISATION | observational tolerability proportions |
| CTGov | NCT04649229 | Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 Completed 2021-05-27 | TiAb | exclude | OUTCOME | mechanistic haemodynamic and renal clearance measures |
| CTGov | NCT02884206 | Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Chronic Heart Failure and Preserved Ejection Fraction (perspective) Completed 2016-11-23 | TiAb | exclude | COMPARATOR | comparator is valsartan; population HFpEF |
| CTGov | NCT04153136 | The enchantment HIV Study Completed 2020-09-11 | TiAb | exclude | POPULATION | HIV with HFpEF |
| CTGov | NCT05243199 | Sacubitril/Valsartan for CKD5 Stage Dialysis Patients Completed 2020-08-01 | TiAb | exclude | POPULATION | CKD stage 5 on dialysis; comparator irbesartan |
| CTGov | NCT02787798 | Evaluation of the Entresto Effect on Sympathetic Nervous System in Patients With Heart Failure Terminated 2016-10 | TiAb | exclude | OUTCOME | microneurography-derived sympathetic activity |
| CTGov | NCT05096039 | Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models Completed 2020-04-10 | TiAb | exclude | RANDOMISATION | claims-based provider performance metrics |
| CTGov | NCT05613140 | Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure Completed 2021-08-02 | TiAb | exclude | RANDOMISATION | observational descriptive statistics |
| CTGov | NCT01922089 | Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients (titration) Completed 2013-11 | TiAb | exclude | COMPARATOR | comparator is a second uptitration regimen, not enalapril |
| CTGov | NCT03066804 | A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (parallax) Completed 2017-08-22 | TiAb | exclude | COMPARATOR | comparator is individualised medical therapy; population HFpEF |
| CTGov | NCT02788656 | Pulmonary Artery Pressure Reduction With ENTresto Terminated 2016-09 | TiAb | exclude | OUTCOME | implantable-monitor pulmonary artery pressure |
| CTGov | NCT02468232 | Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction (PARALLEL-HF) Completed 2015-06-15 | FullText | INCLUDE | — | Registry record for the trial included via PMID 33731544. Composite of CV death or HF hospitalisation reported as hazard ratio 1.09 (0.65-1.82). Note: the registry primary-outcome-measure field was not read - that lookup was blocked by HTTP 429. |
| CTGov | NCT02754518 | Demonstration of Reverse Remodeling Effects of Entresto Using Echocardiography Endocardial Surface Analysis Completed 2016-04 | TiAb | exclude | COMPARATOR | single-arm; reports echocardiographic remodelling |
| CTGov | NCT05096143 | A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs HFrEF Patients Using US Electronic Health Records Completed 2020-06-03 | TiAb | exclude | RANDOMISATION | non-randomised cohort hospitalisation estimates |
| CTGov | NCT02874794 | Study of Effects of Sacubitril/Valsartan vs Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction (EVALUATE-HF) Completed 2016-08-17 | TiAb | exclude | OUTCOME | change in aortic characteristic impedance |
| CTGov | NCT05021419 | Efficacy of a Streamlined Heart Failure Optimization Protocol Completed 2022-07-17 | TiAb | exclude | INTERVENTION | intervention is a care-delivery protocol |
| CTGov | NCT05387967 | Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction Completed 2021-01-01 | TiAb | exclude | RANDOMISATION | single-arm tolerability proportions |
| CTGov | NCT04023227 | Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC (PARACHUTE-HF) Completed 2019-12-10 | FullText | INCLUDE | — | |
| CTGov | NCT05989503 | Initiation of ARNi and SGLT2i in Patients With HFrEF Completed 2023-08-04 | TiAb | exclude | COMPARATOR | comparator is an SGLT2 inhibitor sequencing strategy |
| CTGov | NCT02661217 | Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event (transition) Completed 2016-02-12 | TiAb | exclude | COMPARATOR | comparator is a different initiation timing, not enalapril |
| CTGov | NCT05991284 | Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation Completed 2024-02-29 | TiAb | exclude | POPULATION | HFpEF |
| CTGov | NCT04736433 | Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data Completed 2020-09-22 | TiAb | exclude | RANDOMISATION | claims-based emulation estimates, not a randomised trial |
| CTGov | NCT03988634 | Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a Worsening HF Event (PARAGLIDE-HF) Completed 2019-06-29 | TiAb | exclude | COMPARATOR | comparator is valsartan; population HFpEF |
| CTGov | NCT06697353 | Observational Study of Real-world Outcomes in Patients With Heart Failure Who Initiate Vericiguat in Japan Completed 2024-11-01 | TiAb | exclude | INTERVENTION | intervention is vericiguat |
| CTGov | NCT07341893 | Sacubitril-valsartan in Patients With Heart Failure Completed 2025-08-01 | TiAb | exclude | COMPARATOR | comparator is standard treatment of heart failure |
| CTGov | NCT05117736 | ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure Terminated 2022-03-15 | TiAb | exclude | POPULATION | congenital systemic right ventricle |
| CTGov | NCT05348226 | The envi Study: Effect of Entresto on Left Ventricular Remodelling on Cardiac MRI Completed 2021-06-09 | TiAb | exclude | OUTCOME | cardiac MRI remodelling measures |
| CTGov | NCT02226120 | Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction Completed 2014-10-16 | TiAb | exclude | COMPARATOR | open-label single-arm; reports tolerability proportions |
| CTGov | NCT07527767 | Secondary Use of PARALLEL-HF Data Completed 2022-07-27 | TiAb | exclude | OUTCOME | secondary data-use record for an included trial; no independent effect estimate |
| CTGov | NCT02816736 | Entresto (LCZ696) In Advanced Heart Failure (life Study) Completed 2017-03-02 | TiAb | exclude | COMPARATOR | comparator is valsartan |
| CTGov | NCT06149104 | A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Completed 2023-12-04 | TiAb | exclude | POPULATION | paediatric |
| CTGov | NCT04218435 | Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients Completed 2019-01-01 | TiAb | exclude | RANDOMISATION | observational comparison by CKD status |
| CTGov | NCT01035255 | This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure (PARADIGM-HF) Terminated 2009-12 | FullText | INCLUDE | — | Registry record for the trial included via PMID 25176015. Composite of CV death or first HF hospitalisation as hazard ratio 0.80 (0.73-0.87). Registry status terminated reflects the pre-specified early stop for overwhelming benefit. Note: the registry primary-outcome-measure field was not read - that lookup was blocked by HTTP 429. |
| CTGov | NCT02924727 | Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) Completed 2016-12-09 | TiAb | exclude | COMPARATOR | comparator is ramipril; population acute myocardial infarction |
| CTGov | NCT04434170 | Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure Completed 2018-10-15 | TiAb | exclude | OUTCOME | exercise capacity, natriuretic peptides, remodelling |
| CTGov | NCT04587947 | Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients Completed 2020-04-01 | TiAb | exclude | OUTCOME | autonomic function measures |
| CTGov | NCT02957409 | PAtient RegisTry Assessing Effectiveness and Safety of Heart Failure treatmeNt With LCZ696 acrOss CaNada Completed 2016-05-20 | TiAb | exclude | RANDOMISATION | registry descriptive statistics |
| CTGov | NCT03760588 | Prevention of Cardiac Dysfunction During Breast Cancer Therapy Completed 2019-01-31 | TiAb | exclude | POPULATION | breast cancer therapy cardioprotection |
| CTGov | NCT07088471 | Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan Completed 2024-11-01 | TiAb | exclude | OUTCOME | left atrial echocardiographic measures |
| CTGov | NCT05848206 | Impact of Formulary Coverage of Entresto on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes Completed 2022-03-11 | TiAb | exclude | RANDOMISATION | claims-based abandonment and cost outcomes |
| CTGov | NCT06090487 | Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance Completed 2024-02-01 | TiAb | exclude | COMPARATOR | comparator is dapagliflozin |
| CTGov | NCT05637853 | Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction ACTIVE_NOT_RECRUITING 2022-10-22 | TiAb | exclude | INTERVENTION | intervention is a GDMT sequencing strategy |
| CTGov | NCT03552575 | The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI Completed 2018-07-01 | TiAb | exclude | COMPARATOR | comparator is valsartan |
| CTGov | NCT07130175 | Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure Completed 2022-12-31 | TiAb | exclude | INTERVENTION | intervention is catheter ablation |
| CTGov | NCT02768298 | Exercise Capacity Study of LCZ696 vs Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction Completed 2016-07-12 | TiAb | exclude | OUTCOME | exercise capacity (peak VO2) |
| CTGov | NCT00887588 | LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction (paramount) Completed 2009-11 | TiAb | exclude | COMPARATOR | comparator is valsartan; population HFpEF |
| CTGov | NCT05881720 | Sacubitril/Valsartan Versus Valsartan in Heart Failure Completed 2022-01-01 | TiAb | exclude | COMPARATOR | comparator is valsartan |
| CTGov | NCT03785405 | Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF Completed 2019-05-02 | TiAb | exclude | POPULATION | paediatric |
| CTGov | NCT07465679 | A Real-world Study of Clinical Treatment Guidelines for Patients With HFrEF Treated With Sacubitril/Valsartan Completed 2026-01-28 | TiAb | exclude | RANDOMISATION | observational guideline-adherence statistics |
| CTGov | NCT03506412 | Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction Completed 2018-06-25 | TiAb | exclude | POPULATION | HFpEF |
| CTGov | NCT04491136 | Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (rhythm) Terminated 2020-11-11 | TiAb | exclude | OUTCOME | ventricular arrhythmia burden |
| CTGov | NCT05168787 | Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction Completed 2020-08-13 | TiAb | exclude | RANDOMISATION | observational subgroup effectiveness estimates |
| CTGov | NCT03816306 | Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients Completed 2018-06-01 | TiAb | exclude | RANDOMISATION | single-arm clinical and echocardiographic change |
| CTGov | NCT06029712 | Heart Failure Polypill at a Safety Net Hospital Completed 2024-02-27 | TiAb | exclude | INTERVENTION | intervention is a heart failure polypill |
| CTGov | NCT04141800 | Spanish Study of Hyperkalaemia Incidence and Prognosis in Patients With Heart Failure and Reduced Ejection Fraction Completed 2019-04-30 | TiAb | exclude | RANDOMISATION | observational hyperkalaemia incidence |
In this section: Extracted values, and where each came from · Risk of bias (RoB-2) · Overall judgement per trial · Inter-assessor agreement, as measured · Open disagreements (5) · Integrity flag · Where two sources disagree · Sources · Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio · Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio · What was measured · Pooled result · What this pool holds constant · Contributing trials · Endpoint definitions, read from the registry · The methods rule governing this decision · Leave-one-out sensitivity · Does the answer depend on the pooling method?
One row per extracted value. Every row carries the value, the verbatim sentence it was read from, a resolvable link to the source, and whether the number was read or derived. Where any of those is absent the row says so rather than omitting the value.
| Trial / outcome | Value as extracted | Verbatim source sentence | Source links | Read or derived |
|---|---|---|---|---|
| PARADIGM-HF cvdeath_or_hfh_first | HR 0.8 (95% CI 0.73 to 0.87) | “At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001).” “In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy.” “The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes.” | NCT01035255 · PMID 25176015 · source · primary_oa · registry · regulator_fda · regulator_ema · prior_meta | READ from the source as printed The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source. |
| PARACHUTE-HF cvdeath_or_hfh_first | HR 0.91 (95% CI 0.73 to 1.13) | “The first secondary end point was the composite of time to first HF hospitalization or death from cardiovascular causes ( Figure 2 , C, D, and E), which occurred in 155 patients (33.5%) in the sacubitril/valsartan group and 169 (36.7%) in the enalapril group (HR, 0.91 [95% CI, 0.73-1.13])” “The primary end point was a hierarchical composite outcome tested, in order, of death from cardiovascular causes, hospitalization for HF, or relative change in NT-proBNP from baseline to 12 weeks. The primary analysis was done using a win ratio approach.” “Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female).” | NCT04023227 · PMID 41335448 · source · primary_oa · registry | READ from the source as printed The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source. |
| PARALLEL-HF cvdeath_or_hfh_first | HR 1.09 (95% CI 0.65 to 1.82) | “Over a median follow up of 33.9 months, no significant between-group difference was observed for the primary composite outcome of CV death and HF hospitalization (HR 1.09; 95% CI 0.65-1.82; P=0.6260).” “In the Prospective comparison of ARNI with ACEi to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients (PARALLEL-HF) study, 225 Japanese HFrEF patients (New York Heart Association [NYHA] class II-IV, left ventricular ejection fraction [LVEF] ≤35%) were randomized (1 : 1) to receive sacubitril/valsartan 200 mg bid or enalapril 10 mg bid.” | NCT02468232 · PMID 33731544 · source · primary_oa · registry · prior_meta | READ from the source as printed The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source. |
| ANSWER-HF cvdeath_or_hfh_first | HR 1.83 (95% CI 0.72 to 4.67) | “Cardiovascular death and heart failure hospitalization 12/95 (12.6) 8/95 (8.4) 1.83 (0.72-4.67) 0.205” | NCT04853758 · PMID 41396086 · source | READ from the source as printed Point and interval stored as published. The log point and log standard error are DERIVED here from the width of the published interval on the log scale, and are not claimed to appear in any source. |
the model that assembled this object (anthropic family) did not assess any domain, per protocol section 9. The two assessors are from different families and neither is the assembler.
Variant: effect of assignment to intervention (intention-to-treat), as pre-registered in protocol.md section 9
Unit assessed: the result being pooled, not the trial overall: the composite of cardiovascular death or first hospitalisation for heart failure, as a time-to-first-event hazard ratio
Assessor 1: GPT-5 (openai family). Assessor 2: Gemini 3.1 Pro (google family). each assessor saw only its own trial packet; neither saw the other's answers
| Trial | Domain | Assessor 1 (openai) | Assessor 2 (google) | Agreed | Carried |
|---|---|---|---|---|---|
| paradigm-hf | D1 bias arising from the randomization process | LOW | LOW | yes | LOW |
| paradigm-hf | D2 bias due to deviations from intended interventions (effect of assignment) | LOW | LOW | yes | LOW |
| paradigm-hf | D3 bias due to missing outcome data | LOW | LOW | yes | LOW |
| paradigm-hf | D4 bias in measurement of the outcome | LOW | LOW | yes | LOW |
| paradigm-hf | D5 bias in selection of the reported result | Some concerns | LOW | NO | Some concerns |
| parallel-hf | D1 bias arising from the randomization process | Some concerns | LOW | NO | Some concerns |
| parallel-hf | D2 bias due to deviations from intended interventions (effect of assignment) | LOW | LOW | yes | LOW |
| parallel-hf | D3 bias due to missing outcome data | LOW | LOW | yes | LOW |
| parallel-hf | D4 bias in measurement of the outcome | LOW | LOW | yes | LOW |
| parallel-hf | D5 bias in selection of the reported result | Some concerns | LOW | NO | Some concerns |
| parachute-hf | D1 bias arising from the randomization process | LOW | Some concerns | NO | Some concerns |
| parachute-hf | D2 bias due to deviations from intended interventions (effect of assignment) | Some concerns | Some concerns | yes | Some concerns |
| parachute-hf | D3 bias due to missing outcome data | LOW | LOW | yes | LOW |
| parachute-hf | D4 bias in measurement of the outcome | LOW | LOW | yes | LOW |
| parachute-hf | D5 bias in selection of the reported result | LOW | Some concerns | NO | Some concerns |
| Trial | Assessor 1 (openai) | Assessor 2 (google) | Agreed |
|---|---|---|---|
| paradigm-hf | Some concerns | LOW | NO |
| parallel-hf | Some concerns | LOW | NO |
| parachute-hf | Some concerns | Some concerns | yes |
Per-domain: 10 of 15 agreed (66.7%). Overall: 1 of 3.
This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one.
| Trial | Domain | openai | Carried | |
|---|---|---|---|---|
| paradigm-hf | D5 bias in selection of the reported result | Some concerns | LOW | Some concerns |
| parallel-hf | D1 bias arising from the randomization process | Some concerns | LOW | Some concerns |
| parallel-hf | D5 bias in selection of the reported result | Some concerns | LOW | Some concerns |
| parachute-hf | D1 bias arising from the randomization process | LOW | Some concerns | Some concerns |
| parachute-hf | D5 bias in selection of the reported result | LOW | Some concerns | Some concerns |
Carried at the more cautious of the two, provisionally. Adjudicator: Mahmood Ahmad (named human). Status: PENDING.
assessor 1 cited a statistical analysis plan by version number and release date
'parachute-hf sap version 2.1, release date 29-Apr-2025' appears in assessor 1's the randomisation process and deviations from the intended intervention sources, and it marked protocol available true for those domains. That specificity was not in the packet we supplied. It is either a genuine retrieval or a recalled identifier, and the output alone cannot tell us which.
Action taken: Not adopted. Any domain resting on it is treated as protocol-unavailable until the SAP is retrieved and checked. This is the identifier-from-recall failure mode this project has already been caught by once.
| Trial | Quantity | Registry | Publication | Status |
|---|---|---|---|---|
| PARACHUTE-HF | Serious adverse events | 169/183 | 211/234 | Resolved 2026-08-18 -- both values correct, different observation windows |
PARACHUTE-HF, Serious adverse events. Registry: ClinicalTrials.gov NCT04023227, adverse-events module. Publication: Lopes RD et al., jama 2026;335(1):49-59, PMC12676478.
Our own multi-source extraction pass did not record this discrepancy at all. A blinded comparator found it. The two sources disagree on both numerator and denominator for the same quantity in the same trial, and we carried only one side without noticing the other existed. Recorded here with both values and both pointers rather than resolved, because resolving it requires reading which population and which window each source is reporting, and picking one now would manufacture the appearance of a resolution.
A multi-source pass that agrees with itself is not the same as a pass that checked both sources. This is the class our own harness names as 'consistency does not authenticate a row'.
| Layer | Source | How it was obtained |
|---|---|---|
| Regulator: FDA statistical review | FDA statistical review, NDA 207620 (Entresto), 2015. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000StatR.pdf | Quoted: staged as text extracted from the review PDF. It states the full analysis set and its derivation, and splits the composite into its mutually exclusive first-event parts. |
| Regulator: EMA epar | Entresto epar public assessment report, European Medicines Agency. https://www.ema.europa.eu/en/documents/assessment-report/entresto-epar-public-assessment-report_en.pdf | Quoted: staged as text extracted from the epar pdf. It prints the composite with both denominators and both percentages. |
| Prior synthesis (abstracts staged; full text paywalled) | Two 2026 systematic reviews of sacubitril/valsartan against enalapril in heart failure with reduced ejection fraction due to Chagas cardiomyopathy, both in Cardiology in Review: Daniyal SM et al (PMID 41923142) and AlSejari NY et al (PMID 41941460). https://pubmed.ncbi.nlm.nih.gov/41923142/ | Quoted, and the distinction matters: the abstracts are open and are staged, and they are what carries the patient total this object cannot reconcile. The full texts are paywalled -- each returned a payment-required response on the date recorded here and neither has an open-access or PubMed Central copy -- and the full text is where the included-study list lives. So the count is checkable in the bundle and the list is not, which is precisely why the discrepancy is recorded as unresolved rather than settled. An earlier version cited these reviews with nothing staged at all, and a review leg was right that an unresolved finding resting on an unstaged source is itself an assertion. |
| Prior synthesis | Reyaz I et al. Comparison of outcomes between sacubitril/valsartan and enalapril in patients with heart failure: a systematic review and meta-analysis. Cureus 2023;15(11):e48623. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710849/ | Quoted: open access in PubMed Central. Its characteristics table lists every included study with arm sizes, which is what made the trial-list diff possible and is what surfaced PARALLEL-HF. |
| Primary paper (abstract, open) | McMurray JJV et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014. https://pubmed.ncbi.nlm.nih.gov/25176015/ | Quoted: the journal is not open access; the abstract is, and carries the point estimate, the interval and both event counts with their percentages. |
| Primary paper (full text, open) | Lopes RD et al. Sacubitril/valsartan vs enalapril in heart failure due to Chagas disease: an open-label, multicenter randomized clinical trial. Jama 2026;335(1):49-59. https://pubmed.ncbi.nlm.nih.gov/41335448/ | Quoted: the full text is open in PubMed Central and is staged. The secondary-outcome table carries the hazard ratio this object pools; the abstract does not. |
| Primary paper (abstract, open) | Tsutsui H et al. Efficacy and safety of sacubitril/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction -- results from the PARALLEL-HF study. Circ J 2021;85(5):584-594. https://pubmed.ncbi.nlm.nih.gov/33731544/ | Quoted: the abstract carries the primary composite endpoint with its hazard ratio and interval. |
| Primary paper (abstract, open) | Madrini V et al. Sacubitril-valsartan vs enalapril in heart failure due to Chagas disease: primary results of the ANSWER-HF randomized trial. J Am Coll Cardiol 2025;87(10):1220-1232. https://pubmed.ncbi.nlm.nih.gov/41396086/ | Quoted: staged for an excluded trial, deliberately. ANSWER-HF is the exclusion the measure rule leans on hardest -- right population, right comparator, wrong quantity -- so the row that excludes it has to be checkable at the layer that holds its numbers. An earlier version pointed that row at the registry, which posts no results for this trial at all. |
| Primary paper (open access) | Pathadka S, Yan VKC, Li X, et al. Hospitalization and mortality in patients with heart failure treated with sacubitril/valsartan vs. enalapril: a real-world, population-based study. Front Cardiovasc Med 2020;7:602363. https://pubmed.ncbi.nlm.nih.gov/33553256/ | Quoted: open access in PubMed Central. Staged because this is the one screened-out record that reports this review's own composite as a hazard ratio -- 0.58, 0.45 to 0.75, by Cox regression with inverse-probability-of-treatment weighting -- and is excluded solely for not being randomised. A reader is entitled to check both halves of that. |
| Primary paper (open access) | Bano S, Bai P, Kumar S, et al. Comparison of sacubitril/valsartan versus enalapril in the management of heart failure. Cureus 2021;13(7):e16332. https://pubmed.ncbi.nlm.nih.gov/34395116/ | Quoted: open access in PubMed Central. Staged because its screening row makes a negative claim -- that the paper contains no hazard ratio, no Cox model and no time-to-event analysis -- and a negative claim about a document can only be checked against the document. |
| Primary paper (open access) | Zhao Y, Tian LG, Zhang LX, et al. The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction. Pulm Circ 2022;12(3). https://pubmed.ncbi.nlm.nih.gov/35874853/ | Quoted: open access in PubMed Central. Staged for the same reason as Bano 2021, and for one more: the string "HR" appears in it four times and is heart rate every time, in a baseline table. The screening row says so, and a reviewer should be able to confirm that the check was for the quantity and not for the string. |
| Registry with posted results | ClinicalTrials.gov records for every trial this object names: posted results for the three contributing trials, and the full record for each excluded and each screened trial, staged one file per registration. https://clinicaltrials.gov/study/NCT01035255 | Quoted: each record is staged as the API returned it, and there is one for every registration the object cites -- a review leg found four screening rows pointing at registry pages whose records were not in the bundle, which is a link a reader can follow but a reviewer cannot audit offline. The participant-flow milestones are what let this object show, rather than assert, why an analysis-set denominator is smaller than a randomised one. One record that WAS staged has been removed: NCT02887183 is PROVE-HF, staged during an early mis-identification of PARAGON-HF's registration and never cited by anything here. An uncited file in an evidence bundle is noise that looks like evidence. |
| Comparator | enalapril |
|---|---|
| Estimand | time_to_first — Cox proportional hazards |
| Unit of analysis | participant, with the time to the first component event |
| Case definition | adjudicated cardiovascular death or adjudicated hospitalization for heart failure, whichever occurs first. every contributing trial adjudicates the components centrally, and the trials differ in the aetiology of the heart failure, which the uniformity table records rather than smoothing away |
| Window | from randomisation to the end of the trial's own follow-up |
| Analysis population | each trial's own full analysis set, which in two of the four is smaller than the randomised total for reasons the trial states and this object reproduces |
| Effect scale | combined on the log scale; ESTIMAND UNIFORMITY NOT ESTABLISHED -- the contributing trials have not been shown to measure the same quantity |
HR 0.8715 (0.7461 to 1.018), 95% interval
Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio. random, estimator REML, k = 4.
τ² 0.008597 · I² 32.89% · Q 5.161 on 3 df
Favours: the intervention (lower is better)
I-squared is 32.9% under the registered REML estimator, 41.9% under DerSimonian-Laird and 55.7% under Paule-Mandel, and Q is 5.16 on 3 degrees of freedom (p=0.16). The estimator dependence is the finding: a single I-squared figure quoted without its estimator is not interpretable at this k. The prediction interval spans 0.686 to 1.107, which is the honest statement of how much the trials disagree.
A single effect measure, a single comparator and a single outcome concept, across trials that share no participant and no control group.
Resolved 2026-08-18. The contributing ratio IS a hazard ratio. ANSWER-HF stays in the pool, k remains 4, and the displayed estimate does not change.
This page carried an open question stating that ANSWER-HF's 1.83 (0.72 to 4.67) could not be identified as a hazard ratio and that "the source does not say that it is one". That was wrong, and the source says it twice. The jacc full text was obtained and read on 2026-08-18. Table 2, headed "Clinical Endpoints at 6 Months", has four columns: Outcomes, Sacubitril-Valsartan, Enalapril, and -- verbatim -- "Effect HR (95% CI)". The Statistical Analysis section states, verbatim: "Time-to-event secondary outcomes were also analyzed individually using Kaplan-Meier curves and estimates of cardiovascular death and heart failure hospitalization at 6 months reported using Cox proportional hazard models, with treatment group and research site as fixed-effect factors. HRs, 95% CIs, and 2-sided P values are reported." The measure is a hazard ratio from a Cox proportional hazards model over time to first occurrence, with treatment group and research site as fixed-effect factors.
Identity before any number, because this is the trial the project once conflated with PARACHUTE-HF. The document read was confirmed as ANSWER-HF by registration id, not by label: NCT04853758 is the only registration in the document and appears twice in a registration context -- in the abstract trailer and in the Methods. PARACHUTE-HF appears eight times and every one is a citation of a different trial in the Discussion, carrying its own distinct win ratio of 1.52 (1.28 to 1.82). Nothing was read from this document before that check was made.
An arithmetic witness, independent of any sentence. Table 2's all-cause death row is 8/95 against 8/95, so the crude risk ratio and the crude odds ratio are both exactly 1.000 -- and the published value is 1.08. No crude measure can produce 1.08 from eight versus eight. Only an estimator using time and censoring, adjusted for site, can move that comparison off unity. The same pattern holds across all four rows, every published value exceeding its own crude risk ratio: 1.27 against 1.167, 1.42 against 1.400, 1.83 against 1.500, 1.08 against 1.000. The two figures this page previously quoted are unchanged and are restated here so they do not simply vanish: from 12/95 versus 8/95 the crude risk ratio is 1.50 and the crude odds ratio is 1.57, and neither is 1.83. That was the original observation and it was correct -- it was the inference drawn from it that was wrong. Departure from the crude measures is what a Cox model does; it is not a sign that the measure is unidentified.
Two published claims were false, and both were ours. First: "the source does not say that it is one" -- the column header says HR and the Methods name the model. Second, and worse: "the trial states no time-to-event analysis of this composite anywhere" -- the trial states exactly that, in the sentence quoted above. The hypothesis offered alongside them, that 1.83 might be the win ratio analysed a second way, is refuted: the win ratio is a four-level hierarchical statistic over cardiovascular death, heart-failure hospitalisation, NT-proBNP change and LVEF change, with intervals from bootstrap resampling, reported as 1.81 (1.27 to 2.63) in the Results and 1.80 in the Abstract -- and its clinical-outcomes-only sensitivity analysis is 0.64 (0.22 to 1.66). A statistic whose clinical-only form is 0.64 is not the source of a 1.83 on the clinical composite.
And the object already HELD it. The provenance block on this very trial and this very outcome carries model statement quote -- the Cox sentence above, verbatim and character-identical to the publication -- and it was present in commit 935cf870a, the commit that created the open question, and in every commit since. The object asserted "the source does not say that it is one" in its results section while holding, one level up on the same trial, the sentence in which the source says it. The finding was not blocked by a missing fact; it was blocked by two fields that were never read against each other.
The direction is the point. With ANSWER-HF the pool is HR 0.8715 (0.7461 to 1.0181), which crosses one. Without it, k=3 gives 0.8333 (0.7473 to 0.9292), which does not. Dropping the trial would have converted a null result into a positive one on the strength of an exclusion we made ourselves -- and it would have been wrong, because the ratio is exactly what the pool assumed it was. A withdrawal needs the same evidentiary standard as a claim: withdrawing a correct estimate destroys a true finding and publishes the destruction as a discovery.
The estimate shown is the k=4 value, HR 0.8715 (0.7461 to 1.0181), and it has not changed. What has changed is this paragraph: a question is now an answer. No displayed number moved.
The row is a first-event union despite a caption reading "and", and Table 2's own arithmetic proves it: cardiovascular death 7 and heart-failure hospitalisation 7 sum to 14 while the composite counts 12, so two patients had both and are counted once; in the control arm 6 and 5 sum to 11 against a composite of 8. The caption trap recorded on this trial is confirmed, not assumed.
The open question was published at 935cf870a as a hand edit of the built page, existing in no object, and the first rebuild deleted it -- caught only because the new page's numerals were counted against the served page before pushing. It was moved into the object at 777a8393f. It is answered here, in the object, for the same reason: a finding that lives only in the artefact dies at the next build.
Sensitivity, retained rather than deleted. With answer-hf: HR 0.8715 (0.7461 to 1.0181), k=4 -- null. Without it: 0.8333 (0.7473 to 0.9292), k=3 -- not null. This is kept on the page now that the question is settled, because a reader who saw the earlier version is entitled to check the arithmetic that the resolution turns on, and because the k=4 headline being null is a fact about how much one small trial carries.
Prediction interval 0.6862 to 1.107
| Dimension | Across the pooled cohorts | If it differs, why it is crossed anyway |
|---|---|---|
| effect measure | identical | All four report a hazard ratio for the time to a first event of the same composite. No conversion is performed and none would be valid: the trials excluded from this pool are excluded largely because their quantities cannot be converted into this one. This row read “all three” until 2026-08-18, when the pool had been k=4 for a day; the whole of this table described the pool as it stood before ANSWER-HF was resolved into it, which is the table that justifies the pool describing a different pool from the one published. |
| comparator | identical | All four randomised against enalapril at a target of 10 mg twice daily. ANSWER-HF's own registration names enalapril as the comparator. This is the axis on which paragon-hf, paraglide-hf and PARADISE-MI fail, and it is checked rather than assumed. |
| outcome definition | identical in the three that register it | Cardiovascular death or hospitalization for heart failure, whichever comes first. PARADIGM-HF's registered title says “First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization”; PARALLEL-HF's registered description says “either cardiovascular (CV) death or heart failure (HF) hospitalization”; PARACHUTE-HF's registered secondary says “First Hospitalization Due to Heart Failure or Death From Cardiovascular Causes”, counted “to the first occurrence”. All three are read from the registry and quoted in full in the endpoint-definition table. Answer-hf registers no such endpoint, so on that trial there is nothing to compare and this row does not claim there is. Its publication reports the same two components in the same first-event structure, which is agreement of the reported quantity and not of the registered one. |
| endpoint registered in its own trial | differs | Three of the four trials registered this endpoint before they ran; one did not. PARADIGM-HF and PARALLEL-HF register it as their primary outcome and PARACHUTE-HF as the first of six secondaries. ANSWER-HF registers neither it nor anything equivalent, at any rank, and its registration is not silent by omission -- it declares twenty outcome measures and this is not among them. A quarter of this pool therefore has no protection against selective outcome reporting, and the trial concerned is the one whose estimate is furthest from the rest. It stays in, because removing it would convert a null into a positive result, and a withdrawal needs the same evidence as a claim. |
| aetiology of heart failure | differs | PARACHUTE-HF and ANSWER-HF admitted only chronic Chagas cardiomyopathy, confirmed serologically at entry -- a distinct disease with a different natural history and a high burden of conduction disease. Neither PARADIGM-HF nor PARALLEL-HF restricted aetiology at all, so the pool crosses two narrow-aetiology trials with two unrestricted ones, and that is the most substantive thing it crosses. It is also half the pool rather than a third, which is what this row said before ANSWER-HF was counted into it. What the contributing trials' own sources say about their aetiology MIX differs in how much they say, and this row says only what they support: the epar records ischaemic cardiac disease as the primary cause of heart failure in the majority of PARADIGM-HF participants, and the staged sources for PARALLEL-HF characterise its population by ejection fraction and functional class without describing its aetiology mix at all. An earlier version of this row described both unrestricted trials as largely ischaemic or idiopathic; a review leg was right that the second half of that had no basis in anything staged, and it is the more serious kind of over-claim for sitting inside the table that justifies pooling across aetiology. |
| ejection fraction ceiling | differs | 40% or less in PARADIGM-HF and PARACHUTE-HF; 35% or less in parallel-hf; answer-hf enrolled Chagas cardiomyopathy with reduced ejection fraction. All are within the reduced-ejection-fraction population the question fixes, and they are not the same entry criterion. |
| blinding | differs | PARADIGM-HF and PARALLEL-HF were double-blind. PARACHUTE-HF was OPEN-LABEL with blinded endpoint adjudication. Blinded adjudication protects the outcome ascertainment and does not protect the management decisions that lead to a hospitalization, so the difference is carried into the GRADE risk-of-bias domain rather than dismissed here. |
| endpoint rank within its own trial | differs | This composite is the primary endpoint of PARADIGM-HF and of PARALLEL-HF. In PARACHUTE-HF it is the first secondary endpoint, the primary there being a hierarchical composite analysed by win ratio. A trial is not powered for its secondary endpoints, and the pool crosses that. In answer-hf it has no rank, because it is not registered: that trial's registered primaries are change in ejection fraction and a four-level hierarchical win ratio. “Unregistered” is a fourth state on this axis and not a third kind of secondary. |
| follow up length | differs | Medians of 27 months, 25.2 months and 33.9 months in the three trials that report one; ANSWER-HF's registered outcome window is 6 months, the shortest in the pool by a factor of four. PARADIGM-HF's follow-up ended early by prespecified rule when a boundary for overwhelming benefit was crossed, which is a different reason for a follow-up length than the others have. A composite counted to first event over 6 months and the same composite counted over 34 months are not the same exposure to risk, and this is the dimension on which the pool's shortest trial is also its most discrepant estimate. |
| analysis population | differs | All four use the trial's own full analysis set. In PARACHUTE-HF and ANSWER-HF that equals the randomised total; in PARADIGM-HF and PARALLEL-HF it is smaller, and each cell shows the arithmetic from the randomised total rather than leaving the difference unexplained. |
| Trial | Analysed treatment / control |
HR (95% CI), or events | Source of this cell |
|---|---|---|---|
| PARADIGM-HF NCT01035255 · primary outcome | 4187 / 4212 The trial's full analysis set. It is smaller than the randomised total and the object shows why rather than leaving two numbers side by side: 4209 and 4233 patients were randomised, 8442 in all; 37 were excluded because their sites were closed for serious good-clinical-practice violations and 6 because they were randomised without qualifying and never received double-blind medication; 4209 less 18 less 4 is 4187 and 4233 less 19 less 2 is 4212, which is the 8399 the regulator layers name. The exclusions are site-level and protocol-level rather than outcome-dependent, which is why they are reported and not treated as attrition on the effect. | 0.8 (0.73 to 0.87) on the log scale: -0.2231 (standard error 0.04476) | Primary paper (abstract, open): At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. Randomised. The analysis set is smaller and the difference is reproduced on the cell below rather than left as a discrepancy. |
| PARACHUTE-HF NCT04023227 · FIRST SECONDARY outcome | 462 / 460 The full analysis set, which the registry defines as all participants to whom study treatment was assigned at randomisation, and which equals the randomised total here. | 0.91 (0.73 to 1.13) on the log scale: -0.09431 (standard error 0.1115) | Primary paper (full text, open): The first secondary end point was the composite of time to first HF hospitalization or death from cardiovascular causes ( Figure 2 , C, D, and E), which occurred in 155 patients (33.5%) in the sacubitril/valsartan group and 169 (36.7%) in the enalapril group (HR, 0.91 [95% CI, 0.73-1.13]) The primary end point was a hierarchical composite outcome tested, in order, of death from cardiovascular causes, hospitalization for HF, or relative change in NT-proBNP from baseline to 12 weeks. The primary analysis was done using a win ratio approach. Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female). Randomised, and the same number analysed; no participant is dropped. |
| PARALLEL-HF NCT02468232 · primary outcome | 111 / 112 The analysis set the registry posts for this endpoint, 111 and 112, derived on the record from 112 and 113 randomised less one mis-randomised patient in each arm. This is the same denominator-scope shape as PARADIGM-HF and is shown the same way rather than left as an unexplained difference from 225. | 1.09 (0.65 to 1.82) on the log scale: 0.08618 (standard error 0.2627) | Primary paper (abstract, open): Over a median follow up of 33.9 months, no significant between-group difference was observed for the primary composite outcome of CV death and HF hospitalization (HR 1.09; 95% CI 0.65-1.82; P=0.6260). In the Prospective comparison of ARNI with ACEi to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients (PARALLEL-HF) study, 225 Japanese HFrEF patients (New York Heart Association [NYHA] class II-IV, left ventricular ejection fraction [LVEF] ≤35%) were randomized (1 : 1) to receive sacubitril/valsartan 200 mg bid or enalapril 10 mg bid. Randomised. Two patients, one in each group, were mis-randomised and are outside the analysis set, which the registry record shows as a milestone. |
| ANSWER-HF NCT04853758 · secondary; the trial's primary is change in LVEF outcome | 95 / 95 randomised; modified-ITT 87/87 recorded, not selected | 1.83 (0.72 to 4.67) on the log scale: 0.6043 (standard error 0.477) | T1: Cardiovascular death and heart failure hospitalizationCardiovascular death and heart failure hospitalization 12/95 (12.6) 8/95 (8.4) 1.83 (0.72-4.67) 0.205 190 randomised, 95 per arm. The trial's primary endpoint analysis used a modified ITT of 87 per group which excluded patients who died; that population is recorded on the cell and is not selected for this composite. |
The four contributing trials share no participant and no control group.
What each trial COUNTED, in its own registry record's words, before anything here was pooled. A sentence saying what HAPPENED is not a sentence saying what was COUNTED, and only the second one licenses a pool. Read from the registry on 2026-08-17, 2026-08-18. Follow the registration link to disagree with any row.
| Trial | Rank in its own trial | Registered outcome measure | Description, verbatim | Analysis set / window |
|---|---|---|---|---|
| PARADIGM-HF NCT01035255 | PRIMARY | Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization | Number of participants that had first occurrence of the composite endpoint, which is defined as either CV death or HF hospitalization due to HF. | up to 51 months |
| PARACHUTE-HF NCT04023227 | SECONDARY (the first of six secondary outcomes) | Percentage of Participants With First Hospitalization Due to Heart Failure or Death From Cardiovascular Causes | No description is recorded in this registry field. The registration carries a description for its primary win-ratio endpoint and none for this secondary. The title and the time frame are the whole of what the registry states, and they are quoted here in full rather than supplemented from the publication. | From the date of randomization to the first occurrence (total follow up time up to approximately 36 months) |
| PARALLEL-HF NCT02468232 | PRIMARY | Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints | Composite endpoint is defined as either cardiovascular (CV) death or heart failure (HF) hospitalization in Japanese patients with chronic heart failure (CHF) and reduced ejection fraction. The composite endpoint events occurred on and after End-of-study (EOS) declaration were reported by investigators but those events were not required to be adjudicated by Clinical Endpoint Committee (CEC) and not included in the efficacy analysis. | up to 40 months |
| ANSWER-HF NCT04853758 | NOT REGISTERED AT ANY RANK | Not registered. NCT04853758 registers no outcome measure -- primary, secondary or other -- that is a first-event union of cardiovascular death and heart-failure hospitalisation. The quantity this object pools from this trial exists only in the publication. | There is no field to quote. The registration's two primary outcome measures are “Change of left ventricular ejection fraction (LVEF)” and “Win Ratio Analysis”, the latter described as “Hierarchical composite analysis composed of: 1. Time to cardiovascular death; 2. Time to first heart failure hospitalization; 3. Relative change in NT-proBNP from baseline to final visit; 4. Relative change in left ventricular ejection fraction from baseline to final visit”. Its eighteen secondary outcome measures are Holter, echocardiographic, functional-class and biomarker measures: premature ventricular beats (count and percentage), ventricular arrhythmia density, sustained ventricular tachycardia rate, NYHA class, six ventricular-remodelling measurements, urea, creatinine, potassium, sodium, systemic cytokines, microRNA and NT-proBNP. There are no “other” outcome measures. None of the twenty is the endpoint pooled here. | not applicable -- the endpoint is not registered |
| This trial's registration declares no such endpoint. This is a selective-reporting exposure, not an estimand mismatch. An endpoint absent from the registration cannot be shown to have been specified before the results were seen, and the protection every other row in this table has, this row does not. It is carried into risk of bias and stated on the face of the page. It is not treated as grounds for removing the trial: removing it moves the pooled hazard ratio from 0.8715 (0.7461-1.0181) to 0.8333 (0.7473-0.9292), turning a result that crosses one into one that does not. Dropping the only trial that disagrees, on a defect that argues for disclosure, would manufacture the positive finding this review does not have. | ||||
Decision: Pool four trials reporting the same effect measure for the same outcome concept against the same comparator, producing an average across documented differences in aetiology, ejection-fraction ceiling, blinding and the endpoint's rank within its own trial
Cochrane Handbook sections: 3.2.1, 3.2.3, 3.2.4, 10.9, 10.10.1, 10.10.2, 10.10.4, 10.14
Sections 3.2.1, 3.2.3 and 3.2.4 fix the three axes of the question -- population, comparator, outcome -- and every include and exclude decision in this object names which of the three it turns on, which is why the exclusion table has a criterion column rather than a verdict column. Section 10.9 gives the hazard ratio as the effect measure for time-to-event data and sanctions combining log hazard ratios by generic inverse variance; all four trials report a Cox hazard ratio for the time to a first event of the same composite against enalapril, so the measure is shared and not converted. What the pool crosses is documented under 10.10.1 in the uniformity table: the aetiology of the heart failure, the ejection-fraction ceiling, whether the trial was blinded, and whether this endpoint was that trial's primary or its first secondary. Not one of those is smoothed away and none is claimed to be absent. Section 10.10.4 governs the model and the between-study variance estimator, which the effect-measure sections do not: it records that estimators other than DerSimonian and Laird perform better and that restricted maximum likelihood is now the default, and its subsection on few studies advises comparing the methods when there are only two or three. This pool has four, so the comparison is RUN and sits in the sensitivity block, where the three estimators do not agree closely and that is shown rather than reported as a formality. Section 10.14 is why the leave-one-out analysis is here, and in this pool it is the most important thing on the page: removing the largest trial removes the benefit.
Two decisions. First, whether the pooled benefit depends on any single trial -- and it does. Second, whether it depends on the choice of between-study variance estimator and interval method, which with four studies is not a formality.
| Cohort omitted | k | HR (95% CI) |
|---|---|---|
| paradigm-hf | 3 | 0.966 (0.7897 to 1.182) |
| parachute-hf | 3 | 0.9716 (0.6662 to 1.417) |
| parallel-hf | 3 | 0.8438 (0.7361 to 0.9673) |
| answer-hf | 3 | 0.8392 (0.7429 to 0.948) |
Omitting PARADIGM-HF gives 0.9660 (0.7897 to 1.1818) with I-squared falling to 1.2%. The pooled effect is essentially PARADIGM-HF: the other three trials together sit at or above the null. Omitting ANSWER-HF returns exactly the previous 0.8392 (0.7429 to 0.9480), which is the arithmetic check that the new trial is the only thing that moved.
Cochrane Handbook version 6.5.1, section 10.14: sensitivity analyses examine whether overall findings are robust to potentially influential decisions. Section 10.10.4.4 is what governs the estimator half: it records that methods other than DerSimonian and Laird estimate the between-study variance better and that restricted maximum likelihood is the RevMan default. An earlier version of this field credited that advice to section 10.10.4.5, which does not give it -- 10.10.4.5 is about interpretation with few studies and the method it compares is the confidence interval, not the variance estimator. The citation was attached to a decision it does not govern while the section that does govern it went uncited.
Three between-study-variance estimators, each with Wald and HKSJ intervals. At k=3 Wald excluded the null and HKSJ did not; at k=4 both include it under every estimator, so the interval methods now agree. The point estimate moves from 0.872 to 0.904 across estimators, and I-squared from 32.9% to 55.7%.
| Between-study variance | Interval | Summary (95% CI) | τ² |
|---|---|---|---|
| restricted maximum likelihood (REML) | ordinary (Wald) | 0.8715 (0.7461 to 1.018) | 0.008597 |
| restricted maximum likelihood (REML) | Hartung-Knapp-Sidik-Jonkman (HKSJ) | 0.8715 (0.6571 to 1.156) | 0.008597 |
| DerSimonian-Laird (DL) | ordinary (Wald) | 0.8835 (0.7413 to 1.053) | 0.01264 |
| DerSimonian-Laird (DL) | Hartung-Knapp-Sidik-Jonkman (HKSJ) | 0.8835 (0.6506 to 1.2) | 0.01264 |
| Paule-Mandel (PM) | ordinary (Wald) | 0.9039 (0.7313 to 1.117) | 0.02205 |
| Paule-Mandel (PM) | Hartung-Knapp-Sidik-Jonkman (HKSJ) | 0.9039 (0.6408 to 1.275) | 0.02205 |
The estimator changes the point estimate from 0.872 to 0.904 and I-squared from 32.9% to 55.7%, and changes nothing about the conclusion: every estimator, under both Wald and HKSJ, gives an interval that includes no effect. At k=3 Wald and HKSJ disagreed about the null; at k=4 they agree.
REML with a Wald interval remains the registered headline. It is not chosen because it is the most favourable -- it is the least favourable of the three on I-squared and the narrowest on the interval, and every estimator reaches the same conclusion.
In this section: Which outcomes were analysed · Considered and NOT pooled, with the reason · Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio · Forest plot · Visual abstract · PRISMA flow of records · Funnel plot · Galbraith (radial) plot · Baujat plot · Influence diagnostics · Leave-one-out · Cumulative meta-analysis · Bayesian posterior density · Risk of bias, both assessors · GOSH · Trial-sequential analysis · Meta-regression · L'Abbe plot · Number needed to treat, across baseline risk
One outcome is the registered analysis. Three more are now pooled as secondary, and everything else the trials report cannot be pooled without changing the question.
| Outcome | Measure | k | Result / status |
|---|---|---|---|
| Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio | HR | 3 | Pooled -- the primary result |
| Cardiovascular death (component of the composite) | RR | 4 | RR 0.858 (0.749 to 0.983), I² 16.9% |
| First heart-failure hospitalisation (component of the composite) | RR | 4 | RR 0.878 (0.761 to 1.01), I² 20.4% |
| All-cause death | RR | 4 | RR 0.886 (0.803 to 0.979), I² 7.01% |
The registered estimand is a single quantity: cardiovascular death or first heart-failure hospitalisation, whichever comes first, as a time-to-first-event hazard ratio. These three are risk ratios over the whole follow-up, computed from per-arm counts. A risk ratio and a hazard ratio answer different questions, and the protocol fixes the hazard ratio as the measure, so these cannot be promoted into the primary synthesis.
Two of the three are components of the composite. They share the same participants, so reading them alongside the composite counts the same people more than once. The composite counts first events and is not the sum of its components -- on PARADIGM-HF the components exceed it, which is expected. Nothing here is reconstructed by addition.
parallel-hf all-cause death is ClinicalTrials.gov only -- the Circ J primary paper does not report all-cause mortality at all, so that pair has no second source.
| Win ratio (PARACHUTE-HF primary) | A hierarchical win ratio is not convertible to a hazard ratio or a risk ratio. It compares pairs of patients on an ordered hierarchy of events; there is no arithmetic that turns it into this review's estimand without inventing information. |
|---|---|
| NT-proBNP change (PIONEER-HF and others) | A ratio of change in a biomarker is not an event-time quantity. Excluded on the measure axis at screening, not omitted here. |
| Recurrent-event rate ratios | The estimand is time to first event. A recurrent-event rate ratio counts repeat events and answers a different question; scope decisions fixes this. |
| Quality of life (KCCQ) | Reported on different instruments and timepoints across the four trials, and not by all three. No common scale, so no pool. |
Before 2026-08-13 this object carried exactly one analysed outcome and the page did not say why. That was a real gap in what the page communicated, not merely in what it computed: a reader could not tell whether other outcomes had been considered and rejected or simply never looked at. The three secondary pools existed as per-arm counts in the object all along and had not been pooled.
Drawn from the same stored estimates the table above lists. Box area is proportional to inverse-variance weight.
x-axis range
⬇ SVG (vector) 3 KB ⬇ PNG 4500x1260 145 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 c78583472284f454…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — forest_fit.eps, 5 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — forest_fit.tiff, 16,611 KB.
Changing the range moves the axis window only. The guides stay labelled with the null and the extremes of the plotted intervals, so no plotted value and no printed number differs between these views — and that is checked at build time, not asserted. Ranges not offered because they would crop the data: 0.5 to 2, 0.25 to 4, 0.7 to 1.3.
⬇ SVG (vector) 2 KB ⬇ PNG 4500x2100 295 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 850741fa801ff002…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — visual-abstract.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — visual-abstract.tiff, 27,685 KB.
Projected from the canonical object, so it carries the same k, the same pooled estimate and the same interval as the paper and cannot drift from them. The interval is drawn CROSSING the no-difference line because it does: a graphical abstract travels without its caption, and one that showed a favourable point estimate without showing that its interval includes no effect would be overstating a null result, which is a defect class this review documents in other papers.
⬇ SVG (vector) 3 KB ⬇ PNG 3600x2910 294 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 b81d315e593e83af…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — prisma-flow.eps, 5 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — prisma-flow.tiff, 30,691 KB.
Every stage carries a count. The identification tier is populated from search.databases, and this caption previously said the opposite -- that two boxes were drawn as NOT RECORDED because the counts had never been captured. They had been, all along; a diagram missing its top box reads as an oversight, one that states the gap reads as a decision. The identification tier is populated from search.databases -- each database's hit count as the API returned it, and how many were retrieved -- which sum to exactly the screened corpus, and the corpus's own per-source tally agrees independently. No search was re-run to fill it, so no record entered or left the pool. The two sources return disjoint record types (PMIDs and NCT numbers) and no de-duplication step is recorded, which is why records removed before screening is zero rather than unknown. Exclusion reasons across the whole corpus: randomisation 195, outcome 132, comparator 38, population 35, intervention 14.
⬇ SVG (vector) 3 KB ⬇ PNG 3500x1700 238 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 98e2ac572275a002…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — funnel.eps, 6 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — funnel.tiff, 17,431 KB.
Standard error against the effect, most precise at the top, with the 95% and 99% pseudo-confidence funnel drawn from the pooled estimate and contour bands around the null. At k = 4 a funnel CANNOT be read for asymmetry and none is claimed: it is shown because the positions are real and the emptiness is the finding.
⬇ SVG (vector) 2 KB ⬇ PNG 3500x1500 86 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 3eaceb1a73fa986b…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — galbraith.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — galbraith.tiff, 15,381 KB.
Each trial's standardised effect against its precision.
⬇ SVG (vector) 2 KB ⬇ PNG 3500x1500 104 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 772bdfbf6f53ae2c…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — baujat.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — baujat.tiff, 15,381 KB.
Right means a trial drives heterogeneity; up means it moves the pooled result. Top-right is both.
⬇ SVG (vector) 1 KB ⬇ PNG 3500x1500 89 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 dab20113bc6246cd…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — influence.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — influence.tiff, 15,381 KB.
Leverage against Cook's distance, from metafor's influence diagnostics.
⬇ SVG (vector) 2 KB ⬇ PNG 3500x920 154 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 ec71aab4847ab304…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — leave-one-out.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — leave-one-out.tiff, 9,433 KB.
The pool refitted with each trial removed in turn.
⬇ SVG (vector) 2 KB ⬇ PNG 3500x920 161 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 b71542b3bcb40eaf…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — cumulative.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — cumulative.tiff, 9,433 KB.
The pool as each trial reported, in year order.
⬇ SVG (vector) 5 KB ⬇ PNG 3500x1500 93 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 3a0dc30eeebd5489…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — posterior.eps, 13 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — posterior.tiff, 15,381 KB.
grid integration, 201x201, flat prior on the pooled log effect and half-Cauchy(scale=1) on the between-study SD (Gelman 2006)
⬇ SVG (vector) 7 KB ⬇ PNG 3130x1340 157 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 7a977b52482caafd…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — rob-traffic-light.eps, 21 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — rob-traffic-light.tiff, 12,287 KB.
Every cell carries BOTH independent cross-family assessments and they are not reconciled: showing one column would be a reconciliation presented as an observation. Glyph as well as colour, so the panel survives greyscale printing and colour-blind reading. A trial with no judgement is shown as a row of not-assessed markers rather than omitted, so a gap in the assessment cannot be mistaken for a clean assessment. Agreement as measured: {'per domain agreed': 10, 'per domain total': 15, 'per domain rate pct': 66.7, 'overall agreed': 1, 'overall total': 3, 'measured not asserted': True, 'comparison to screening': "This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one."}.
⬇ SVG (vector) 1 KB ⬇ PNG 3500x540 81 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 1ac0f91ef8ab0183…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — gosh.eps, 2 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — gosh.tiff, 5,537 KB.
Deliberately not drawn. Every subset meta-analysis of 4 trials is 15 points; a cloud that small cannot show the multimodality GOSH exists to reveal, and a reader would take the picture as evidence of its absence.
⬇ SVG (vector) 1 KB ⬇ PNG 3500x650 87 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 25ed9800fdf56614…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — tsa.eps, 2 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — tsa.tiff, 6,665 KB.
TSA boundaries depend entirely on a target information size that must be pre-specified. This review's protocol registers none, so any boundary drawn here would be a parameter chosen after seeing the data -- which is the practice TSA exists to protect against.
⬇ SVG (vector) 1 KB ⬇ PNG 3500x540 87 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 0a34e86921018df9…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — bubble.eps, 2 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — bubble.tiff, 5,537 KB.
The protocol pre-specifies no moderator, and at k = 4 a meta-regression would be fitted on 4 points. Not drawn rather than drawn with a caveat: a bubble plot invites reading a slope, and there is no slope here that any reader should read.
⬇ SVG (vector) 2 KB ⬇ PNG 3500x1500 133 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 a2a8af212f9a5a20…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — labbe.eps, 4 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — labbe.tiff, 15,381 KB.
Each trial's own two risks, read from its 2x2. Below the diagonal favours the intervention.
⬇ SVG (vector) 3 KB ⬇ PNG 3500x1500 93 KB
All raster formats were generated at build time from the same SVG as the graphic above (SHA-256 b02217e8c096cf1c…), at 600 dpi for a 6-inch print width, on a white ground. They are not screenshots of the page and do not change with the theme you are reading in.
Submission formats written to the figures directory, not embedded here because an uncompressed 600 dpi TIFF is tens of megabytes: EPS (vector, journal's first choice for line art) — nnt-curve.eps, 7 KB; TIFF (uncompressed, 600 dpi -- journal fallback) — nnt-curve.tiff, 15,381 KB.
The number needed to treat depends on the risk a patient starts with. This applies the pooled risk ratio across a range of control risks so a reader can read off the value for the patient in front of them.
In this section: Summary of findings · Reproducibility artifact · Other recorded qualifications · Comparison with published syntheses · The syntheses reconciled against · Where the numbers differ, and why · Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio · Certainty of the evidence (GRADE) · Did the completed RoB-2 assessment move this rating?
| Outcome | k | Pooled effect | Certainty |
|---|---|---|---|
| Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio | 4 (lower bound) | HR 0.872 (0.746 to 1.02) | Low12 |
| Canonical object | ssot/arni-hfref/arni-hfref.json |
|---|---|
| Registered at | 961400264a06 2026-08-10T05:13:40Z |
| Permalink | https://github.com/mahmood726-cyber/rapidmeta-finerenone/commit/961400264a06bd940bef11e02b528ea0f73a8dee |
| Schema | 2 |
| Object last updated | 2026-08-09 |
| Page generated | 2026-08-25 08:10 UTC |
| Generator build | fa7ef6686 (uncommitted generator changes -- NOT REPRODUCIBLE from this stamp alone). The standard this page was built to is NOT ESTABLISHED: this object carries no build_stamp, so the version above is the standard that exists now, not the one this page was built against. |
| Statistical engine | metafor 5.0.1 under R 4.6.0, generic inverse variance on the same log point and log standard error this object stores |
Everything a third party needs to rebuild this page. Each figure on the Analysis tab downloads as an SVG carrying exactly the values shown.
Statements this review records about the limits of what it establishes, which are not shown elsewhere on this page. They are reproduced from the object verbatim and are not summarised.
| Analysed scope | The trial's full analysis set. It is smaller than the randomised total and the object shows why rather than leaving two numbers side by side: 4209 and 4233 patients were randomised, 8442 in all; 37 were excluded because their sites were closed for serious good-clinical-practice violations and 6 because they were randomised without qualifying and never received double-blind medication; 4209 less 18 less 4 is 4187 and 4233 less 19 less 2 is 4212, which is the 8399 the regulator layers name. The exclusions are site-level and protocol-level rather than outcome-dependent, which is why they are reported and not treated as attrition on the effect. |
|---|---|
| Analysed scope | The full analysis set, which the registry defines as all participants to whom study treatment was assigned at randomisation, and which equals the randomised total here. |
| Registry results confirm the stored counts | resultsSection outcome “Percentage of Participants With First Hospitalization Due to Heart Failure or Death From Cardiovascular Causes”: 33.5 in the sacubitril/valsartan group, 36.7 in the enalapril group. 155/462 = 33.55% and 169/460 = 36.74%. The stored arm sizes and event counts are the registry's own. |
| The cause in the registry own words | "Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 55 months. Deaths were also collected in the survival follow-up phase from 31 days after last dose of study medication until the end of the study, for an additional 8 months. These were not considered AEs." -- ClinicalTrials.gov timeFrame, verbatim, read 2026-08-18. |
| Neither value is adopted over the other | Both stand, each labelled with its window. The original decision to record both and refuse to choose was correct; what was missing was the reason. |
| Analysed scope | The analysis set the registry posts for this endpoint, 111 and 112, derived on the record from 112 and 113 randomised less one mis-randomised patient in each arm. This is the same denominator-scope shape as PARADIGM-HF and is shown the same way rather than left as an unexplained difference from 225. |
| Endpoint rank in its own trial superseded | a secondary endpoint; the trial's primary is change in left ventricular ejection fraction |
| Why it does not move | Two reasons, and the second is the load-bearing one. First, RoB-2 confirmed the substance of the downgrade rather than removing it. Both assessors, independently and from different model families, rated PARACHUTE-HF domain 2 as some concerns on the open-label deviations point, which is the first of the three features the rating was already built on. The second assessor also rated its domain 5 as some concerns on the selective-reporting point, which is the second feature. The assessment agreed with the reasoning the rating rested on. Second, and this is why 'no domain reached HIGH' does not discharge the downgrade: RoB-2 has no domain for a trial stopped early for benefit. Early stopping is not a randomization failure, a deviation, missing data, a measurement problem, or selective reporting of a result; it is a stopping-rule effect on the magnitude of the estimate, and the RoB-2 tool does not ask about it in any of its five domains. PARADIGM-HF was stopped early by prespecified rule for overwhelming benefit and the leave-one-out analysis shows the pooled benefit rests on that trial. That third feature is therefore untouched by a clean RoB-2 result, and it alone sustains a serious rating. Reading 'no domain HIGH' as grounds to remove the downgrade would be mistaking the silence of a tool for the absence of a problem. |
| Conditions under which it would move | If the named human adjudicates the five open disagreements toward LOW, and separately judges that the early-stopping effect is adequately carried by the imprecision and leave-one-out analyses rather than here, then 'not serious' becomes defensible and certainty would rise to moderate. That is a human decision on the record, not an automatic consequence of the assessment. |
| Why not downgraded despite the spread | Superseded at k=4 and flagged for re-reading rather than rewritten. The previous text argued that the low I-squared band justified no downgrade while the spread was carried by imprecision. Both inputs changed: I-squared is now 32.9% to 55.7% depending on estimator, and the four point estimates run 0.80 to 1.83. Whether that still supports 'not serious' is a judgement to be re-argued, not a label to be re-applied, and it is left open rather than settled by the script that changed the numbers. |
| The witness that needs no methods section | An arithmetic witness, independent of any sentence. Table 2's all-cause death row is 8/95 against 8/95, so the crude risk ratio and the crude odds ratio are both exactly 1.000 -- and the published value is 1.08. No crude measure can produce 1.08 from eight versus eight. Only an estimator using time and censoring, adjusted for site, can move that comparison off unity. The same pattern holds across all four rows, every published value exceeding its own crude risk ratio: 1.27 against 1.167, 1.42 against 1.400, 1.83 against 1.500, 1.08 against 1.000. The two figures this page previously quoted are unchanged and are restated here so they do not simply vanish: from 12/95 versus 8/95 the crude risk ratio is 1.50 and the crude odds ratio is 1.57, and neither is 1.83. That was the original observation and it was correct -- it was the inference drawn from it that was wrong. Departure from the crude measures is what a Cox model does; it is not a sign that the measure is unidentified. |
| What was wrong in what we published | Two published claims were false, and both were ours. First: "the source does not say that it is one" -- the column header says HR and the Methods name the model. Second, and worse: "the trial states no time-to-event analysis of this composite anywhere" -- the trial states exactly that, in the sentence quoted above. The hypothesis offered alongside them, that 1.83 might be the win ratio analysed a second way, is refuted: the win ratio is a four-level hierarchical statistic over cardiovascular death, heart-failure hospitalisation, NT-proBNP change and LVEF change, with intervals from bootstrap resampling, reported as 1.81 (1.27 to 2.63) in the Results and 1.80 in the Abstract -- and its clinical-outcomes-only sensitivity analysis is 0.64 (0.22 to 1.66). A statistic whose clinical-only form is 0.64 is not the source of a 1.83 on the clinical composite. |
| The answer was already in this object | And the object already HELD it. The provenance block on this very trial and this very outcome carries model statement quote -- the Cox sentence above, verbatim and character-identical to the publication -- and it was present in commit 935cf870a, the commit that created the open question, and in every commit since. The object asserted "the source does not say that it is one" in its results section while holding, one level up on the same trial, the sentence in which the source says it. The finding was not blocked by a missing fact; it was blocked by two fields that were never read against each other. |
| Why this ordering and not the reverse | Excluding the trial converts a null result into a positive one by our own choice, and the Handbook gives no basis for the exclusion. Presenting the exclusion as a sensitivity analysis discloses the same fact without letting our judgement manufacture the finding. The direction of the error decides: a wrong inclusion leaves a null intact; a wrong exclusion publishes a positive result we created. |
| What this does not establish | Not that ANSWER-HF's estimate is wrong -- the measure question was separately resolved and 1.83 (0.72-4.67) is a hazard ratio. Not that the pool is correct: the other uniformity axes (aetiology, follow-up length, ejection-fraction ceiling) differ and are stated separately on the page. This field decides eligibility only. |
| Verbatim scope | Covers bias arising when 'the reported result is selected (based on its direction, magnitude or statistical significance) from among multiple intervention effect estimates that were calculated by the trial authors'. |
| Why this was done and why it had not been | Auditing a topic's provenance is not auditing its arithmetic. This page has had more scrutiny than any other in the corpus -- ANSWER-HF's endpoint registration status, its measure question, its identity, its Handbook treatment -- and none of that recomputed the number the page publishes. The earlier headline-reproduction sweep returned 514 of 514, but it compared page to object: it establishes that the projection is faithful and says nothing about whether the object's own arithmetic is right. Those are two different questions and only the first had been answered. |
| Step 1 inputs against their own reported effects | Each trial's stored log point and log standard error were recomputed from the HR and CI recorded beside them. All four agree to 1e-6 or better: PARADIGM-HF 0.80 (0.73-0.87), PARACHUTE-HF 0.91 (0.73-1.13), PARALLEL-HF 1.09 (0.65-1.82), ANSWER-HF 1.83 (0.72-4.67). |
| What this does not establish | Not that the four trials should be pooled -- that is the estimand and eligibility question settled elsewhere on this object, and re-derivation is arithmetic, not judgement. Not that the per-trial HRs are correctly read from their sources: this checked the object's internal consistency, from stored HR and CI through to the pooled value. Whether 0.80 is what PARADIGM-HF reports is a source check and is separate. Not that any other topic re-derives; 18 remain unchecked. |
| Why that quantity is never stored as a hazard ratio | A recurrent-event rate ratio counts repeat events per person over time; a time-to-first hazard ratio counts each person once, at their first event. The two share a scale and a direction and answer different questions, and storing this trial's 0.87 in a hazard-ratio field would be indistinguishable, to any reader and to most software, from a hazard ratio of 0.87. It is stored nowhere in this object except in this sentence. |
| Limitation of this instrument | The prompt given to screener B said that an undetermined later resolved is worth more than a confident wrong exclusion. That wording plausibly pushed it toward undetermined, and 91 of 91 disagreements running one way is consistent with an induced bias as well as with genuine caution. The agreement rate is therefore reported as measured but should not be read as an unbiased estimate of inter-screener reliability. Re-running screener B on neutral wording is the check, and it has not been done. |
| Review scope | sacubitril/valsartan against enalapril in heart failure, any outcome, any design |
| Review scope | sacubitril/valsartan against enalapril in heart failure with reduced ejection fraction due to Chagas cardiomyopathy |
| Access limitation | Both reviews are staged, at the depth that is open. Their abstracts are readable and are in the bundle, and they are the source of the patient total below. Their full texts are paywalled -- each returned a payment-required response when fetched on the date recorded here, and neither has a PubMed Central or other open-access copy -- and the full text is where the included-study list lives. The count is therefore checkable and the list is not, which is the whole shape of this unresolved item. |
| Why it does not change the pool | It does not change k and it must not. The patients it names are PARADIGM-HF patients, already counted once in this pool at the level of the randomisation they belong . An earlier version of this field said the opposite -- that nothing about the shortfall was known, not even a name -- and that had stopped being true the moment the ANSWER-HF registry record was staged. A stated unknown is something a reader trusts, so carrying one that the bundle itself refutes is worse than the gap it was describing. |
| Access limitation | One comparison review was fully readable and its included-study table is what made this reconciliation possible. The other relevant reviews -- those covering the Chagas sub-question -- are paywalled: each returned a payment-required response when fetched on the date recorded here and none has an open-access copy, so their included-study lists could not be read and only their abstracts could. Where a list could not be read, no agreement is claimed from a matching count: that is the coincidence-of-counts overclaim this step exists to avoid, and the arithmetic that fails to reconcile is written out instead. |
| What the commit evidence does not establish | It does not establish prospectiveness. A commit proves when text entered this repository; it cannot prove that no earlier or parallel version existed elsewhere, that the data had not already been seen when the text was written, or that the analysis plan was fixed before the results were known. It also says nothing about the independence of the people who wrote it. Those are claims about conduct, and a timestamp cannot carry them. |
| Why they must not be added up | Two of the three are components of the composite. They share the same participants, so reading them alongside the composite counts the same people more than once. The composite counts first events and is not the sum of its components -- on PARADIGM-HF the components exceed it, which is expected. Nothing here is reconstructed by addition. |
| Source caveat | parallel-hf all-cause death is ClinicalTrials.gov only -- the Circ J primary paper does not report all-cause mortality at all, so that pair has no second source. |
| Scope | PRISMA 2020, 42 items. Status recorded per item; boxes are not filled to make the diagram look complete. |
| Scope | sacubitril/valsartan against enalapril in heart failure, any outcome, randomised or observational |
| The decision every field now states | Answer-hf is in the pool. k=4. It is flagged HIGH risk on selection of the reported result, because its contributed endpoint is not registered at any rank in its own registration. k=3 stands as the sensitivity analysis, not the primary. |
| Why this matters more than a tidy up | Omitting ANSWER-HF gives HR 0.8333 (0.7473-0.9292); including it gives 0.8715 (0.7461-1.0181). The interval crosses 1 only with it in. A reader who checks this object found it contradicting itself about the single trial that decides the inference. |
| Registry facts backfilled | Read from ClinicalTrials.gov API v2 on 2026-08-21. The judgements above were not revisited -- this adds the registry evidence beside a verdict that was made from it and did not record it, so a blind second assessor can be shown the same facts. A second assessment built on fewer facts is not a comparable assessment. |
| Was a second assessment possible here | Yes, and the earlier refusal was wrong. These three entries are keyed `paradigm-hf`, `parallel-hf` and `parachute-hf` and carry no `nct` field, so the backfill first reported them as 'the registration cannot be identified'. The object HELD the mapping two keys away: inputs.trials and results.by_outcome.*.per_trial both give paradigm-hf -> NCT01035255, parallel-hf -> NCT02468232, parachute-hf -> NCT04023227. Not a permanent refusal and not an obstacle in the evidence -- a lookup that read one field where this corpus uses two. |
| Why this topic disagrees on everything | ARNI is the authored docmodel topic. Its risk-of-bias entries were written as prose judgements with domain keys the randomisation process..selection of the reported result and no registry fields at all -- the facts were backfilled on 2026-08-21, after those judgements were made. So assessor 1 judged from sources this comparison cannot see, and assessor 2 judged from the registry alone. The 100% rate is not a measure of the assessors; it is the fact-allow-list problem in its purest form, on the one topic where the first assessment did not come from the registry. |
Every paper this project ships carries this section. A synthesis that reports only its own result asks a reader to take the field on trust; one that reconciles itself against the published syntheses on the same question, names what they got right as prominently as what they got wrong, and shows the denominator, can be checked. The classes applied below are the classes this review must itself survive. On the night this section was written, this object failed three of them: analysis panels computed at k=3 under a k=4 headline, a title stating a study count its own contents contradicted, and a figure labelled as a diagnostic it was not drawing.
13 checks were applied to this review and 9 came back clean. The denominator is stated because a list of only the failures is not a finding, it is a selection.
Confirmations are listed in the same table, in the same detail, as errors. Two checks were designed to catch a fault and instead cleared the paper: including a cohort study is inside their own stated eligibility, and omitting a small-study test at nine studies is what the Handbook advises.
| Check | Verdict | What was found |
|---|---|---|
| Stated study count against the rows of its own Table 1 count-stated-vs-table | CONFIRMED checked and clean | The abstract and Results both say nine. Table 1 carries exactly nine author rows: Bano, Desai, Li, McMurray, Pathadka, Piepoli, Tsutsui, Velazquez, Zhao. Counted from the staged full text, not taken from the abstract. Quoted: “A total of nine studies were included in this meta-analysis.” — Abstract; Results, paragraph 1 |
| Stated design mix against the Design column of Table 1 design-counts | CONFIRMED checked and clean | Eight rows are typed RCT and one, Pathadka 2020, RC. The stated split is exact. Quoted: “Out of nine studies, eight were RCTs.” — Results, paragraph 1 |
| PARADIGM-HF arm sizes against our own source-read values paradigm-arms | CONFIRMED checked and clean | Their Table 1 gives 4187 and 4212. This object read 4187 and 4212 from the trial's own publication and registry record. Identical. Quoted: “McMurray et al. 2014 RCT ... 4187 ... Enalapril 10 mg twice 4212” — Table 1 |
| PARALLEL-HF arm sizes against our own source-read values parallel-arms | CONFIRMED checked and clean | Their Table 1 gives 111 and 112, matching this object exactly. This is the trial their list caused us to recover, so their record is also the reason our k rose from two to three. Quoted: “Tsutsui et al. 2021 RCT ... 111 ... Enalapril 10 mg twice 112” — Table 1 |
| Internal arithmetic of the study-selection flow prisma-arithmetic | CONFIRMED checked and clean | 1,066 retrieved, 985 screened after duplicates, 28 full texts, nine included. Monotone decreasing and internally consistent; no stage exceeds the one above it. Quoted: “We obtained 1,066 studies through online database searching. After removing duplicates, 985 studies were initially screened” — Results, paragraph 1 |
| Whether their omission of PARACHUTE-HF is an error or a date search-date-vs-our-newer-trial | CONFIRMED checked and clean | Their search closed 15 September 2023. PARACHUTE-HF reported in 2026. Its absence from their review is correct and is not counted against them. A reconciliation that scored this as a miss would be scoring them for not seeing the future. Quoted: “systematically searched online databases including PubMed, Cochrane Library, and Web of Science from inception till September 15, 2023” — Abstract; Methods |
| Whether including a retrospective cohort breaches their own stated eligibility cohort-against-own-criterion | CONFIRMED checked and clean | It does not. Their pre-specified criteria admit observational designs explicitly, so Pathadka 2020 is inside their own protocol. This object excludes it because this question is restricted to randomised evidence, which is a different question and not a fault in theirs. Checked precisely because population-included-against-the-paper's-own-criterion is one of the classes we look for, and here it is clean. Quoted: “The pre-defined inclusion criteria were observational studies (retrospective cohorts and prospective cohorts) or RCTs comparing sacubitril” — Methods |
| Whether the influential non-randomised study was tested sensitivity-reported | CONFIRMED checked and clean | It was, and the result is reported in the body rather than buried: removing Pathadka moves all-cause mortality from 0.57 to 0.85 and heterogeneity from 94 per cent to 0. Reporting a sensitivity analysis that overturns your own headline is good practice and is recorded here as such. Quoted: “We performed sensitivity analysis by removing the study conducted by Pathadka et al. as it was a retrospective study.” — Results, All-Cause Mortality |
| Absence of a funnel plot or small-study test no-publication-bias-test | CONFIRMED checked and clean | None is reported, and at nine studies none is expected: the Cochrane Handbook advises against interpreting these tests below about ten. Their omission is defensible and is not counted as a defect. This object applies the same caution to its own Egger's test at k = 4. whole paper |
| Whether the Discussion's significance claim matches the primary estimate discussion-significance-overstated | ERROR a defect, in the source named | The primary all-cause mortality estimate is RR 0.57 with a 95 per cent interval of 0.31 to 1.04. That interval contains 1, so the comparison is not statistically significant. The Discussion nevertheless states that all three outcomes, all-cause mortality among them, were significantly higher. The statement is true of their RCT-only sensitivity result, 0.85 (0.78 to 0.93), and is not true of the analysis the abstract leads . It is an error of precision rather than a fabricated number, and it is recorded that way. Quoted: “The present meta-analysis reported that the risk of all-cause mortality, cardiovascular mortality, and cardiovascular hospitalization was significantly higher in patients receiving enalapril compared to patients receiving sacubitril/valsartan.” — Discussion, paragraph 1 |
| Whether the abstract's headline carries the heterogeneity it rests on abstract-headline-omits-i2 | ERROR a defect, in the source named | The abstract reports RR 0.57 (0.31 to 1.04) for all-cause mortality with no mention that I-squared for that pool is 94 per cent, nor that removing one retrospective study takes it to 0 and moves the estimate to 0.85. A pooled estimate at I-squared 94 is an average over results that disagree, and an abstract is where most readers stop. Their own body text is transparent about both facts; the abstract is not. Quoted: “Significant heterogeneity was reported among the study results (p = 0.001; I-square: 94%).” — Results, All-Cause Mortality; Abstract |
| Per-study risk-of-bias or quality appraisal no-risk-of-bias-appraisal | ABSENT the thing checked for is not there | No Cochrane RoB, Jadad, Newcastle-Ottawa or equivalent appears anywhere in the text. The JBI reference is to the study-SELECTION protocol, not to an appraisal of the included studies. Risk of bias is a required PRISMA item, and pooling a retrospective cohort with randomised trials is exactly the situation it exists to surface. Quoted: “The selection and critical appraisal of studies adhered to the Joanna Briggs Institute's (JBI) protocol, which offers a more precise and stringent set of criteria for the study selection process.” — Methods |
| Prospective protocol registration no-registration | ABSENT the thing checked for is not there | PROSPERO is not mentioned and no registration of any kind is stated, so the analysis cannot be checked against a pre-specified plan. Recorded as an absence rather than an error: an unregistered review is not a wrong one. This object states its own registration as a timestamped public commit with an ordering test, so it is a standard we hold ourselves . whole paper |
| 38084196 | Reyaz I, et al. Comparison of outcomes between sacubitril/valsartan and enalapril in patients with heart failure: a systematic review and meta-analysis. Cureus 2023;15(11):e48623. Three differences, and none of them makes either review wrong. They admit observational designs and this object does not. They pool risk ratios over whole follow-up; this object pools a time-to-first-event hazard ratio, a different quantity. Their search closed in September 2023, before two of the four trials pooled here existed. |
|---|
| This review | HR 0.872 (0.746 to 1.018) for cardiovascular death or first heart-failure hospitalisation, k=4, time-to-first-event. |
|---|---|
| The published synthesis | RR 0.76 (0.66 to 0.86) for cardiovascular hospitalisation and RR 0.75 (0.62 to 0.91) for cardiovascular mortality, reported as separate outcomes. |
| Why they differ | Four reasons, none of which is an error by either side: a different estimand (hazard of a first event against risk over whole follow-up); a different eligible set (they admit observational designs, we do not); a different search window (ours includes two trials published after theirs closed); and a different composite (they report hospitalisation and cardiovascular death separately, we pool the composite of the two). Decomposed rather than asserting ours is right: on the trials and the quantity the two reviews share, they agree. |
How they were identified: By lookup, never recall. The comparison review's identifiers were resolved through the PubMed ID converter on 2026-08-14: DOI 10.7759/cureus.48623 returns PMID 38084196 and pmcid PMC10710849. Its full text is staged in this bundle and every quotation below was read from that file.
Certainty: Pending — not rated. The risk-of-bias assessment this rating reads is unadjudicated, so no certainty level is published for this outcome
Started at high — every contributing study is a randomised controlled trial.
start high; risk_of_bias serious (-1), imprecision serious (-1); total -2 -> low. The risk_of_bias rating was re-examined against the completed RoB-2 assessment on 2026-08-12 and did not move; see domains.risk_of_bias.rob2_effect_on_this_rating.
| Domain | Rating | Why it was rated that way |
|---|---|---|
| Risk of bias | serious | Three separate features, each read from a staged source rather than assumed. PARACHUTE-HF describes itself as an 'open-label, multicenter randomized clinical trial' with blinded endpoint adjudication; blinded adjudication protects how an event is classified but not the unblinded management decisions that produce a heart failure hospitalization, which is one of the two components. In the same trial this composite is the first secondary endpoint, the primary being a win ratio, so the result pooled here comes from that trial's secondary hierarchy and carries the multiplicity and selective-reporting exposure that goes with it; the separate question of the trial not being powered for this endpoint is random error and is carried in the imprecision domain, not here. PARADIGM-HF 'was stopped early, according to prespecified rules ... because the boundary for an overwhelming benefit with LCZ696 had been crossed', and a trial stopped early for benefit tends to overstate the effect it was stopped for -- which matters here because the leave-one-out analysis shows the pooled benefit rests on that trial. One level, not two: the trials are randomised, centrally adjudicated and large, and none of the three features is a failure of randomisation. |
| Inconsistency | not serious | — |
| Indirectness | not serious | All four trials enrol the population the question names, randomise the intervention the question names against the comparator the question names, and report the outcome the question names. The Chagas aetiology of one trial makes its population narrower than the others, not indirect: it is heart failure with reduced ejection fraction, entered on an ejection fraction of 40% or less and NYHA class II to IV, exactly as the other two are. Directness is judged against the review's own question, and this question is about heart failure with reduced ejection fraction rather than about any one aetiology of it. |
| Imprecision | serious | — |
| Publication bias | not assessable | — |
No, it does NOT move. It was serious before the assessment and is serious after it.
Two reasons, and the second is the load-bearing one. First, RoB-2 confirmed the substance of the downgrade rather than removing it. Both assessors, independently and from different model families, rated PARACHUTE-HF domain 2 as some concerns on the open-label deviations point, which is the first of the three features the rating was already built on. The second assessor also rated its domain 5 as some concerns on the selective-reporting point, which is the second feature. The assessment agreed with the reasoning the rating rested on. Second, and this is why 'no domain reached HIGH' does not discharge the downgrade: RoB-2 has no domain for a trial stopped early for benefit. Early stopping is not a randomization failure, a deviation, missing data, a measurement problem, or selective reporting of a result; it is a stopping-rule effect on the magnitude of the estimate, and the RoB-2 tool does not ask about it in any of its five domains. PARADIGM-HF was stopped early by prespecified rule for overwhelming benefit and the leave-one-out analysis shows the pooled benefit rests on that trial. That third feature is therefore untouched by a clean RoB-2 result, and it alone sustains a serious rating. Reading 'no domain HIGH' as grounds to remove the downgrade would be mistaking the silence of a tool for the absence of a problem.
The opposite reading, recorded rather than suppressed: The opposite reading is available and is recorded here rather than suppressed: under a common mapping, trials at some concerns with none at HIGH support 'not serious', which would raise certainty from low to moderate. We do not adopt it, for the stopping-rule reason above, and because five of fifteen domain judgements are still unadjudicated -- changing a published certainty rating on the strength of a disagreement set nobody has resolved would be the wrong direction to move under uncertainty.
What would change it: If the named human adjudicates the five open disagreements toward LOW, and separately judges that the early-stopping effect is adequately carried by the imprecision and leave-one-out analyses rather than here, then 'not serious' becomes defensible and certainty would rise to moderate. That is a human decision on the record, not an automatic consequence of the assessment.
In this section: Manuscript — document view · Sacubitril/valsartan against enalapril in heart failure with reduced ejection fraction: a systematic review and meta-analysis of the four randomised trials that report cardiovascular death or heart failure hospitalization as a time-to-first hazard ratio · Contents · Abstract · Introduction · Methods · Protocol and registration · Eligibility criteria · Information sources and search · Study selection and data collection · Effect measures and synthesis · Risk of bias · Certainty and robustness · Recorded detail · Results · Study selection · Trial characteristics · Primary synthesis · Robustness · Cross-engine verification · Risk of bias · Certainty of the evidence · Subgroup analysis · Small-study effects · Comparison with published syntheses · Tables and figures · Extracted values, and where each came from · Certainty of the evidence · Risk of bias in the included results · Disagreements between sources · Comparison with published syntheses · Reyaz I, et al. Comparison of outcomes between sacubitril/valsartan and enalapril in patients with heart failure: a syst · Where our result differs from theirs · Statistical output, quoted verbatim · Discussion · Principal findings · Interpreting the estimate · Heterogeneity · The leave-one-out finding · Why the risk-of-bias rating did not change · Comparison with other evidence · Strengths · Limitations · Conclusions · Sections not written, and why · Funding and conflicts of interest · References · Keywords · Data availability · Software availability · Note on registration · Tables · Figure legends · Figures · Submission conformance
Rendered from the same block sequence the Word file is built from: 18 tables and 16 figures, in the same order, with the same numbering. The figures are the identical PNG files the .docx embeds, not a second render. Built 2026-08-17T16:19:14Z.
Downloads
In adults with heart failure and reduced ejection fraction, what is the hazard of a first cardiovascular death or heart failure hospitalization with sacubitril/valsartan compared with enalapril?
Submission readiness: NOT YET DETERMINED. Every number in this document is projected from a single canonical object; sections that could not be written from it say so in place.
Background. Angiotensin receptor-neprilysin inhibition changed the treatment of heart failure with reduced ejection fraction on the strength of a single large trial. Because that trial dominates the guidelines and every later synthesis, what the accumulated randomised evidence shows when it is not treated as the answer on its own is a different question, and the one this review asks.
Methods. PubMed and ClinicalTrials.gov were searched on 2026-08-12 with no language, date or publication-status filter. Randomised trials of sacubitril/valsartan against enalapril in adults with heart failure and reduced ejection fraction were eligible if they reported the composite of cardiovascular death or first hospitalisation for heart failure as a time-to-first-event hazard ratio. Hazard ratios were pooled on the log scale by generic inverse variance under a random-effects model with the REML estimator. Risk of bias used the Cochrane risk-of-bias tool for randomised trials, effect-of-assignment variant, assessed independently by two assessors. Certainty used the Grading of Recommendations Assessment, Development and Evaluation approach.
Results. 423 records were screened and 4 trials met all eligibility conditions. Those trials randomised 9,779 participants. Of those, 9,734 participants were analysed. The pooled hazard ratio was 0.872 (0.746 to 1.02), an interval that includes no effect. Heterogeneity was moderate and estimator-dependent, with I-squared 32.9 percent under the registered estimator. The pooled result is dominated by one trial: omitting the largest gives 0.966 (0.79 to 1.18), and each of the three remaining trials has an interval that includes no effect. No risk-of-bias domain was rated high in the three trials that were assessed (PARADIGM-HF, PARALLEL-HF and PARACHUTE-HF); the fourth contributing trial was not assessed, so this is not a statement about the synthesis as a whole. Certainty is not rated pending adjudication.
Conclusions. Across 4 randomised trials the pooled estimate is compatible with no difference between sacubitril/valsartan and enalapril for a first cardiovascular death or heart failure hospitalisation. The point estimate favours sacubitril/valsartan and rests almost entirely on one large trial; the three smaller trials are individually and jointly compatible with no effect. This is an argument for reading that one trial as the evidence base rather than treating the pooled average as confirmation of it.
Heart failure with reduced ejection fraction carries a mortality and rehospitalisation burden that renin-angiotensin system inhibition reduces but does not remove. Angiotensin receptor-neprilysin inhibition was developed to act on a second pathway at the same time, combining neprilysin inhibition, which raises natriuretic peptide concentrations, with angiotensin receptor blockade.
The pivotal comparison against enalapril reported a substantial reduction in the composite of cardiovascular death or heart failure hospitalisation and was stopped early by prespecified rule for overwhelming benefit. That trial is the reason the drug entered guidelines, and it remains by a wide margin the largest randomised comparison of these two agents on this endpoint.
Three later randomised comparisons against the same active comparator have reported the same composite in different populations. None was powered to detect the effect the pivotal trial found, one reports the composite as a secondary rather than a primary endpoint, and two enrolled a single aetiology. They are nonetheless the only additional randomised evidence on this estimand.
A meta-analysis in which one trial contributes most of the information is often criticised as adding nothing to that trial. The criticism is worth taking seriously rather than deflecting, and it is why this review reports leave-one-out as a principal result rather than a sensitivity appendix. The question it can answer is not whether the drug works, which the pivotal trial addresses directly, but how much of the pooled estimate survives that trial's removal.
The protocol was registered before any query was executed, as a timestamped commit in a public repository, and is reachable at a SHA-pinned permalink that cannot be rewritten without changing the hash. The interval between registration and the first executed query was +51 min 31 s to the attempt, +54 min 52 s to the first successful execution, and the ordering is re-tested at every build rather than asserted once. Amendments are recorded as further commits, each marked according to whether it precedes or post-dates the first search, so a reader can see which decisions were made in ignorance of the results and which were not.
Trials were eligible if they randomised adults with heart failure and reduced ejection fraction to sacubitril/valsartan or to enalapril and reported the composite of cardiovascular death or first heart failure hospitalisation as a time-to-first-event hazard ratio. The fourth condition is a condition on the reported quantity, not on quality. Several excluded records are large, well conducted, and directly concerned with this drug; they are excluded because they report a different estimand, and the supplement records for each one which axis it failed and what it reported instead.
PubMed and ClinicalTrials.gov were searched on 2026-08-12. The query strings are reproduced in the supplement exactly as sent, with the endpoint, the parameters, the filters and the UTC time of execution, so that the search can be re-run rather than merely described. No language, date or publication-status filter was applied. 423 records were returned and every one is listed with its disposition.
Records were screened against the eligibility axes, and each exclusion records the axis that failed and, where the failure was on a reported quantity, the quantity the record gave instead. One inclusion decision reversed a screener's original exclusion; that adjudication is shown as an override naming the adjudicator and the time, rather than being absorbed silently into the included set.
Hazard ratios were analysed on the log scale by generic inverse variance, with the standard error implied by each published interval. A random-effects model was fitted with the REML estimator of the between-study variance; DerSimonian-Laird was not used, because it is known to be biased when the number of trials is small, and with 4 trials that condition holds. Heterogeneity is reported as tau-squared alongside I-squared, because I-squared is a proportion and says nothing about the magnitude of the between-trial spread. Results were computed with metafor under R at build time; the figures on this page are drawn from the stored estimates, not recomputed in the browser.
Each pooled result was assessed with RoB-2 using the effect-of-assignment variant, at the level of the result being pooled rather than the trial overall. Two assessors worked independently, drawn from different model families and excluding whichever assembled this object. Every signalling question answer is published in the supplement. Agreement is reported as measured, before reconciliation, and disagreements that remain open are shown as open.
Certainty was rated with GRADE. Robustness was examined by leave-one-out and by refitting under alternative between-study variance estimators, following the Cochrane Handbook's guidance that sensitivity analysis should test the decisions capable of changing the conclusion. The whole analysis was independently recomputed by a second engine and the two were compared to a stated tolerance.
Registered as a timestamped public commit in https://github.com/mahmood726-cyber/rapidmeta-finerenone at path ssot/arni-hfref/arni-hfref.json. Commit 961400264a06, committed 2026-08-10T05:13:40Z. The protocol commit precedes the first executed query on both readings of 'first query'. The 12:19:18Z attempt is reported even though it returned nothing, because reporting only the successful execution would move the first-query time three minutes later and make the claim look better than it is. This is the test a PROSPERO record cannot offer: the timestamps are set by the repository and by the APIs, not by us, and both are independently checkable.
A randomised trial of sacubitril/valsartan against enalapril, in adults with heart failure and reduced ejection fraction, reporting cardiovascular death or heart failure hospitalization as a time-to-first-event hazard ratio. All four conditions, and the last is a condition on the QUANTITY reported, not on the trial's quality: several excluded trials are large, well conducted and directly on topic, and report something that is not this.
The search ran across PubMed and ClinicalTrials.gov for randomised comparisons of sacubitril/valsartan with enalapril in heart failure, and was then extended by the reconciliation step: the included-study list of every retrievable published synthesis of the same comparison was read and diffed against this one in both directions. That second pass is what found PARALLEL-HF, which the brief this object was built from did not name.
Each database's query string is recorded in the canonical object exactly as executed, with the endpoint, the parameters, the filters, the execution timestamp and the hit count the API returned, and all of it is reproduced in the extended data (search_capture.csv). The search is therefore reproducible from this record. This paragraph previously asserted the opposite -- that no query string was recorded and the search was not reproducible -- while the strings sat in the object six paragraphs away.
Random-effects model with the REML estimator.
| Stage | n | Detail |
|---|---|---|
| Records identified from databases and registers | 423 | PubMed: 331; ClinicalTrials.gov API v2: 92 |
| Records removed before screening | 0 | No de-duplication step is recorded; the retrieved totals sum exactly to the screened corpus. Corpus tally: CTGov 92, PubMed 331 |
| Records screened on title and abstract | 423 | |
| Records excluded at title and abstract | 412 | |
| Records undetermined at title and abstract | 2 | Not counted as exclusions. |
| Reports assessed for eligibility at full text | 9 | |
| Reports excluded at full text | 2 | |
| Studies contributing to the synthesis | 7 |
423 records were screened and 4 trials met all four eligibility conditions. Those trials randomised 9,779 participants. Of those, 9,734 participants were analysed. The count of eligible trials is reported as a LOWER BOUND rather than as a settled number, because a small number of records could not be resolved to a decision from what is publicly reachable; treating an unresolved record as an exclusion would be an assumption presented as a count. The flow of records through screening, with the stages this corpus never recorded stated as such, is shown in the PRISMA figure.
The 4 trials differ in ways that matter for interpretation. One is a large double-blind trial reporting this composite as its own primary endpoint. Two enrolled chronic Chagas cardiomyopathy, one of them open-label with blinded adjudication and reporting this composite behind a win-ratio primary. One is double-blind and small. Characteristics are in Table 1 and per-arm counts in Table 2. Characteristics of the included trials are given in the table of included studies and their per-arm event counts in the table of per-arm counts.
The pooled hazard ratio was 0.872 (0.746 to 1.02, 95% interval), favouring sacubitril/valsartan over enalapril. Between-trial heterogeneity was low: I-squared 32.9%, tau-squared 0.0086, with Q of 5.16 on 3 degrees of freedom. The individual estimates range from 0.8 to 1.83, and that spread is real even though the heterogeneity statistics are small, because three of the four intervals include the null and two of those span more than a doubling of risk. The per-trial and pooled estimates are shown in the forest plot. The prediction interval for a future study runs from 0.686 to 1.11.
The pooled result is not robust to the removal of the largest trial. Omitting it gives 0.966 (0.79 to 1.18), an interval that includes the null. The three smaller trials are therefore individually and jointly compatible with no effect on this composite, and the pooled estimate is best read as the large trial's result, slightly attenuated by the three smaller trials, which neither confirm nor contradict it. Refitting under alternative between-study variance estimators did not change this conclusion. Each refit is shown in the leave-one-out figure and tabulated in the leave-one-out table; 2 of 4 refits still exclude no difference.
The whole synthesis was recomputed independently and the two engines agreed on the point estimate and both bounds to within the stated tolerance, with Q and its degrees of freedom matching exactly. This establishes that the arithmetic is reproducible; it does not establish that the inputs are correct, and it is reported as the former only.
No domain in any trial was rated at high risk of bias by either assessor. The two assessors agreed on 10/15 domain judgements (66.7%), and on 1 of 3 overall judgements. That agreement rate is markedly lower than the agreement observed at screening, and it is published because an unreported agreement rate is not the same as a high one. Per-domain judgements from both assessors are shown in the risk-of-bias figure.
GRADE certainty for this outcome is low, downgraded for risk of bias and for imprecision. The completed RoB-2 assessment was checked against the risk-of-bias downgrade and did not change it, for reasons given in the discussion.
One subgroup analysis was performed and it was NOT pre-specified. Splitting the pool by aetiology gives 0.838 (0.675 to 1.04) across the 2 trials in unrestricted heart failure and 1.11 (0.598 to 2.05) across the 2 trials restricted to Chagas cardiomyopathy. The test for interaction returns p = 0.538 and a ratio of hazard ratios of 1.16 (0.717 to 1.89), so the difference between the strata is compatible with chance. Splitting on aetiology does not explain the heterogeneity: the residual I-squared within strata is higher than the overall value, not lower. Because the analysis is post hoc it is reported as hypothesis-generating and is labelled post hoc wherever it appears, in keeping with the Cochrane Handbook v6.5 section 10.11.5 caution against presenting unplanned subgroup contrasts as findings.
A funnel plot is shown and Egger's regression test was run for completeness, returning an intercept of -0.3 with p = 0.0106. Neither is interpreted. At 4 trials the Cochrane Handbook v6.5 section 13.3.5.4 advises against interpreting funnel asymmetry or its tests below about ten studies, and the movement of this p value when the fourth trial entered is what a test with almost no power does rather than evidence about publication bias. No claim about small-study effects is made in either direction.
One published synthesis on the same comparison had a readable included-study table and was reconciled against this review trial by trial. 13 checks were applied to it, of which 9 came back clean, 2 identified an error and 2 identified a reporting item that is absent. Its included-study list is also the reason this review's k rose during the build: PARALLEL-HF was eligible on every axis of the frozen question, was absent from the brief this object was built from, and was recovered from that list, verified against its own publication and registry record, and pooled. The full reconciliation, the quoted evidence for every check with its location, and the decomposition of where the two reviews differ are given in the section on comparison with published syntheses.
| Trial | Registry ID | Year | Design | Population | Analysed (T/C) |
|---|---|---|---|---|---|
| PARADIGM-HF | NCT01035255 | 2014 | phase 3, double-blind, randomised one to one against an acti | adults with NYHA class II to IV heart failure and | 4187 / 4212 |
| PARACHUTE-HF | NCT04023227 | 2026 | phase 4, multicentre, randomised one to one against an activ | adults with NYHA class II to IV heart failure, an | 462 / 460 |
| PARALLEL-HF | NCT02468232 | 2021 | phase 3, randomised one to one against an active comparator, | Japanese adults with NYHA class II to IV chronic h | 111 / 112 |
| ANSWER-HF | NCT04853758 | 2026 | phase 4, randomised, double-blind, 1:1 against an active com | adults with heart failure, LVEF below 40%, NYHA II | 95 / 95 |
| Trial | Intervention events / n | Comparator events / n | Source tier |
|---|---|---|---|
| PARADIGM-HF | 914 / 4187 | 1117 / 4212 | T1+T2 |
| PARACHUTE-HF | 155 / 462 | 169 / 460 | T1 |
| PARALLEL-HF | 30 / 111 | 28 / 112 | T1+T2 |
| ANSWER-HF | 12 / 95 | 8 / 95 | T1 |
One row per extracted value, carrying the value, the verbatim sentence it was read from, a resolvable link to the source, and whether the number was read or derived. Where any of those is absent the row says so rather than omitting the value. This table is the audit surface: it is what a reader uses to check this review against its sources without trusting it.
| Trial / outcome | Value as extracted | Verbatim source sentence | Source links | Read or derived |
|---|---|---|---|---|
| PARADIGM-HF / cardiovascular death or hospitalisation for heart failure, whichever comes first | 0.8 (95% CI 0.73 to 0.87) | “At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001).” “In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy.” “The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes.” | NCT NCT01035255 | PMID 25176015 | https://pubmed.ncbi.nlm.nih.gov/25176015/ | READ from the source as printed -- The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source. |
| PARACHUTE-HF / cardiovascular death or hospitalisation for heart failure, whichever comes first | 0.91 (95% CI 0.73 to 1.13) | “The first secondary end point was the composite of time to first HF hospitalization or death from cardiovascular causes ( Figure 2 , C, D, and E), which occurred in 155 patients (33.5%) in the sacubitril/valsartan group and 169 (36.7%) in the enalapril group (HR, 0.91 [95% CI, 0.73-1.13])” “The primary end point was a hierarchical composite outcome tested, in order, of death from cardiovascular causes, hospitalization for HF, or relative change in NT-proBNP from baseline to 12 weeks. The primary analysis was done using a win ratio approach.” “Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female).” | NCT NCT04023227 | PMID 41335448 | https://pubmed.ncbi.nlm.nih.gov/41335448/ | READ from the source as printed -- The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source. |
| PARALLEL-HF / cardiovascular death or hospitalisation for heart failure, whichever comes first | 1.09 (95% CI 0.65 to 1.82) | “Over a median follow up of 33.9 months, no significant between-group difference was observed for the primary composite outcome of CV death and HF hospitalization (HR 1.09; 95% CI 0.65-1.82; P=0.6260).” “In the Prospective comparison of ARNI with ACEi to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients (PARALLEL-HF) study, 225 Japanese HFrEF patients (New York Heart Association [NYHA] class II-IV, left ventricular ejection fraction [LVEF] ≤35%) were randomized (1 : 1) to receive sacubitril/valsartan 200 mg bid or enalapril 10 mg bid.” | NCT NCT02468232 | PMID 33731544 | https://pubmed.ncbi.nlm.nih.gov/33731544/ | READ from the source as printed -- The point estimate and interval are stored as published. The log point and log standard error are DERIVED here, the standard error from the width of the published interval on the log scale, and are not claimed to appear in any source. |
| ANSWER-HF / cardiovascular death or hospitalisation for heart failure, whichever comes first | 1.83 (95% CI 0.72 to 4.67) | “Cardiovascular death and heart failure hospitalization 12/95 (12.6) 8/95 (8.4) 1.83 (0.72-4.67) 0.205” | NCT NCT04853758 | PMID 41396086 | https://pubmed.ncbi.nlm.nih.gov/41396086/ | READ from the source as printed -- Point and interval stored as published. The log point and log standard error are DERIVED here from the width of the published interval on the log scale, and are not claimed to appear in any source. |
| Trial | Endpoint | Intervention events / n | Comparator events / n | Published effect | Source tier |
|---|---|---|---|---|---|
| PARADIGM-HF | Cardiovascular death | 558 / 4187 | 693 / 4212 | None published | T1+T2 |
| PARADIGM-HF | First heart-failure hospitalisation | 537 / 4187 | 658 / 4212 | None published | T1+T2 |
| PARADIGM-HF | All-cause death | 711 / 4187 | 835 / 4212 | None published | T1+T2 |
| PARACHUTE-HF | Cardiovascular death | 110 / 462 | 117 / 460 | None published | T1 |
| PARACHUTE-HF | First heart-failure hospitalisation | 102 / 462 | 111 / 460 | None published | T1 |
| PARACHUTE-HF | All-cause death | 129 / 462 | 134 / 460 | HR 0.98 (0.77 to 1.25), P = 0.88 | T1+T2 |
| PARALLEL-HF | Cardiovascular death | 13 / 111 | 11 / 112 | None published | T1+T2 |
| PARALLEL-HF | First heart-failure hospitalisation | 25 / 111 | 20 / 112 | None published | T1+T2 |
| PARALLEL-HF | All-cause death | 19 / 111 | 16 / 112 | None published | T2 ONLY -- SINGLE SOURCE |
| ANSWER-HF | Cardiovascular death | 7 / 95 | 6 / 95 | HR 1.27 (0.43 to 3.81), P = 0.665 | T1 |
| ANSWER-HF | First heart-failure hospitalisation | 7 / 95 | 5 / 95 | HR 1.42 (0.45 to 4.46), P = 0.553 | T1 |
| ANSWER-HF | All-cause death | 8 / 95 | 8 / 95 | HR 1.08 (0.4 to 2.89), P = 0.879 | T1 |
Table 5 lists them. They are shown because they are reported, and are NOT pooled: this review's estimand is the composite. A first-event composite is not the sum of its components -- on PARACHUTE-HF the components exceed it -- so no composite anywhere in this review is reconstructed by addition. ‘None published’ means no effect estimate for that endpoint was found in the sources read for that trial; the per-arm counts were, and are shown. It is not a derivation this review declined to make and it is not an extraction miss. Where a trial's own reason is recorded it is given below.
PARACHUTE-HF, Cardiovascular death: Table 2 reports this endpoint as a tier of the primary hierarchical win ratio, with win percentages rather than a hazard ratio. No HR is published for it, so none is shown and none is derived. Recorded so the empty cell reads as the source's silence rather than as an extraction miss.
PARACHUTE-HF, First heart-failure hospitalisation: Table 2 reports this endpoint as a tier of the primary hierarchical win ratio, with win percentages rather than a hazard ratio. No HR is published for it, so none is shown and none is derived. Recorded so the empty cell reads as the source's silence rather than as an extraction miss.
Pooled HR 0.872 (0.746 to 1.02), k = 4. I-squared 32.9%, tau-squared 0.0086, Q 5.16 on 3 degrees of freedom.
| Measure | Pooled (95% interval) | I-squared (%) | k |
|---|---|---|---|
| Risk ratio | 0.872 (0.777 to 0.979) | 25.2 | 4 |
| Odds ratio | 0.825 (0.712 to 0.955) | 17.8 | 4 |
| Risk difference | -0.0231 (-0.0629 to 0.0167) | 44.1 | 4 |
| Trial omitted | Pooled estimate (95% interval) | I-squared (%) |
|---|---|---|
| paradigm-hf | 0.966 (0.79 to 1.18) | 1.2 |
| parachute-hf | 0.972 (0.666 to 1.42) | 52.9 |
| parallel-hf | 0.844 (0.736 to 0.967) | 26.5 |
| answer-hf | 0.839 (0.743 to 0.948) | 22.2 |
| Estimator | Interval method | Point | Lower | Upper | tau-squared |
|---|---|---|---|---|---|
| REML | Wald | 0.872 | 0.746 | 1.02 | 0.0086 |
| REML | HKSJ | 0.872 | 0.657 | 1.16 | 0.0086 |
| DL | Wald | 0.883 | 0.741 | 1.05 | 0.0126 |
| DL | HKSJ | 0.883 | 0.651 | 1.2 | 0.0126 |
| PM | Wald | 0.904 | 0.731 | 1.12 | 0.022 |
| PM | HKSJ | 0.904 | 0.641 | 1.28 | 0.022 |
| Record | Registry / PMID | Decision | Reason |
|---|---|---|---|
| PARAGON-HF | NCT01920711 PMID 31475794 | excluded | Fails the frozen question on all three axes, and any one of them is sufficient. POPULATION: it enrolled an ejection fraction of 45% or higher, which is preserved rather than reduced. COMPARATOR: it randomised against VALSARTAN, not enalapril. MEASURE: its primary is the cumulative number of cardiovascular deaths and TOTAL, first and recurrent, heart failure hospitalizations, analysed as a RATE RAT |
| PARADISE-MI | NCT02924727 | excluded | POPULATION: acute myocardial infarction with left-ventricular dysfunction or pulmonary congestion, not chronic heart failure with reduced ejection fraction. COMPARATOR: RAMIPRIL, not enalapril. OUTCOME: its composite counts INCIDENT heart failure -- a first presentation in people who did not have heart failure at randomisation -- which is not hospitalization for heart failure in an established hea |
| PARAGLIDE-HF | NCT03988634 PMID 37212758 | excluded | POPULATION: ejection fraction above 40% after a worsening heart failure event. COMPARATOR: VALSARTAN. MEASURE: the primary is the time-averaged proportional change in NT-proBNP, a biomarker ratio-of-change, and its hierarchical secondary is a win ratio. Neither is a hazard ratio for a clinical event. |
| ANSWER-HF | NCT04853758 PMID 41396086 | excluded | This is the hardest exclusion in the table and the only one that passes the population and the comparator: 190 patients with heart failure with reduced ejection fraction due to Chagas cardiomyopathy, randomised double-blind against ENALAPRIL. It fails on the MEASURE. Its primary endpoint is the change in left-ventricular ejection fraction at six months, and its only composite analysis of cardiovas |
| PIONEER-HF | NCT02554890 | screened, not eligible | Right population and right comparator -- acute decompensated heart failure with reduced ejection fraction, randomised against enalapril -- and the wrong quantity over the wrong horizon. The brief noted a conflict between a rule excluding follow-up under twelve weeks and a rule keyed to the trial's own endpoint, and left both standing. It is resolved here against the frozen question and only one ru |
| EVALUATE-HF | NCT02874794 | screened, not eligible | Randomised against enalapril in heart failure with reduced ejection fraction, and its endpoint is a vascular-mechanics measurement. It reports no hazard ratio for the composite. |
| OUTSTEP-HF | NCT02900378 | screened, not eligible | Randomised against enalapril in heart failure with reduced ejection fraction. Its endpoint is an activity measure, not a clinical event, and it reports no hazard ratio for the composite. |
| PARALLAX | NCT03066804 | screened, not eligible | Fails the population as well as the measure: it enrolled an ejection fraction above 40%, and its comparator is individualised medical therapy rather than enalapril alone. |
| HFN-LIFE | NCT02816736 | screened, not eligible | Advanced, NYHA class IV heart failure, randomised against VALSARTAN rather than enalapril, with a biomarker endpoint. Recorded because the brief listed a trial called LIFE and this is the trial that name resolves to. |
| Pathadka 2020 | PMID 33553256 | screened, not eligible | This is the only excluded record in this object that reports THE QUANTITY THIS REVIEW POOLS, for THE COMPOSITE THIS REVIEW POOLS, and it is excluded anyway. It is not a randomised trial: it is a population-based new-user cohort drawn from the Hong Kong-wide electronic health record, 1056 people dispensed sacubitril/valsartan against 2181 dispensed enalapril, with treatment assigned by prescribers |
| Bano 2021 | PMID 34395116 | screened, not eligible | Right population and right comparator: a randomised comparison of sacubitril/valsartan with enalapril, in equal allocation, in heart failure at a tertiary hospital in Pakistan, 181 against 183, followed for twelve months or to an event. It fails on the measure. Its full text contains no hazard ratio, no Cox model and no time-to-event analysis of any kind; it reports proportions and relative risk r |
| Zhao 2022 | PMID 35874853 | screened, not eligible | A randomised comparison of sacubitril/valsartan with enalapril, 52 against 45, in pulmonary hypertension due to heart failure with reduced ejection fraction, followed for six months. Population and comparator hold; the measure does not. Its declared primary endpoint is echocardiographic right-ventricular function, and it reports no hazard ratio for any clinical event -- it states only that readmis |
| Li 2019 | screened, eligibility could not be established | Eligibility is undetermined, not decided. Neither inclusion nor exclusion is asserted here, and the trial is NOT pooled -- so this row records a limit of the search rather than a judgement about the trial. Its likely weight is small and is stated rather than used as a reason to stop looking: 126 randomised participants against the 8399 of the largest trial already pooled. If this trial does report |
This log covers the records the review adjudicated. The object does not hold the full set retrieved by the search, nor the stage at which each decision was taken, so a title/abstract versus full-text split cannot be shown. That gap is stated here rather than implied by a shorter table.
| Domain | Rating | Basis |
|---|---|---|
| Risk of bias | serious | Three separate features, each read from a staged source rather than assumed. PARACHUTE-HF describes itself as an 'open-label, multicenter randomized clinical trial' with blinded endpoint adjudication; blinded adjudication protects how an event is classified but not the unblinded management decisions that produce a heart failure hospitalization, which is one of the two components. In the same trial |
| Inconsistency | not serious | |
| Indirectness | not serious | All four trials enrol the population the question names, randomise the intervention the question names against the comparator the question names, and report the outcome the question names. The Chagas aetiology of one trial makes its population narrower than the others, not indirect: it is heart failure with reduced ejection fraction, entered on an ejection fraction of 40% or less and NYHA class II |
| Imprecision | serious | |
| Publication bias | not assessable |
Overall certainty: pending, not rated. start high; risk of bias serious (-1), imprecision serious (-1); total -2 -> low. The risk-of-bias rating was re-examined against the completed RoB-2 assessment on 2026-08-12 and did not move.
Assessed with Cochrane RoB-2 for randomized trials, effect of ASSIGNMENT to intervention (intention-to-treat), as pre-registered in PROTOCOL.md section 9. the result being pooled, not the trial overall: the composite of cardiovascular death or first hospitalisation for heart failure, as a time-to-first-event hazard ratio Two assessors worked independently: assessor 1 was GPT-5 (openai family) and assessor 2 was Gemini 3.1 Pro (google family). Neither assembled the canonical object. each assessor saw only its own trial packet; neither saw the other's answers
| Trial | Domain | Assessor 1 (openai) | Assessor 2 (google) | Agreed |
|---|---|---|---|---|
| paradigm-hf | D1 bias arising from the randomization process | LOW | LOW | yes |
| paradigm-hf | D2 bias due to deviations from intended interventions (effect of assignment) | LOW | LOW | yes |
| paradigm-hf | D3 bias due to missing outcome data | LOW | LOW | yes |
| paradigm-hf | D4 bias in measurement of the outcome | LOW | LOW | yes |
| paradigm-hf | D5 bias in selection of the reported result | SOME CONCERNS | LOW | NO |
| parallel-hf | D1 bias arising from the randomization process | SOME CONCERNS | LOW | NO |
| parallel-hf | D2 bias due to deviations from intended interventions (effect of assignment) | LOW | LOW | yes |
| parallel-hf | D3 bias due to missing outcome data | LOW | LOW | yes |
| parallel-hf | D4 bias in measurement of the outcome | LOW | LOW | yes |
| parallel-hf | D5 bias in selection of the reported result | SOME CONCERNS | LOW | NO |
| parachute-hf | D1 bias arising from the randomization process | LOW | SOME CONCERNS | NO |
| parachute-hf | D2 bias due to deviations from intended interventions (effect of assignment) | SOME CONCERNS | SOME CONCERNS | yes |
| parachute-hf | D3 bias due to missing outcome data | LOW | LOW | yes |
| parachute-hf | D4 bias in measurement of the outcome | LOW | LOW | yes |
| parachute-hf | D5 bias in selection of the reported result | LOW | SOME CONCERNS | NO |
| Trial | Assessor 1 | Assessor 2 | Agreed |
|---|---|---|---|
| paradigm-hf | SOME CONCERNS | LOW | NO |
| parallel-hf | SOME CONCERNS | LOW | NO |
| parachute-hf | SOME CONCERNS | SOME CONCERNS | yes |
Inter-assessor agreement, measured before any reconciliation: 10 of 15 domain judgements agreed (66.7%), and 1 of 3 overall judgements agreed. This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one.
| Trial | Domain | Assessor 1 | Assessor 2 | Carried | Status |
|---|---|---|---|---|---|
| paradigm-hf | D5 | SOME CONCERNS | LOW | SOME CONCERNS | AWAITING ADJUDICATION by the named human (Mahmood Ahmad) |
| parallel-hf | D1 | SOME CONCERNS | LOW | SOME CONCERNS | AWAITING ADJUDICATION by the named human (Mahmood Ahmad) |
| parallel-hf | D5 | SOME CONCERNS | LOW | SOME CONCERNS | AWAITING ADJUDICATION by the named human (Mahmood Ahmad) |
| parachute-hf | D1 | LOW | SOME CONCERNS | SOME CONCERNS | AWAITING ADJUDICATION by the named human (Mahmood Ahmad) |
| parachute-hf | D5 | LOW | SOME CONCERNS | SOME CONCERNS | AWAITING ADJUDICATION by the named human (Mahmood Ahmad) |
Integrity flag. assessor 1 cited a statistical analysis plan by version number and release date 'PARACHUTE-HF SAP version 2.1, release date 29-Apr-2025' appears in assessor 1's D1 and D2 sources, and it recorded the protocol as available for those domains. That specificity was not in the packet we supplied. It is either a genuine retrieval or a recalled identifier, and the output alone cannot tell us which. NOT adopted. Any domain resting on it is treated as protocol-unavailable until the SAP is retrieved and checked. This is the identifier-from-recall failure mode this project has already been caught by once.
Effect on the GRADE risk-of-bias rating: it does NOT move. It was serious before the assessment and remains serious. Two reasons, and the second is the load-bearing one. First, RoB-2 confirmed the substance of the downgrade rather than removing it. Both assessors, independently and from different model families, rated PARACHUTE-HF domain 2 as SOME CONCERNS on the open-label deviations point, which is the first of the three features the rating was already built on. The second assessor also rated its domain 5 as SOME CONCERNS on the selective-reporting point, which is the second feature. The assessment agreed with the reasoning the rating rested on. Second, and this is why 'no domain reached HIGH' does not discharge the downgrade: RoB-2 has no domain for a trial stopped early for benefit. Early stopping is not a randomization failure, a deviation, missing data, a measurement problem, or selective reporting of a result; it is a stopping-rule effect on the magnitude of the estimate, and the RoB-2 tool does not ask about it in any of its five domains. PARADIGM-HF was stopped early by prespecified rule for overwhelming benefit and the leave-one-out analysis shows the pooled benefit rests on that trial. That third feature is therefore untouched by a clean RoB-2 result, and it alone sustains a serious rating. Reading 'no domain HIGH' as grounds to remove the downgrade would be mistaking the silence of a tool for the absence of a problem.
The opposite reading is available and is recorded here rather than suppressed: under a common mapping, trials at SOME CONCERNS with none at HIGH support 'not serious', which would raise certainty from low to moderate. We do not adopt it, for the stopping-rule reason above, and because five of fifteen domain judgements are still unadjudicated -- changing a published certainty rating on the strength of a disagreement set nobody has resolved would be the wrong direction to move under uncertainty.
| Trial | Quantity | Registry | Publication | Status |
|---|---|---|---|---|
| PARACHUTE-HF | Serious adverse events | 169/183 | 211/234 | UNRESOLVED -- both values recorded, neither adopted |
PARACHUTE-HF, Serious adverse events. Registry pointer: ClinicalTrials.gov NCT04023227, adverse-events module. Publication pointer: Lopes RD et al., JAMA 2026;335(1):49-59, PMC12676478. Our own multi-source extraction pass did not record this discrepancy at all. A blinded comparator found it. The two sources disagree on both numerator and denominator for the same quantity in the same trial, and we carried only one side without noticing the other existed. Recorded here with both values and both pointers rather than resolved, because resolving it requires reading which population and which window each source is reporting, and picking one now would manufacture the appearance of a resolution. A multi-source pass that agrees with itself is not the same as a pass that checked both sources. This is the class our own harness names as 'consistency does not authenticate a row'.
Every paper this project ships carries this section. A synthesis that reports only its own result asks a reader to take the field on trust; one that reconciles itself against the published syntheses on the same question, names what they got right as prominently as what they got wrong, and shows the denominator, can be checked. The classes applied below are the classes this review must itself survive. On the night this section was written, this object failed three of them: analysis panels computed at k=3 under a k=4 headline, a title stating a study count its own contents contradicted, and a figure labelled as a diagnostic it was not drawing.
By lookup, never recall. The comparison review's identifiers were resolved through the PubMed ID converter on 2026-08-14: DOI 10.7759/cureus.48623 returns PMID 38084196 and PMCID PMC10710849. Its full text is staged in this bundle and every quotation below was read from that file.
PMID 38084196; PMCID PMC10710849; DOI 10.7759/cureus.48623. Resolved by ID conversion on 2026-08-14, not from memory.
Their scope: sacubitril/valsartan against enalapril in heart failure, any outcome, randomised or observational. Their k: 9. Their search closed 2023-09-15.
Three differences, and none of them makes either review wrong. They admit observational designs and this object does not. They pool RISK RATIOS over whole follow-up; this object pools a time-to-first-event HAZARD RATIO, a different quantity. Their search closed in September 2023, before two of the four trials pooled here existed.
| Side | Trial | Disposition here | Reason |
|---|---|---|---|
| only theirs | Tsutsui 2021 (PARALLEL-HF) | recovered | Eligible on every axis of the frozen question and absent from the brief this object was built from. Recovered, sourced to its own publication and its own registry record, and pooled. |
| only theirs | Velazquez 2019 (PIONEER-HF) | excluded | reports NT-proBNP change, not a hazard ratio for the composite; in the screening log |
| only theirs | Desai 2019 (EVALUATE-HF) | excluded | reports aortic characteristic impedance; in the screening log |
| only theirs | Piepoli 2021 (OUTSTEP-HF) | excluded | reports physical activity by accelerometry; in the screening log |
| only theirs | Pathadka 2020 | excluded | a population-based new-user cohort, not a randomised trial, and excluded on that alone -- it DOES report this review's composite as a hazard ratio, 0.58 (0.45 to 0.75). In the screening log with that endpoint recorded. This review's own sensitivity analysis removes it for being retrospective; this object's question is answered from randomised evidence only. |
| only theirs | Bano 2021 | excluded | a randomised trial whose open-access full text reports arm proportions and relative risk reductions and contains no time-to-event analysis; in the screening log |
| only theirs | Li 2019 | undetermined | NOT decided. The trial could not be retrieved -- no DOI, no PubMed record, no Crossref match -- so neither inclusion nor exclusion is asserted. In the screening log as undetermined, with what is known from this review's own table and what is not. An earlier version of this entry claimed it reports no time-to-first hazard ratio, which was an assertion about a document nobody here has read. |
| only theirs | Zhao 2022 | excluded | a randomised trial whose declared primary endpoint is echocardiographic right-ventricular function and which reports no hazard ratio for any clinical event; in the screening log |
| only ours | PARACHUTE-HF | held | published in 2026, after this review's search |
| in both | McMurray 2014 (PARADIGM-HF) | pooled or screened | Present in their included-study table and in this object's records. |
| Check | Verdict | What was compared |
|---|---|---|
| Stated study count against the rows of its own Table 1 | CONFIRMED | The abstract and Results both say nine. Table 1 carries exactly nine author rows: Bano, Desai, Li, McMurray, Pathadka, Piepoli, Tsutsui, Velazquez, Zhao. Counted from the staged full text, not taken from the abstract. |
| Stated design mix against the Design column of Table 1 | CONFIRMED | Eight rows are typed RCT and one, Pathadka 2020, RC. The stated split is exact. |
| PARADIGM-HF arm sizes against our own source-read values | CONFIRMED | Their Table 1 gives 4187 and 4212. This object read 4187 and 4212 from the trial's own publication and registry record. Identical. |
| PARALLEL-HF arm sizes against our own source-read values | CONFIRMED | Their Table 1 gives 111 and 112, matching this object exactly. This is the trial their list caused us to RECOVER, so their record is also the reason our k rose from two to three. |
| Internal arithmetic of the study-selection flow | CONFIRMED | 1,066 retrieved, 985 screened after duplicates, 28 full texts, nine included. Monotone decreasing and internally consistent; no stage exceeds the one above it. |
| Whether their omission of PARACHUTE-HF is an error or a date | CONFIRMED | Their search closed 15 September 2023. PARACHUTE-HF reported in 2026. Its absence from their review is CORRECT and is not counted against them. A reconciliation that scored this as a miss would be scoring them for not seeing the future. |
| Whether including a retrospective cohort breaches their OWN stated eligibility | CONFIRMED | It does not. Their pre-specified criteria admit observational designs explicitly, so Pathadka 2020 is inside their own protocol. This object excludes it because THIS question is restricted to randomised evidence, which is a different question and not a fault in theirs. Checked precisely because population-included-against-the-paper's-own-criterion is one of the classes we look for, and here it is clean. |
| Whether the influential non-randomised study was tested | CONFIRMED | It was, and the result is reported in the body rather than buried: removing Pathadka moves all-cause mortality from 0.57 to 0.85 and heterogeneity from 94 per cent to 0. Reporting a sensitivity analysis that overturns your own headline is good practice and is recorded here as such. |
| Absence of a funnel plot or small-study test | CONFIRMED | None is reported, and at nine studies none is expected: the Cochrane Handbook advises against interpreting these tests below about ten. Their omission is defensible and is NOT counted as a defect. This object applies the same caution to its own Egger's test at k = 4. |
| Whether the Discussion's significance claim matches the primary estimate | ERROR | The primary all-cause mortality estimate is RR 0.57 with a 95 per cent interval of 0.31 to 1.04. That interval CONTAINS 1, so the comparison is not statistically significant. The Discussion nevertheless states that all three outcomes, all-cause mortality among them, were significantly higher. The statement is true of their RCT-only sensitivity result, 0.85 (0.78 to 0.93), and is not true of the analysis the abstract leads with. It is an error of precision rather than a fabricated number, and it is recorded that way. |
| Whether the abstract's headline carries the heterogeneity it rests on | ERROR | The abstract reports RR 0.57 (0.31 to 1.04) for all-cause mortality with no mention that I-squared for that pool is 94 per cent, nor that removing one retrospective study takes it to 0 and moves the estimate to 0.85. A pooled estimate at I-squared 94 is an average over results that disagree, and an abstract is where most readers stop. Their own body text is transparent about both facts; the abstract is not. |
| Per-study risk-of-bias or quality appraisal | ABSENT | No Cochrane RoB, Jadad, Newcastle-Ottawa or equivalent appears anywhere in the text. The JBI reference is to the study-SELECTION protocol, not to an appraisal of the included studies. Risk of bias is a required PRISMA item, and pooling a retrospective cohort with randomised trials is exactly the situation it exists to surface. |
| Prospective protocol registration | ABSENT | PROSPERO is not mentioned and no registration of any kind is stated, so the analysis cannot be checked against a pre-specified plan. Recorded as an absence rather than an error: an unregistered review is not a wrong one. This object states its own registration as a timestamped public commit with an ordering test, so it is a standard we hold ourselves to. |
13 checks were applied to this review and 9 came back clean. The denominator is stated because a list of only the failures is not a finding, it is a selection. Confirmations are listed in the same table, in the same detail, as errors. Two checks were designed to catch a fault and instead cleared the paper: including a cohort study is inside their own stated eligibility, and omitting a small-study test at nine studies is what the Handbook advises.
| Claim checked | Verbatim quotation | Location | Adjudication |
|---|---|---|---|
| Stated study count against the rows of its own Table 1 | A total of nine studies were included in this meta-analysis. | Abstract; Results, paragraph 1 | CONFIRMED |
| Stated design mix against the Design column of Table 1 | Out of nine studies, eight were RCTs. | Results, paragraph 1 | CONFIRMED |
| PARADIGM-HF arm sizes against our own source-read values | McMurray et al. 2014 RCT ... 4187 ... Enalapril 10 mg twice 4212 | Table 1 | CONFIRMED |
| PARALLEL-HF arm sizes against our own source-read values | Tsutsui et al. 2021 RCT ... 111 ... Enalapril 10 mg twice 112 | Table 1 | CONFIRMED |
| Internal arithmetic of the study-selection flow | We obtained 1,066 studies through online database searching. After removing duplicates, 985 studies were initially screened | Results, paragraph 1 | CONFIRMED |
| Whether their omission of PARACHUTE-HF is an error or a date | systematically searched online databases including PubMed, Cochrane Library, and Web of Science from inception till September 15, 2023 | Abstract; Methods | CONFIRMED |
| Whether including a retrospective cohort breaches their OWN stated eligibility | The pre-defined inclusion criteria were observational studies (retrospective cohorts and prospective cohorts) or RCTs comparing sacubitril | Methods | CONFIRMED |
| Whether the influential non-randomised study was tested | We performed sensitivity analysis by removing the study conducted by Pathadka et al. as it was a retrospective study. | Results, All-Cause Mortality | CONFIRMED |
| Absence of a funnel plot or small-study test | [nothing to quote: the item is absent from the paper] | whole paper | CONFIRMED |
| Whether the Discussion's significance claim matches the primary estimate | The present meta-analysis reported that the risk of all-cause mortality, cardiovascular mortality, and cardiovascular hospitalization was significantly higher in patients receiving enalapril compared to patients receiving sacubitril/valsartan. | Discussion, paragraph 1 | ERROR (material) |
| Whether the abstract's headline carries the heterogeneity it rests on | Significant heterogeneity was reported among the study results (p = 0.001; I-square: 94%). | Results, All-Cause Mortality; Abstract | ERROR (reporting) |
| Per-study risk-of-bias or quality appraisal | The selection and critical appraisal of studies adhered to the Joanna Briggs Institute's (JBI) protocol, which offers a more precise and stringent set of criteria for the study selection process. | Methods | ABSENT |
| Prospective protocol registration | [nothing to quote: the item is absent from the paper] | whole paper | ABSENT |
This review: HR 0.872 (0.746 to 1.018) for cardiovascular death or first heart-failure hospitalisation, k=4, time-to-first-event.
That review: RR 0.76 (0.66 to 0.86) for cardiovascular hospitalisation and RR 0.75 (0.62 to 0.91) for cardiovascular mortality, reported as separate outcomes.
Four reasons, none of which is an error by either side: a different estimand (hazard of a FIRST event against risk over whole follow-up); a different eligible set (they admit observational designs, we do not); a different search window (ours includes two trials published after theirs closed); and a different composite (they report hospitalisation and cardiovascular death separately, we pool the composite of the two). Decomposed rather than asserting ours is right: on the trials and the quantity the two reviews share, they agree.
Every result below carries the VERBATIM printed output of the call that produced it, captured with capture.output() rather than re-typed. A bare number can only be checked against the object that produced it, and the object is ours; a quoted metafor call carries its own k, its own estimator, its own heterogeneity and its own package version, so a reader can audit the provenance without trusting us. It would have made this project's worst defect visible on sight: a printed k = 4 sitting under a leave-one-out panel drawn from three studies is obvious, where a bare 0.839 is not.
The quoted output is parsed and compared against the projected values at the moment it is stored -- k, I-squared, Q and the back-transformed estimate with its interval. A quotation that disagrees with the number printed beside it is worse than no quotation, because it looks like provenance. The write refuses if they disagree.
Environment: R version 4.6.0 (2026-04-24 ucrt); metafor 5.0.1
| Result | Call | Verbatim output |
|---|---|---|
| Primary pooled hazard ratio, random-effects REML on the log scale | rma(yi = log_hr, sei = log_se, method = "REML", level = 95) | Random-Effects Model (k = 4; tau^2 estimator: REML) tau^2 (estimated amount of total heterogeneity): 0.0086 (SE = 0.0211) tau (square root of estimated tau^2 value): 0.0927 I^2 (total heterogeneity / total variability): 32.89% H^2 (total variability / sampling variability): 1.49 Test for Heterogeneity: Q(df = 3) = 5.1613, p-val = 0.1604 Model Results: estimate se zval pval ci.lb ci.ub -0.1375 0.0793 -1.7340 0.0829 -0.2929 0.0179 . --- Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 |
| Prediction interval for a future study | predict(m, transf = exp) | pred ci.lb ci.ub pi.lb pi.ub 0.8715 0.7461 1.0181 0.6862 1.1070 |
| Confidence interval for tau-squared, Q-profile | confint(m) |
estimate ci.lb ci.ub
tau^2 0.0086 0.0000 1.6878
tau 0.0927 0.0000 1.2992
I^2(%) 32.8942 0.0000 98.9716
H^2 1.4902 1.0000 97.2356
|
| Egger's regression test for funnel asymmetry | regtest(m, model = "lm") | Regression Test for Funnel Plot Asymmetry Model: weighted regression with multiplicative dispersion Predictor: standard error Test for Funnel Plot Asymmetry: t = 9.6519, df = 2, p = 0.0106 Limit Estimate (as sei -> 0): b = -0.2999 (CI: -0.3630, -0.2368) |
| Leave-one-out refits | leave1out(m) |
estimate se zval pval ci.lb ci.ub Q Qp
-paradigm-hf -0.0346 0.1028 -0.3361 0.7368 -0.2361 0.1670 2.2922 0.3179
-parachute-hf -0.0288 0.1925 -0.1495 0.8811 -0.4062 0.3486 4.2692 0.1183
-parallel-hf -0.1698 0.0697 -2.4370 0.0148 -0.3064 -0.0332 4.0097 0.1347
-answer-hf -0.1753 0.0622 -2.8180 0.0048 -0.2972 -0.0534 2.3515 0.3086
tau2 I2 H2
-paradigm-hf 0.0008 1.2038 1.0122
-parachute-hf 0.0612 52.8513 2.1209
-parallel-hf 0.0049 26.5444 1.3614
-answer-hf 0.0035 22.2398 1.2860
|
| Cumulative meta-analysis in year order | cumul(m) |
k estimate se zval pval ci.lb ci.ub Q Qp
paradigm-hf 1 -0.2231 0.0448 -4.9856 0.0000 -0.3109 -0.1354 0.0000 1.0000
parachute-hf 2 -0.1992 0.0501 -3.9724 0.0001 -0.2974 -0.1009 1.1505 0.2835
parallel-hf 3 -0.1753 0.0622 -2.8180 0.0048 -0.2972 -0.0534 2.3515 0.3086
answer-hf 4 -0.1375 0.0793 -1.7340 0.0829 -0.2929 0.0179 5.1613 0.1604
tau2 I2 H2
paradigm-hf 0.0000 0.0000 1.0000
parachute-hf 0.0011 13.0779 1.1505
parallel-hf 0.0035 22.2398 1.2860
answer-hf 0.0086 32.8942 1.4902
|
| Influence diagnostics | influence(m) |
rstudent dffits cook.d cov.r tau2.del QE.del hat weight
paradigm-hf -1.6324 -2.5403 1.6849 1.6821 0.0008 2.2922 0.5932 59.3192
parachute-hf -0.1970 -0.7327 1.8795 5.8954 0.0612 4.2692 0.2991 29.9131
parallel-hf 0.9120 0.4176 0.1662 0.7723 0.0049 4.0097 0.0810 8.1043
answer-hf 1.6087 0.4821 0.2274 0.6155 0.0035 2.3515 0.0266 2.6634
dfbs inf
paradigm-hf -2.1977 *
parachute-hf -0.6924 *
parallel-hf 0.4789
answer-hf 0.6129
|
| Count-based pool on the RR scale (secondary estimand) | escalc(measure = "RR", ai, n1i, ci, n2i); rma(method = "REML") | Random-Effects Model (k = 4; tau^2 estimator: REML) tau^2 (estimated amount of total heterogeneity): 0.0040 (SE = 0.0119) tau (square root of estimated tau^2 value): 0.0633 I^2 (total heterogeneity / total variability): 25.18% H^2 (total variability / sampling variability): 1.34 Test for Heterogeneity: Q(df = 3) = 4.1498, p-val = 0.2457 Model Results: estimate se zval pval ci.lb ci.ub -0.1365 0.0590 -2.3140 0.0207 -0.2521 -0.0209 * --- Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 |
| Count-based pool on the OR scale (secondary estimand) | escalc(measure = "OR", ai, n1i, ci, n2i); rma(method = "REML") | Random-Effects Model (k = 4; tau^2 estimator: REML) tau^2 (estimated amount of total heterogeneity): 0.0055 (SE = 0.0217) tau (square root of estimated tau^2 value): 0.0740 I^2 (total heterogeneity / total variability): 17.79% H^2 (total variability / sampling variability): 1.22 Test for Heterogeneity: Q(df = 3) = 3.9046, p-val = 0.2720 Model Results: estimate se zval pval ci.lb ci.ub -0.1927 0.0748 -2.5740 0.0101 -0.3393 -0.0460 * --- Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 |
| Count-based pool on the RD scale (secondary estimand) | escalc(measure = "RD", ai, n1i, ci, n2i); rma(method = "REML") | Random-Effects Model (k = 4; tau^2 estimator: REML) tau^2 (estimated amount of total heterogeneity): 0.0007 (SE = 0.0014) tau (square root of estimated tau^2 value): 0.0269 I^2 (total heterogeneity / total variability): 44.14% H^2 (total variability / sampling variability): 1.79 Test for Heterogeneity: Q(df = 3) = 5.0714, p-val = 0.1666 Model Results: estimate se zval pval ci.lb ci.ub -0.0231 0.0203 -1.1352 0.2563 -0.0629 0.0167 --- Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 |
| Between-study variance estimator REML, Wald and Hartung-Knapp intervals | rma(yi, sei, method = "REML") and ... test = "knha" | Random-Effects Model (k = 4; tau^2 estimator: REML) tau^2 (estimated amount of total heterogeneity): 0.0086 (SE = 0.0211) tau (square root of estimated tau^2 value): 0.0927 I^2 (total heterogeneity / total variability): 32.89% H^2 (total variability / sampling variability): 1.49 Test for Heterogeneity: Q(df = 3) = 5.1613, p-val = 0.1604 Model Results: estimate se zval pval ci.lb ci.ub -0.1375 0.0793 -1.7340 0.0829 -0.2929 0.0179 . --- Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 ## Hartung-Knapp-Sidik-Jonkman: Random-Effects Model (k = 4; tau^2 estimator: REML) tau^2 (estimated amount of total heterogeneity): 0.0086 (SE = 0.0211) tau (square root of estimated tau^2 value): 0.0927 I^2 (total heterogeneity / total variability): 32.89% H^2 (total variability / sampling variability): 1.49 Test for Heterogeneity: Q(df = 3) = 5.1613, p-val = 0.1604 Model Results: estimate se tval df pval ci.lb ci.ub -0.1375 0.0887 -1.5496 3 0.2190 -0.4199 0.1449 --- Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 |
| Between-study variance estimator DL, Wald and Hartung-Knapp intervals | rma(yi, sei, method = "DL") and ... test = "knha" | Random-Effects Model (k = 4; tau^2 estimator: DL) tau^2 (estimated amount of total heterogeneity): 0.0126 (SE = 0.0271) tau (square root of estimated tau^2 value): 0.1124 I^2 (total heterogeneity / total variability): 41.88% H^2 (total variability / sampling variability): 1.72 Test for Heterogeneity: Q(df = 3) = 5.1613, p-val = 0.1604 Model Results: estimate se zval pval ci.lb ci.ub -0.1238 0.0896 -1.3826 0.1668 -0.2994 0.0517 --- Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 ## Hartung-Knapp-Sidik-Jonkman: Random-Effects Model (k = 4; tau^2 estimator: DL) tau^2 (estimated amount of total heterogeneity): 0.0126 (SE = 0.0271) tau (square root of estimated tau^2 value): 0.1124 I^2 (total heterogeneity / total variability): 41.88% H^2 (total variability / sampling variability): 1.72 Test for Heterogeneity: Q(df = 3) = 5.1613, p-val = 0.1604 Model Results: estimate se tval df pval ci.lb ci.ub -0.1238 0.0962 -1.2880 3 0.2881 -0.4298 0.1822 --- Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 |
| Between-study variance estimator PM, Wald and Hartung-Knapp intervals | rma(yi, sei, method = "PM") and ... test = "knha" | Random-Effects Model (k = 4; tau^2 estimator: PM) tau^2 (estimated amount of total heterogeneity): 0.0220 (SE = 0.0382) tau (square root of estimated tau^2 value): 0.1485 I^2 (total heterogeneity / total variability): 55.69% H^2 (total variability / sampling variability): 2.26 Test for Heterogeneity: Q(df = 3) = 5.1613, p-val = 0.1604 Model Results: estimate se zval pval ci.lb ci.ub -0.1010 0.1081 -0.9346 0.3500 -0.3129 0.1108 --- Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 ## Hartung-Knapp-Sidik-Jonkman: Random-Effects Model (k = 4; tau^2 estimator: PM) tau^2 (estimated amount of total heterogeneity): 0.0220 (SE = 0.0382) tau (square root of estimated tau^2 value): 0.1485 I^2 (total heterogeneity / total variability): 55.69% H^2 (total variability / sampling variability): 2.26 Test for Heterogeneity: Q(df = 3) = 5.1613, p-val = 0.1604 Model Results: estimate se tval df pval ci.lb ci.ub -0.1010 0.1081 -0.9346 3 0.4189 -0.4450 0.2430 --- Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 |
Across 4 randomised trials and 9,734 participants, the pooled hazard of a first cardiovascular death or heart failure hospitalisation with sacubitril/valsartan relative to enalapril was 0.872 (0.746 to 1.02), an interval that includes no difference, with a pooled hazard ratio of 0.872 (0.746 to 1.02). The more informative finding is not that number but its structure: it is almost entirely the contribution of one trial, and it does not survive that trial's removal.
A pooled hazard ratio of 0.872 on this composite is a clinically meaningful reduction if it is real, but the interval does not exclude the null: it runs from 0.746 to 1.018. When ANSWER-HF entered, the pool crossed from an interval that excluded no difference to one that does not, and that crossing is reported rather than described as a robustness footnote. In a four-trial synthesis where one trial carries most of the weight -- PARADIGM-HF holds 59% of it -- the interval is doing less work than it appears to in either direction. The honest reading is that the pivotal trial is the evidence, and that this meta-analysis quantifies how little the three subsequent trials change it, rather than adding independent support.
I-squared of 32.9% falls in the band conventionally described as low, and tau-squared is 0.0086. It would be a mistake to read that as agreement between the trials. I-squared is the proportion of total variability attributable to between-trial differences, and when two of four trials have wide intervals the within-trial variance is large, so the proportion attributable to between-trial variation is small almost by construction. The point estimates range from 0.8 to 1.83, which spans a clinically important reduction and essentially no effect. The low heterogeneity statistic and the wide spread of point estimates are both true, and reporting the first without the second would mislead.
Removing the largest trial moves the pooled estimate to 0.966 (0.79 to 1.18). This is the single most important result in the review and it is reported as a principal finding rather than as a sensitivity check, because a synthesis whose conclusion depends on one of its four inputs should say so where a reader cannot miss it. It does not mean the effect is absent: the three remaining trials are small and their intervals are wide, so they are compatible both with the pivotal trial's effect and with none. It means the pooled interval's exclusion of the null should not be read as four trials agreeing.
The completed RoB-2 assessment found no domain at high risk in any trial, which might be taken as grounds to remove the GRADE risk-of-bias downgrade. It was not, for a reason worth stating plainly: RoB-2 has no domain for a trial stopped early for benefit. Early stopping is not a randomisation failure, a deviation from intended intervention, missing outcome data, a measurement problem, or selective reporting of a result. The largest trial was stopped early by prespecified rule for overwhelming benefit, and trials stopped early for benefit tend to overstate the effect they were stopped for. A clean RoB-2 therefore cannot discharge that concern, and reading the absence of a high-risk domain as the absence of a problem would mistake the silence of an instrument for evidence.
This review reconciles itself against the one published synthesis on this comparison whose included-study table could be read, trial by trial, and reports the checks applied to it with their denominator in the section on comparison with published syntheses. What can be said from within this review is that its estimate is close to the pivotal trial's own published hazard ratio, which follows arithmetically from that trial's weight and is therefore not independent corroboration.
The protocol was registered before the first query with a machine-checkable ordering test. Every screened record is published with its disposition. Both risk-of-bias assessors' full answers are published unreconciled, with the agreement rate as measured. Every number on every surface is projected from one canonical object, so the manuscript, the tables, the figures and the web page cannot disagree with one another. A disagreement between two sources that this review's own extraction missed is published as an unresolved disagreement rather than silently resolved.
In adults with heart failure and reduced ejection fraction, the pooled hazard of a first cardiovascular death or heart failure hospitalisation with sacubitril/valsartan compared with enalapril was 0.872 (0.746 to 1.02) at a certainty this review has not yet rated, an interval consistent with no difference. The estimate rests almost entirely on one large trial and does not survive its removal. One trial carries almost all of the information, and the pooled interval includes no difference; three further trials have not resolved it.
Formal comparison with previous meta-analyses. This review's search was designed to find randomised trials reporting the estimand, not to find previous syntheses. Writing a comparison would require either a second search that was not run or recall of literature that was not retrieved, and recalled literature is the failure mode this project has already been caught by once.
Funding statement and competing interests. The object records neither. They are required for submission and their absence is stated here rather than filled with a placeholder declaration.
The canonical object records neither a funding statement nor a conflict-of-interest declaration for this review.
1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. PMID 25176015 doi:10.1056/NEJMoa1409077 https://pubmed.ncbi.nlm.nih.gov/25176015/ [link checked: 200]
2. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al.. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-1620. PMID 31475794 doi:10.1056/NEJMoa1908655 https://pubmed.ncbi.nlm.nih.gov/31475794/ [link checked: 200]
3. Bano S, Bai P, Kumar S, Kumar N, Ali A, Pariya F, et al.. Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure. Cureus. 2021;13(7):e16332. PMID 34395116 doi:10.7759/cureus.16332 https://pubmed.ncbi.nlm.nih.gov/34395116/ [link checked: 200]
4. Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al.. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study. Circ J. 2021;85(5):584-594. PMID 33731544 doi:10.1253/circj.CJ-20-0854 https://pubmed.ncbi.nlm.nih.gov/33731544/ [link checked: 200]
5. Pathadka S, Yan VKC, Li X, Tse G, Wan EYF, Lau H, et al.. Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study. Front Cardiovasc Med. 2021;7:602363. PMID 33553256 doi:10.3389/fcvm.2020.602363 https://pubmed.ncbi.nlm.nih.gov/33553256/ [link checked: 200]
6. Zhao Y, Tian LG, Zhang LX, Ma T, Di L, Wang YB, et al.. The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction. Pulm Circ. 2022;12(3):e12034. PMID 35874853 doi:10.1002/pul2.12034 https://pubmed.ncbi.nlm.nih.gov/35874853/ [link checked: 200]
7. Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al.. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol. 2023;82(1):1-12. PMID 37212758 doi:10.1016/j.jacc.2023.04.019 https://pubmed.ncbi.nlm.nih.gov/37212758/ [link checked: 200]
8. Madrini V, Souza PVR, Fernandes F, Ianni BM, Martins AS, Luzuriaga GJ, et al.. Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial. J Am Coll Cardiol. 2026;87(10):1220-1232. PMID 41396086 doi:10.1016/j.jacc.2025.10.053 https://pubmed.ncbi.nlm.nih.gov/41396086/ [link checked: 200]
9. Daniyal SM, Tabish S, Burhan M, Noor A, Jalal AA, Khalid A, et al.. Sacubitril/Valsartan Versus Enalapril in Chagas Cardiomyopathy With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. Cardiol Rev. 2026. PMID 41923142 doi:10.1097/CRD.0000000000001242 https://pubmed.ncbi.nlm.nih.gov/41923142/ [link checked: 200]
10. Lopes RD, Bocchi EA, Echeverría LE, Demacq C, de Barros E Silva PGM, Barbosa LM, et al.. Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial. JAMA. 2026;335(1):49-59. PMID 41335448 doi:10.1001/jama.2025.19808 https://pubmed.ncbi.nlm.nih.gov/41335448/ [link checked: 200]
10 references. Every one is a work rather than a database, carries a link, and the link's reachability was tested at build time and reported above whether it passed or not.
heart failure, reduced ejection fraction, sacubitril/valsartan, angiotensin receptor-neprilysin inhibitor, enalapril, meta-analysis, systematic review, hazard ratio
Underlying data. No new participant-level data were generated. All data underlying this review are derived from published randomised trials and from public registry records, and every record is identified in the extended data.
Extended data. Zenodo: Extended data for: sacubitril/valsartan versus enalapril in heart failure with reduced ejection fraction. [persistent identifier not yet minted]
NOT YET MINTED. Recorded as absent rather than filled with a plausible string: a wrong identifier in a Data Availability Statement points a reader at someone else's data, which is worse than no identifier at all.
This project contains the following extended data:
canonical_object.json. The single object every number in this article is projected from.
screening_log.csv. All 423 records the search returned, with the stage, the decision, the eligibility axis that failed, and what each excluded record reported instead.
search_capture.csv. Each database with the query string exactly as executed, the endpoint, parameters, filters and the hit count returned.
PRISMA_flow.md. Flow counted from the screening log at build time.
PRISMA_checklist.md. PRISMA 2020, item by item; items not reported are answered No.
extended_data_tables.docx. Extraction with per-cell provenance, all sensitivity and estimator analyses, secondary pooled outcomes, the full GRADE profile, risk-of-bias judgements from both assessors with the unresolved disagreements, the reconciliation record, the attestation record, and the executed code.
README.md. Written for a reader holding only the identifier and none of the article's context.
MANIFEST.sha256. Checksums for every file above.
Data are available under the terms of the CC0 1.0 Universal (CC0 1.0) Public Domain Dedication
Note on licensing. The software and the data carry DIFFERENT licences and are different objects. Code: MIT -- Attribution and retention of the licence notice. Data: CC0-1.0 -- None. All rights waived.
Source code available from: https://github.com/mahmood726-cyber/rapidmeta-finerenone
Version control: https://github.com/mahmood726-cyber/rapidmeta-finerenone
Archived source code at time of publication: [not yet available]
Licence: MIT
NOT YET DEPOSITED. Zenodo must be authorised against the repository and a tagged release cut; Zenodo then mints a version-specific identifier for that tag and a concept identifier that always resolves to the latest. The VERSION-SPECIFIC one belongs in this article, because that is the code that produced these results; the concept one belongs in the repository README.
This review's protocol was registered as a timestamped, SHA-pinned public commit rather than in PROSPERO. The commit precedes the first executed query by a recorded margin and the ordering is machine-checkable at every build, which is stronger evidence of prospective registration than a registry entry provides. It is NOT, however, the token the journal asks for, and the difference is stated here rather than presented as equivalent. Mahmood should decide whether to also register in PROSPERO.
Table 1. PRISMA flow of records, as counts
Table 2. Characteristics of the included trials
Table 3. Per-arm events and denominators for the pooled composite
Table 4. Extracted values, and where each came from
Table 5. Component endpoints and each trial's published effect
Table 6. The same 2x2 on three scales (sensitivity to the primary hazard-ratio pool)
Table 7. Leave-one-out sensitivity analysis
Table 8. Between-study-variance estimator comparison
Table 9. Screening log: every record adjudicated, with its decision and the reason for it
Table 10. GRADE summary of findings
Table 11. Risk of bias by domain and trial, both assessors shown separately and unreconciled
Table 12. Overall risk-of-bias judgement per trial, by the standard algorithm
Table 13. Open disagreements, carried at the more cautious judgement pending adjudication
Table 14. Quantities on which registry and publication disagree
Table 15. Trial-by-trial reconciliation against their included set
Table 16. Checks applied to the published synthesis, with verdicts
Table 17. Quoted evidence for each check, with its location and our adjudication
Table 18. Statistical output quoted verbatim, with the call that produced it
Figure 1. Forest plot. Changing the range moves the axis window only. The guides stay labelled with the null and the extremes of the plotted intervals, so no plotted value and no printed number differs between these views — and that is checked at build time, not asserted. Ranges not offered because they would crop the data: 0.5 to 2, 0.25 to 4, 0.7 to 1.3.
Figure 2. Visual abstract. Projected from the canonical object, so it carries the same k, the same pooled estimate and the same interval as the paper and cannot drift from them. The interval is drawn CROSSING the no-difference line because it does: a graphical abstract travels without its caption, and one that showed a favourable point estimate without showing that its interval includes no effect would be overstating a null result, which is a defect class this review documents in other papers.
Figure 3. PRISMA flow of records. Every stage carries a count. The identification tier is populated from search.databases, and this caption previously said the opposite -- that two boxes were drawn as NOT RECORDED because the counts had never been captured. They had been, all along; a diagram missing its top box reads as an oversight, one that states the gap reads as a decision. The identification tier is populated from search.databases -- each database's hit count as the API returned it, and how many were retrieved -- which sum to exactly the screened corpus, and the corpus's own per-source tally agrees independently. No search was re-run to fill it, so no record entered or left the pool. The two sources return disjoint record types (PMIDs and NCT numbers) and no de-duplication step is recorded, which is why records removed before screening is zero rather than unknown. Exclusion reasons across the whole corpus: randomisation 195, outcome 132, comparator 38, population 35, intervention 14.
Figure 4. Funnel plot. Standard error against the effect, most precise at the top, with the 95% and 99% pseudo-confidence funnel drawn from the pooled estimate and contour bands around the null. At k = 4 a funnel CANNOT be read for asymmetry and none is claimed: it is shown because the positions are real and the emptiness is the finding.
Figure 5. Galbraith (radial) plot. Each trial's standardised effect against its precision.
Figure 6. Baujat plot. Right means a trial drives heterogeneity; up means it moves the pooled result. Top-right is both.
Figure 7. Influence diagnostics. Leverage against Cook's distance, from metafor's influence diagnostics.
Figure 8. Leave-one-out. The pool refitted with each trial removed in turn.
Figure 9. Cumulative meta-analysis. The pool as each trial reported, in year order.
Figure 10. Bayesian posterior density. grid integration, 201x201, flat prior on the pooled log effect and half-Cauchy(scale=1) on the between-study SD (Gelman 2006)
Figure 11. Risk of bias, both assessors. Every cell carries BOTH independent cross-family assessments and they are not reconciled: showing one column would be a reconciliation presented as an observation. Glyph as well as colour, so the panel survives greyscale printing and colour-blind reading. A trial with no judgement is shown as a row of not-assessed markers rather than omitted, so a gap in the assessment cannot be mistaken for a clean assessment. Agreement as measured, not asserted: the two assessors agreed on 10 of 15 domain judgements (66.7 per cent) and on 1 of 3 overall judgements. This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one.
Figure 12. GOSH. Deliberately not drawn. Every subset meta-analysis of 4 trials is 15 points; a cloud that small cannot show the multimodality GOSH exists to reveal, and a reader would take the picture as evidence of its absence.
Figure 13. Trial-sequential analysis. TSA boundaries depend entirely on a target information size that must be pre-specified. This review's protocol registers none, so any boundary drawn here would be a parameter chosen after seeing the data -- which is the practice TSA exists to protect against.
Figure 14. Meta-regression. The protocol pre-specifies no moderator, and at k = 4 a meta-regression would be fitted on 4 points. Not drawn rather than drawn with a caveat: a bubble plot invites reading a slope, and there is no slope here that any reader should read.
Figure 15. L'Abbe plot. Each trial's own two risks, read from its 2x2. Below the diagonal favours the intervention.
Figure 16. Number needed to treat, across baseline risk. The number needed to treat depends on the risk a patient starts with. This applies the pooled risk ratio across a range of control risks so a reader can read off the value for the patient in front of them.
Figure 1. Forest plot. Changing the range moves the axis window only. The guides stay labelled with the null and the extremes of the plotted intervals, so no plotted value and no printed number differs between these views — and that is checked at build time, not asserted. Ranges not offered because they would crop the data: 0.5 to 2, 0.25 to 4, 0.7 to 1.3.
Figure 2. Visual abstract. Projected from the canonical object, so it carries the same k, the same pooled estimate and the same interval as the paper and cannot drift from them. The interval is drawn CROSSING the no-difference line because it does: a graphical abstract travels without its caption, and one that showed a favourable point estimate without showing that its interval includes no effect would be overstating a null result, which is a defect class this review documents in other papers.
Figure 3. PRISMA flow of records. Every stage carries a count. The identification tier is populated from search.databases, and this caption previously said the opposite -- that two boxes were drawn as NOT RECORDED because the counts had never been captured. They had been, all along; a diagram missing its top box reads as an oversight, one that states the gap reads as a decision. The identification tier is populated from search.databases -- each database's hit count as the API returned it, and how many were retrieved -- which sum to exactly the screened corpus, and the corpus's own per-source tally agrees independently. No search was re-run to fill it, so no record entered or left the pool. The two sources return disjoint record types (PMIDs and NCT numbers) and no de-duplication step is recorded, which is why records removed before screening is zero rather than unknown. Exclusion reasons across the whole corpus: randomisation 195, outcome 132, comparator 38, population 35, intervention 14.
Figure 4. Funnel plot. Standard error against the effect, most precise at the top, with the 95% and 99% pseudo-confidence funnel drawn from the pooled estimate and contour bands around the null. At k = 4 a funnel CANNOT be read for asymmetry and none is claimed: it is shown because the positions are real and the emptiness is the finding.
Figure 5. Galbraith (radial) plot. Each trial's standardised effect against its precision.
Figure 6. Baujat plot. Right means a trial drives heterogeneity; up means it moves the pooled result. Top-right is both.
Figure 7. Influence diagnostics. Leverage against Cook's distance, from metafor's influence diagnostics.
Figure 8. Leave-one-out. The pool refitted with each trial removed in turn.
Figure 9. Cumulative meta-analysis. The pool as each trial reported, in year order.
Figure 10. Bayesian posterior density. grid integration, 201x201, flat prior on the pooled log effect and half-Cauchy(scale=1) on the between-study SD (Gelman 2006)
Figure 11. Risk of bias, both assessors. Every cell carries BOTH independent cross-family assessments and they are not reconciled: showing one column would be a reconciliation presented as an observation. Glyph as well as colour, so the panel survives greyscale printing and colour-blind reading. A trial with no judgement is shown as a row of not-assessed markers rather than omitted, so a gap in the assessment cannot be mistaken for a clean assessment. Agreement as measured, not asserted: the two assessors agreed on 10 of 15 domain judgements (66.7 per cent) and on 1 of 3 overall judgements. This is markedly lower than the two-assessor agreement seen at screening, which is what we predicted before running it. Screening asks whether a record meets stated eligibility axes, which is close to a lookup. RoB-2 asks for a graded judgement under uncertainty, where 'no information' and 'some concerns' are reached by different routes. Almost no published review reports its RoB-2 inter-assessor agreement at all, so there is no external benchmark. We publish it because an unreported agreement rate is not the same as a high one.
Figure 12. GOSH. Deliberately not drawn. Every subset meta-analysis of 4 trials is 15 points; a cloud that small cannot show the multimodality GOSH exists to reveal, and a reader would take the picture as evidence of its absence.
Figure 13. Trial-sequential analysis. TSA boundaries depend entirely on a target information size that must be pre-specified. This review's protocol registers none, so any boundary drawn here would be a parameter chosen after seeing the data -- which is the practice TSA exists to protect against.
Figure 14. Meta-regression. The protocol pre-specifies no moderator, and at k = 4 a meta-regression would be fitted on 4 points. Not drawn rather than drawn with a caveat: a bubble plot invites reading a slope, and there is no slope here that any reader should read.
Figure 15. L'Abbe plot. Each trial's own two risks, read from its 2x2. Below the diagonal favours the intervention.
Figure 16. Number needed to treat, across baseline risk. The number needed to treat depends on the risk a patient starts with. This applies the pooled risk ratio across a range of control risks so a reader can read off the value for the patient in front of them.
Profile. F1000Research
Figures. EPS generated as the journal's first preference for line art; uncompressed TIFF at 600 dpi carried as the stated fallback; JPEG dropped (not accepted, and lossy on line art); SVG retained for the web page only, where it is the master the others derive from.
Supplementary. The journal accepts none. Extended data is built as a deposit package for an approved repository under CC0 or CC-BY and cited in the Data Availability Statement by DOI.
Abstract. Structured, 300 words maximum, Background / Methods / Results / Conclusions, no citations.
Tables and figures. Legends and tables placed at the end, not inline.
Prisma. Checklist and flow diagram deposited and cited by DOI.
Registration. Protocol registered as a timestamped, SHA-pinned public commit. PROSPERO is the token the journal names; ours is arguably stronger evidence of ordering but is NOT the same token, and that difference is flagged rather than presented as equivalent.
NOT YET SUBMITTABLE. Data Availability Statement carries no persistent identifier for the extended data. No archived source-code identifier (Zenodo) for the code. figure title is 64 words; the limit is 15: 'Forest plot. Changing the range moves the axis window only. The guides' figure title is 80 words; the limit is 15: 'Visual abstract. Projected from the canonical object, so it carries th' figure title is 161 words; the limit is 15: 'PRISMA flow of records. Every stage carries a count. The identificatio' figure title is 59 words; the limit is 15: 'Funnel plot. Standard error against the effect, most precise at the to' figure title is 18 words; the limit is 15: 'Baujat plot. Right means a trial drives heterogeneity; up means it mov' figure title is 21 words; the limit is 15: 'Bayesian posterior density. grid integration, 201x201, flat prior on t' figure title is 173 words; the limit is 15: 'Risk of bias, both assessors. Every cell carries BOTH independent cros' figure title is 37 words; the limit is 15: 'GOSH. Deliberately not drawn. Every subset meta-analysis of 4 trials i' figure title is 44 words; the limit is 15: 'Trial-sequential analysis. TSA boundaries depend entirely on a target ' figure title is 45 words; the limit is 15: 'Meta-regression. The protocol pre-specifies no moderator, and at k = 4' figure title is 17 words; the limit is 15: "L'Abbe plot. Each trial's own two risks, read from its 2x2. Below the " figure title is 47 words; the limit is 15: 'Number needed to treat, across baseline risk. The number needed to tre'
In this section: Cardiovascular death or hospitalization for heart failure, whichever comes first, as a hazard ratio · Diagnostics · Per-trial influence and weight · Leave-one-out, numerically · Where these numbers came from · The same 2x2, on three scales · Number needed to treat · Baseline risk, per trial · Benford first-digit screen · What these counts are, and are not · Further analyses — what was run, and what was not
| Statistic | Value | Method and caution |
|---|---|---|
| Prediction interval | 0.686 to 1.11 | t_{k-1}, Cochrane Handbook v6.5 |
| Between-study variance | 0.0086 (0 to 1.69) | Q-profile (Viechtbauer 2007) |
| Egger's regression | intercept -0.3, p = 0.0106 | Run for completeness. With k = 4 the test has almost no power and the Cochrane Handbook advises against interpreting it below about ten studies. Reported as a computed value, not as evidence about small-study effects. Recomputed at k = 4. The p value moved from 0.101 to 0.01056 when ANSWER-HF entered, and that movement is exactly what a test with almost no power does when a fourth point is added -- it is not a finding about small-study effects and must not be read as one. |
| Bayesian posterior | 0.846 (0.568 to 1.46) | grid integration, 201x201, flat prior on the pooled log effect and half-Cauchy(scale=1) on the between-study SD (Gelman 2006) |
| Peters' test | intercept -0.268, p = 0.0305 | Peters 2006 regresses the log odds ratio on the inverse of total sample size, which the Cochrane Handbook v6.5 section 13.3.5 recommends for binary outcomes in place of Egger, whose test is biased on the odds-ratio scale. With k = 4 it still has almost no power and is reported as a computed value, not as evidence. Recomputed at k=4. The intercept was stored as an empty list and rendered on the page as an empty pair of brackets where the number belongs -- the same defect as Egger's standard error, a value the extraction failed to read presented as though the field did not apply. |
| Trial | Weight | Leverage | Cook's D | Std. residual |
|---|---|---|---|---|
| paradigm-hf | 59.3% | 0.593 | 1.68 | -1.63 |
| parachute-hf | 29.9% | 0.299 | 1.88 | -0.197 |
| parallel-hf | 8.1% | 0.081 | 0.166 | 0.912 |
| answer-hf | 2.66% | 0.0266 | 0.227 | 1.61 |
Read the weight column beside the leave-one-out rows: a trial carrying most of the weight is the trial the answer rests on.
| Omitted | Pooled | I-squared |
|---|---|---|
| paradigm-hf | 0.966 (0.79 to 1.18) | 1.2% |
| parachute-hf | 0.972 (0.666 to 1.42) | 52.9% |
| parallel-hf | 0.844 (0.736 to 0.967) | 26.5% |
| answer-hf | 0.839 (0.743 to 0.948) | 22.2% |
Computed at build time by metafor 5.0.1 under R 4.6.0 from the log point and log standard error this object stores. The page projects these stored values; opening it recomputes nothing, and no reader action can change any of them. Recomputed at k=4 on 2026-08-13: this whole block, including its own `fit`, was still the k=3 analysis after ANSWER-HF entered the pool, so a leave-one-out of three rows and a prediction interval from three trials were being shown beside a four-trial headline. The recomputation was gated on reproducing the pooled result already stored here (agreement to 1e-7 on the point estimate) and is corroborated by the leave-one-out row omitting ANSWER-HF, which returns 0.839195 -- the previous k=3 pool, to 2e-7.
| Measure | Pooled | I-squared |
|---|---|---|
| Risk ratio | 0.872 (0.777 to 0.979) | 25.2% |
| Odds ratio | 0.825 (0.712 to 0.955) | 17.8% |
| Risk difference | -0.0231 (-0.0629 to 0.0167) | 44.1% |
None of these three is this review's primary result — that remains the pooled hazard ratio, which uses time to first event rather than counting people once. An odds ratio is not collapsible, which is why Handbook 10.4.2 asks for both when baseline risks differ.
Not defined for this outcome. The authoritative pooled risk difference is −0.023 (−0.063 to +0.017), an interval that crosses zero — it includes no difference. A number needed to treat is defined only for a risk difference whose interval excludes zero, so none is stated here: a finite NNT would assert a benefit the pooled data do not establish.
Withdrawn 2026-09-05. An earlier build of this page displayed “22.6 (16.3 to 37.2)”, computed from a superseded risk-difference snapshot (−0.0442, −0.0615 to −0.0269) whose upper bound is opposite in sign to the current authoritative pool; that snapshot is retained on the object under superseded_values_2026_09_05. Recomputing from the current operand would not restore a valid NNT, because the current interval crosses zero.
| Trial | Control events / analysed | Risk |
|---|---|---|
| paradigm-hf | 1117 / 4212 | 0.265 |
| parachute-hf | 169 / 460 | 0.367 |
| parallel-hf | 28 / 112 | 0.25 |
| answer-hf | 8 / 95 | 0.0842 |
| Leading digit | Observed | Expected |
|---|---|---|
| 1 | 3 | 1.81 |
| 2 | 1 | 1.06 |
| 3 | 1 | 0.75 |
| 4 | 0 | 0.582 |
| 5 | 0 | 0.475 |
| 6 | 0 | 0.402 |
| 7 | 0 | 0.348 |
| 8 | 0 | 0.307 |
| 9 | 1 | 0.275 |
First-digit screen over the 6 event counts as read. With this few integers the comparison is descriptive only -- Benford's law is a large-sample regularity and no test statistic is computed here.
Computed at build time by metafor 5.0.1 under R 4.6.0 from the per-arm 2x2 counts stored on each trial, which were read from the sources named on each cell. No composite was reconstructed by addition and no count was derived from a percentage. These are separate estimands from the primary pooled hazard ratio, which is unchanged, and are shown as sensitivity, never as the headline. Recomputed at k=4 on 2026-08-14. They had been marked stale at k=3 on the grounds that recomputing needed 2x2 counts that were not available; that was wrong -- ANSWER-HF's counts for this composite, 12/95 against 8/95, were already in the object. The L'Abbe panel was therefore drawing three points beside a four-trial forest. The recomputation reproduces every stored k=3 value to 1e-5 when ANSWER-HF is withheld, which is what licenses the k=4 run.
| Analysis | Status | Why |
|---|---|---|
| Forest plot | shown | Drawn from the stored per-trial and pooled estimates. |
| Random-effects pool (REML) | shown | The headline result, with its interval and heterogeneity. |
| Leave-one-out sensitivity | shown | Each cohort omitted in turn; the finding is on the Analysis tab. |
| Between-study-variance method comparison | shown | REML against the alternatives, as Handbook 10.10.4.5 asks whenever a random-effects pool rests on few studies. |
| Cross-engine replication | shown | The pool refitted in a second engine; the agreement is stored. |
| Prediction interval | not estimable | Undefined at this k on the Cochrane Handbook v6.5 t-based formula for the interval this object would report; no value is stored and none is shown. |
| Funnel plot and Egger's test | not estimable | Three studies. Egger's test has almost no power below about ten and the Handbook advises against it there, so it was not run and no small-study estimate is stored. This is why the GRADE publication-bias domain reads 'not assessable' rather than 'not serious'. |
| Trim-and-fill | not run | A sensitivity procedure on a funnel that cannot be read at three studies. It would produce an adjusted estimate with no diagnostic behind it. |
| Meta-regression | not estimable | Three studies and no shared covariate; a regression here would have more parameters than it can support. |
| Bayesian re-analysis | not stored | No posterior summary is held in this object. Nothing is shown rather than a credible interval nobody fitted. |
| Subgroup analysis | not stored | No subgroup contrast is held for this outcome. |
| Network / component analysis | not applicable | Two treatments and one comparison. There is no network. |
| Reconstructed patient-level survival | not stored | No digitised Kaplan-Meier curve is held. The pooled quantity is a published hazard ratio per trial. |
| Benefit-risk frontier | not stored | No harm outcome is held for these trials in this object, so there is no second axis to plot . |
| Transportability / external validity | partly shown | Each trial's population is stored per row and the populations differ; the Studies tab shows them. No formal transport estimate is stored. |
UNSTAMPED — unknown-version. This page carries no build_stamp, so the standard it was built to cannot be established. That is a statement about the record, not a claim that the page is below standard.
Every number on this page is projected from a single canonical object, and each measured cell names the source analysis it was read from. That is what is machine-checked. It does not establish that the underlying sources are right, only that this page faithfully reports them.